UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from______ to_______

Commission file number 1-13602

The Female Health Company
(Name of registrant as specified in its charter)

Wisconsin
(State of Incorporation) 39-1144397
(I.R.S. Employer Identification No.)

515 N. State Street, Suite 2225
Chicago, IL 60654
(Address of principal executive offices)

312-595-9123
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐  Accelerated filer x
Non-accelerated filer ☐  Smaller reporting company ☐
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as determined by rule 12b-2 of the Exchange Act). Yes ☐ No x

As of August 5, 2011, the registrant had 27,734,174 shares of $0.01 par value common stock outstanding.
## INDEX

<table>
<thead>
<tr>
<th>PART I.</th>
<th>FINANCIAL INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cautionary Statement Regarding Forward Looking Statements</td>
<td>3</td>
</tr>
<tr>
<td>Item 1. Financial Statements</td>
<td>4</td>
</tr>
<tr>
<td>Unaudited Condensed Consolidated Balance Sheets - June 30, 2011 and September 30, 2010</td>
<td>4</td>
</tr>
<tr>
<td>Unaudited Condensed Consolidated Statements of Income - Three Months Ended June 30, 2011 and June 30, 2010</td>
<td>5</td>
</tr>
<tr>
<td>Unaudited Condensed Consolidated Statements of Income - Nine Months Ended June 30, 2011 and June 30, 2010</td>
<td>6</td>
</tr>
<tr>
<td>Notes to Unaudited Condensed Consolidated Financial Statements</td>
<td>8</td>
</tr>
<tr>
<td>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</td>
<td>17</td>
</tr>
<tr>
<td>Item 3. Quantitative and Qualitative Disclosures About Market Risk</td>
<td>32</td>
</tr>
<tr>
<td>Item 4. Controls and Procedures</td>
<td>32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PART II.</th>
<th>OTHER INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Item 5. Other Information</td>
<td>33</td>
</tr>
<tr>
<td>Item 6. Exhibits</td>
<td>34</td>
</tr>
</tbody>
</table>
Certain statements included in this quarterly report on Form 10-Q which are not statements of historical fact are intended to be, and are hereby identified as "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievement expressed or implied by such forward-looking statements. Such factors include, among others, the following: the Company's inability to secure adequate capital to fund working capital requirements and advertising and promotional expenditures; factors related to increased competition from existing and new competitors including new product introduction, price reduction and increased spending on marketing; limitations on the Company's opportunities to enter into and/or renew agreements with international partners, the failure of the Company or its partners to successfully market, sell and deliver its product in international markets, and risks inherent in doing business on an international level, such as laws governing medical devices that differ from those in the U.S., unexpected changes in the regulatory requirements, political risks, export restrictions, tariffs and other trade barriers and fluctuations in currency exchange rates; the disruption of production at the Company's manufacturing facilities due to raw material shortages, labor shortages and/or physical damage to the Company's facilities; the Company's inability to manage its growth and to adapt its administrative, operational and financial control systems to the needs of the expanded entity and the failure of management to anticipate, respond to and manage changing business conditions; the loss of the services of executive officers and other key employees and the Company's continued ability to attract and retain highly-skilled and qualified personnel; the costs and other effects of litigation, governmental investigations, legal and administrative cases and proceedings, settlements and investigations; payment of dividends is in the discretion of the Board of Directors and the Company may not have sufficient cash flows to continue to pay dividends; and developments or assertions by or against the Company relating to intellectual property rights.
### THE FEMALE HEALTH COMPANY AND SUBSIDIARIES

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

#### ASSETS

<table>
<thead>
<tr>
<th>Item</th>
<th>June 30, 2011</th>
<th>September 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$3,284,070</td>
<td>$2,918,776</td>
</tr>
<tr>
<td>Restricted cash</td>
<td>4,639</td>
<td>4,578</td>
</tr>
<tr>
<td>Certificate of deposit</td>
<td>63,062</td>
<td>-</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>1,338,735</td>
<td>4,460,517</td>
</tr>
<tr>
<td>Income tax receivable</td>
<td>28,561</td>
<td>28,179</td>
</tr>
<tr>
<td>Inventories, net</td>
<td>2,127,551</td>
<td>2,194,330</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>369,412</td>
<td>284,948</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>1,900,000</td>
<td>1,900,000</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>$9,116,030</td>
<td>$11,791,328</td>
</tr>
<tr>
<td><strong>OTHER ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EQUIPMENT, FURNITURE AND FIXTURES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equipment, furniture and fixtures</td>
<td>3,755,657</td>
<td>3,720,637</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(1,672,125)</td>
<td>(1,322,577)</td>
</tr>
<tr>
<td>Property, plant and equipment, net</td>
<td>2,083,532</td>
<td>2,398,060</td>
</tr>
<tr>
<td><strong>Deferred income taxes</strong></td>
<td>4,000,000</td>
<td>4,000,000</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$15,319,906</td>
<td>$18,368,101</td>
</tr>
</tbody>
</table>

#### LIABILITIES AND STOCKHOLDERS’ EQUITY

<table>
<thead>
<tr>
<th>Item</th>
<th>June 30, 2011</th>
<th>September 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$573,061</td>
<td>$586,596</td>
</tr>
<tr>
<td>Accrued expenses and other current liabilities</td>
<td>629,056</td>
<td>906,994</td>
</tr>
<tr>
<td>Accrued compensation</td>
<td>300,663</td>
<td>444,843</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td>1,502,780</td>
<td>1,938,433</td>
</tr>
<tr>
<td>Obligations under capital leases</td>
<td>-</td>
<td>12,999</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>90,206</td>
<td>-</td>
</tr>
<tr>
<td>Deferred grant income</td>
<td>113,689</td>
<td>132,312</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>152,227</td>
<td>152,227</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td>1,858,902</td>
<td>2,235,971</td>
</tr>
<tr>
<td>Commitments and Contingencies</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>STOCKHOLDERS’ EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convertible preferred stock, Class A, Series 1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Convertible preferred stock, Class A, Series 3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Convertible preferred stock, Class B</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Common stock</td>
<td>296,490</td>
<td>293,675</td>
</tr>
<tr>
<td>Additional paid-in-capital</td>
<td>67,948,856</td>
<td>67,313,616</td>
</tr>
<tr>
<td>Accumulated other comprehensive loss</td>
<td>(381,519)</td>
<td>(581,519)</td>
</tr>
<tr>
<td>Accumulated deficit</td>
<td>(47,820,191)</td>
<td>(44,544,073)</td>
</tr>
<tr>
<td>Treasury stock, at cost</td>
<td>(6,382,632)</td>
<td>(6,349,569)</td>
</tr>
<tr>
<td><strong>TOTAL STOCKHOLDERS’ EQUITY</strong></td>
<td>13,461,004</td>
<td>16,132,130</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</strong></td>
<td>$15,319,906</td>
<td>$18,368,101</td>
</tr>
</tbody>
</table>

See notes to unaudited condensed consolidated financial statements.
## Unaudited Condensed Consolidated Statements of Income

<table>
<thead>
<tr>
<th></th>
<th>June 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2011</td>
<td>2010</td>
</tr>
<tr>
<td><strong>Product sales</strong></td>
<td>$3,515,303</td>
<td>$1,742,961</td>
</tr>
<tr>
<td><strong>Royalty income</strong></td>
<td>2,136</td>
<td>11,250</td>
</tr>
<tr>
<td><strong>Net revenues</strong></td>
<td>3,517,439</td>
<td>1,754,211</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>1,703,754</td>
<td>814,764</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>1,813,685</td>
<td>939,447</td>
</tr>
<tr>
<td><strong>Operating expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advertising and promotion</td>
<td>114,226</td>
<td>38,029</td>
</tr>
<tr>
<td>Selling, general and administrative</td>
<td>1,246,890</td>
<td>922,024</td>
</tr>
<tr>
<td>Research and development</td>
<td>2,068</td>
<td>-</td>
</tr>
<tr>
<td>Restructuring costs, net</td>
<td>-</td>
<td>(41,656)</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>1,363,184</td>
<td>918,397</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>450,501</td>
<td>21,050</td>
</tr>
<tr>
<td><strong>Non-operating income (expense):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest, net and other (expense) income</td>
<td>(546)</td>
<td>10,566</td>
</tr>
<tr>
<td>Foreign currency transaction (loss) gain</td>
<td>(18,022)</td>
<td>17,190</td>
</tr>
<tr>
<td><strong>Total non-operating (expense) income</strong></td>
<td>(18,568)</td>
<td>27,756</td>
</tr>
<tr>
<td><strong>Income before income taxes</strong></td>
<td>431,933</td>
<td>48,806</td>
</tr>
<tr>
<td><strong>Income tax expense (benefit)</strong></td>
<td>15,266</td>
<td>(26,353)</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>$416,667</td>
<td>$75,159</td>
</tr>
<tr>
<td><strong>Basic earnings per common share outstanding</strong></td>
<td>$0.02</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Basic weighted average common shares outstanding</strong></td>
<td>27,301,422</td>
<td>27,216,798</td>
</tr>
<tr>
<td><strong>Diluted earnings per common share outstanding</strong></td>
<td>$0.01</td>
<td>$0.00</td>
</tr>
<tr>
<td><strong>Diluted weighted average common shares outstanding</strong></td>
<td>28,971,510</td>
<td>28,819,516</td>
</tr>
</tbody>
</table>

See notes to unaudited condensed consolidated financial statements.
# The Female Health Company and Subsidiaries

## Unaudited Condensed Consolidated Statements of Income

<table>
<thead>
<tr>
<th></th>
<th>Nine Months Ended</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>June 30, 2011</td>
<td>2011</td>
<td>2010</td>
</tr>
<tr>
<td><strong>Product sales</strong></td>
<td>$11,412,666</td>
<td>$14,410,669</td>
<td></td>
</tr>
<tr>
<td><strong>Royalty income</strong></td>
<td>43,386</td>
<td>11,363</td>
<td></td>
</tr>
<tr>
<td><strong>Net revenues</strong></td>
<td>$11,456,052</td>
<td>$14,422,032</td>
<td></td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>5,818,216</td>
<td>6,099,701</td>
<td></td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>$5,637,836</td>
<td>$8,322,331</td>
<td></td>
</tr>
<tr>
<td><strong>Operating expenses:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advertising and promotion</td>
<td>245,444</td>
<td>197,190</td>
<td></td>
</tr>
<tr>
<td>Selling, general and administrative</td>
<td>4,395,691</td>
<td>4,910,689</td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>10,929</td>
<td>381</td>
<td></td>
</tr>
<tr>
<td>Restructuring costs, net</td>
<td>-</td>
<td>1,926,444</td>
<td></td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>$4,652,064</td>
<td>$7,034,704</td>
<td></td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>$985,772</td>
<td>$1,287,627</td>
<td></td>
</tr>
<tr>
<td><strong>Non-operating income (expense):</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest, net and other (expense) income</td>
<td>(2,922)</td>
<td>27,904</td>
<td></td>
</tr>
<tr>
<td>Foreign currency transaction loss</td>
<td>(74,251)</td>
<td>(62,259)</td>
<td></td>
</tr>
<tr>
<td><strong>Total non-operating expense</strong></td>
<td>(77,173)</td>
<td>(34,355)</td>
<td></td>
</tr>
<tr>
<td><strong>Income before income taxes</strong></td>
<td>$908,599</td>
<td>$1,253,272</td>
<td></td>
</tr>
<tr>
<td><strong>Income tax expense</strong></td>
<td>24,266</td>
<td>31,931</td>
<td></td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>$884,333</td>
<td>$1,221,341</td>
<td></td>
</tr>
</tbody>
</table>

**Basic earnings per common share outstanding**

|                         | $0.03             | $0.05 |

**Basic weighted average common shares outstanding**

|                         | 27,282,597        | 26,906,295 |

**Diluted earnings per common share outstanding**

|                         | $0.03             | $0.04 |

**Diluted weighted average common shares outstanding**

|                         | 28,987,263        | 28,491,308 |

See notes to unaudited condensed consolidated financial statements.
THE FEMALE HEALTH COMPANY AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

<table>
<thead>
<tr>
<th>OPERATING ACTIVITIES</th>
<th>Nine Months Ended</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income</td>
<td></td>
<td>$884,333</td>
<td>$1,221,341</td>
</tr>
<tr>
<td>Adjustments to reconcile net income to net cash provided by operating activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td></td>
<td>349,548</td>
<td>319,482</td>
</tr>
<tr>
<td>Amortization of deferred gain on sale/leaseback</td>
<td></td>
<td>-</td>
<td>(657,605)</td>
</tr>
<tr>
<td>Amortization of deferred income from grant</td>
<td></td>
<td>(18,623)</td>
<td>(18,623)</td>
</tr>
<tr>
<td>Interest added to certificate of deposit</td>
<td></td>
<td>(2,409)</td>
<td>(2,091)</td>
</tr>
<tr>
<td>Share-based compensation</td>
<td></td>
<td>570,743</td>
<td>371,524</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities</td>
<td></td>
<td>2,827,103</td>
<td>2,163,261</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td></td>
<td>4,610,695</td>
<td>3,397,289</td>
</tr>
</tbody>
</table>

| INVESTING ACTIVITIES | | | |
| (Increase) decrease in restricted cash | (61) | 5,618 |
| Capital expenditures | (35,020) | (25,575) |
| Net cash used in investing activities | (35,081) | (19,957) |

| FINANCING ACTIVITIES | | | |
| Proceeds from exercise of stock options | | - | 157,900 |
| Proceeds from exercise of warrants | | - | 725,600 |
| Taxes paid in lieu of shares | | - | (313,760) |
| Purchases of common stock for treasury shares | | (33,063) | (170,447) |
| Dividends paid on common stock | | (4,158,239) | (2,749,258) |
| Payments on capital lease obligations | | (19,018) | (22,308) |
| Net cash used in financing activities | | (4,210,320) | (2,372,273) |

| Net increase in cash | | 365,294 | 1,005,059 |
| Cash at beginning of period | | 2,918,776 | 2,810,197 |

| CASH AT END OF PERIOD | | $3,284,070 | $3,815,256 |

Schedule of noncash financing and investing activities:

- Income taxes paid | $23,952 | $103,931 |
- Reduction of accrued expense upon issuance of shares | 221,970 | 92,180 |
- Dividends declared (unpaid dividend on restricted stock) | 16,000 | 9,200 |

See notes to unaudited condensed consolidated financial statements.
NOTE 1 - Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited but in the opinion of management contain all the adjustments (consisting of those of a normal recurring nature) considered necessary to present fairly the financial position and the results of operations and cash flow for the periods presented in conformity with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements.

Operating results for the three and nine months ended June 30, 2011, are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2011. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the fiscal year ended September 30, 2010.

Principles of Consolidation and Nature of Operations

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, The Female Health Company – UK, and its wholly owned subsidiaries, The Female Health Company - UK, plc and The Female Health Company (M) SDN.BHD. All significant intercompany transactions and accounts have been eliminated in consolidation. The Female Health Company (“FHC” or the "Company") is currently engaged in the marketing, manufacture and distribution of a consumer health care product, the FC2 female condom (“FC2”). The Female Health Company - UK, is the holding company of The Female Health Company - UK, plc, which is located in a 6,400 sq. ft. leased office facility located in London, England. The Female Health Company (M) SDN.BHD leases a 16,000 sq. ft. manufacturing facility located in Selangor D.E., Malaysia.

The FC2 female condom is currently sold or available in either or both commercial (private sector) and public sector markets in 120 countries. The product is marketed directly to consumers in 13 countries by various country-specific commercial partners.

The Company also derives revenue from licensing its intellectual property under an agreement with its exclusive distributor in India, Hindustan Lifecare Limited (“HLL”). HLL is authorized to manufacture FC2 at HLL’s facility in Kochi, India for sale in India. HLL is the Company’s exclusive distributor in India and the Company receives a royalty based on the number of units sold by HLL in India. Such revenue appears as royalty income on the Consolidated Statements of Income for the three and nine months ended June 30, 2011 and 2010, and is recognized in the period in which the sale is made by HLL.

The Company’s standard credit terms vary from 30 to 90 days, depending on the class of trade and customary terms within a territory, so accounts receivable is affected by the mix of purchasers within the quarter. As is typical in the Company's business, extended credit terms may occasionally be offered as a sales promotion. For the past twelve months, the Company’s average days sales outstanding has averaged approximately 54 days. Over the past five years, the Company’s bad debt expense has been less than .01% of product sales. The balance in the allowance for doubtful accounts was approximately $45,000 at June 30, 2011 and $40,000 at September 30, 2010.
Restricted cash

Restricted cash relates to security provided to one of the Company’s U.K. banks for performance bonds issued in favor of customers. Such security has been extended infrequently and only on occasions where it has been a contract term expressly stipulated as an absolute requirement by the customer. The expiration of the bond is defined by the completion of the event such as, but not limited to, delivery of goods or at a period of time after product has been distributed.

Foreign Currency and Change in Functional Currency

Prior to October 1, 2009 the functional currency of the Company’s subsidiaries was the local currency, in accordance with Accounting Standards Codification (ASC) Topic 830, Foreign Currency Matters. Effective October 1, 2009, the Company determined that there were significant changes in facts and circumstances and the Company’s subsidiaries adopted the U.S. dollar as their functional currency. The Company recognized a foreign currency transaction loss of $18,022 and $74,251 for the three and nine months ended June 30, 2011, respectively, compared to a gain of $17,190 and a loss of $62,259 for the three and nine months ended June 30, 2010, respectively. The consistent use of the U.S. dollar as functional currency across the Company reduces its foreign currency risk and stabilizes its operating results.

NOTE 2 – Earnings per Share

Basic EPS is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants and unvested shares granted to employees and directors.

<table>
<thead>
<tr>
<th>Denominator:</th>
<th>Three Months Ended June 30,</th>
<th>Nine Months Ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighted average common shares outstanding – basic</td>
<td>27,301,422</td>
<td>27,216,798</td>
</tr>
<tr>
<td>Net effect of dilutive securities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Options</td>
<td>1,234,933</td>
<td>1,325,378</td>
</tr>
<tr>
<td>Warrants</td>
<td>58,905</td>
<td>62,090</td>
</tr>
<tr>
<td>Unvested restricted shares</td>
<td>376,250</td>
<td>215,250</td>
</tr>
<tr>
<td>Total net effect of dilutive securities</td>
<td>1,670,088</td>
<td>1,602,718</td>
</tr>
<tr>
<td>Weighted average common shares outstanding – diluted</td>
<td>28,971,510</td>
<td>28,819,516</td>
</tr>
<tr>
<td>Earnings per common share – basic</td>
<td>$ 0.02</td>
<td>$ 0.00</td>
</tr>
<tr>
<td>Earnings per common share – diluted</td>
<td>$ 0.01</td>
<td>$ 0.00</td>
</tr>
</tbody>
</table>

All the outstanding warrants and stock options were included in the computation of diluted net income per share during the three and nine months ended June 30, 2011 and 2010.
NOTE 3 - Inventories

The components of inventory consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2011</th>
<th>September 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw material and work in process</td>
<td>$725,309</td>
<td>$594,108</td>
</tr>
<tr>
<td>Finished goods</td>
<td>1,428,242</td>
<td>1,615,222</td>
</tr>
<tr>
<td>Inventory, gross</td>
<td>2,153,551</td>
<td>2,209,330</td>
</tr>
<tr>
<td>Less: inventory reserves</td>
<td>(26,000)</td>
<td>(15,000)</td>
</tr>
<tr>
<td>Inventory, net</td>
<td>$2,127,551</td>
<td>$2,194,330</td>
</tr>
</tbody>
</table>

NOTE 4 – Line of Credit

On August 1, 2011, the Company entered into a Second Amended and Restated Loan Agreement (the “Loan Agreement”) with Heartland Bank (the “Bank”) to extend the term of the Company’s revolving line of credit to August 1, 2012 and revise the structure of the revolving line of credit. The previous structure consisted of a revolving note for up to $1,000,000 with borrowings limited to 50% of eligible accounts receivable and a revolving note for up to $1,000,000 with borrowings limited to the amount of a supporting letter of credit issued by The World Bank or another issuer of equivalent credit quality approved by the Bank. The new structure consists of a single revolving note for up to $2,000,000 with the Bank, with borrowings limited to a borrowing base determined based on 70% or 80% of eligible accounts receivable plus 50% of eligible inventory. Significant restrictive covenants in the Loan Agreement include prohibitions on any merger, consolidation or sale of all or a substantial portion of the Company’s assets and limits on the payment of dividends or the repurchase of shares. The Loan Agreement does not contain any financial covenants that require compliance with ratios or amounts. Dividends and share repurchases are permitted as long as after giving effect to the dividend or share repurchase the Company has a ratio of total liabilities to total stockholders’ equity of no more than 1:1. The revolving note with the Bank will expire August 1, 2012. Borrowings on the revolving note bear interest at a rate of the base rate plus 0.5%. The note is collateralized by substantially all of the assets of the Company. No amounts were outstanding under the previous revolving notes at June 30, 2011, and September 30, 2010.

NOTE 5 – Share-Based Payments

In March 2008, the Company’s shareholders approved the 2008 Stock Incentive Plan which will be utilized to provide equity opportunities and performance-based incentives to attract, retain and motivate those persons who make (or are expected to make) important contributions to the Company. A total of 2,000,000 shares are available for issuance under this plan. As of June 30, 2011, 693,682 shares had been issued under this plan and no shares were issued in the quarter then ended. Of the total grants under this plan from its adoption to June 30, 2011, stock options covering a total of 150,000 shares have been granted, and all other grants were in the form of restricted stock or other share awards.
Stock Options

Under the Company’s previous share based long-term incentive compensation plan, the 1997 Stock Option Plan, the Company granted non-qualified stock options to employees. There are no shares available for grant under this plan which expired on December 31, 2006. Options issued under this plan expire 10 years after the date of grant and generally vested 1/36 per month, with full vesting after three years. Under the Company’s 2008 Stock Incentive Plan, options issued expire 10 years after the date of grant and vest 1/36 per month, with full vesting after three years. The Company did not grant any options during either the three or nine months ended June 30, 2011 or 2010.

Compensation expense is recognized only for share-based payments expected to vest. The Company estimates forfeitures at the date of grant based on historical experience and future expectations. Stock compensation expense related to options for the three and nine months ended June 30, 2011, was approximately $23,000 and $68,000, respectively, and $23,000 and $70,000 for the three and nine months ended June 30, 2010, respectively.

No stock options were exercised during the three and nine months ended June 30, 2011. During the three and nine months ended June 30, 2010, stock option holders exercised 30,000 and 325,000 stock options, respectively, using the cashless exercise option available under the plan which entitled them to 20,962 and 186,220 shares of common stock, respectively. During the nine months ended June 30, 2010, proceeds of $157,900 were received from the exercise of 110,000 stock options. Of the 435,000 stock options exercised in the nine months ended June 30, 2010, 425,000 were exercised by independent board members and senior management. The intrinsic value of the options exercised was $116,000 and $1,792,000 for the three and nine months ended June 30, 2010, respectively. There was no realized tax benefit from options exercised for the three months ended June 30, 2010, based on the “with and without” approach.

The following table summarizes the stock options outstanding and exercisable at June 30, 2011:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>1,834,000</td>
<td>2.62</td>
<td>$1.61</td>
<td>$6,217,000</td>
<td>1,788,167</td>
<td>2.49</td>
<td>$1.55</td>
<td>$6,167,000</td>
</tr>
</tbody>
</table>

The aggregate intrinsic value in the table above is before income taxes, based on the Company’s closing stock price of $5.00 per share as of the last business day of the period ended June 30, 2011. As of June 30, 2011, the Company had unrecognized compensation expense of approximately $83,000 related to unvested stock options. These expenses will be recognized over approximately 11 months. The deferred tax asset and realized benefit from stock options exercised and other share-based payments for the periods ended June 30, 2011 and 2010, was not recognized, based on the Company’s election of the “with and without” approach.
Restricted Stock

The Company issues restricted stock to employees, directors and consultants. Such issuances may have vesting periods that range from one to three years or the issuances may be contingent on continued employment for periods that range from one to three years. In addition, the Company has issued stock awards to certain employees that contain vesting provisions or provide for future issuance contingent on continued employment.

No shares of restricted stock were granted during the three months ended June 30, 2011 or June 30, 2010. The Company granted a total of 288,750 shares of restricted stock or shares issuable pursuant to promises to issue shares of common stock during the nine months ended June 30, 2011. The fair value of the awards granted was approximately $1,657,000. All such shares of restricted stock vest and all such shares must be issued pursuant to promises to issue common stock between September 2011 and December 2013, provided the grantee has not voluntarily terminated service or been terminated for cause prior to the vesting or issuance date. The Company granted a total of 35,250 shares of restricted stock or shares issuable pursuant to promises to issue shares of common stock during the nine months ended June 30, 2010. The fair value of the awards granted was approximately $166,000. All such shares of restricted stock vested or were issued in September 2010.

2,500 shares of restricted stock were forfeited during the nine months ended June 30, 2011, and no shares of restricted stock were forfeited during the three months ended June 30, 2011 or the nine months ended June 30, 2010.

The Company granted a total of 288,750 shares of restricted stock or shares issuable pursuant to promises to issue shares of common stock during the nine months ended June 30, 2011. The fair value of the awards granted was approximately $1,657,000. All such shares of restricted stock vest and all such shares must be issued pursuant to promises to issue common stock between September 2011 and December 2013, provided the grantee has not voluntarily terminated service or been terminated for cause prior to the vesting or issuance date. The Company granted a total of 35,250 shares of restricted stock or shares issuable pursuant to promises to issue shares of common stock during the nine months ended June 30, 2010. The fair value of the awards granted was approximately $166,000. All such shares of restricted stock vested or were issued in September 2010.

No warrants were issued in the nine months ended June 30, 2011 or 2010.

There were no warrant exercises in the nine months ended June 30, 2011. There is no unrecognized compensation cost related to warrants as of June 30, 2011.

During the nine months ended June 30, 2010, a warrant holder exercised 30,000 warrants using the cashless exercise option available within the warrant agreement which entitled the warrant holder to 23,085 shares of common stock. During the nine months ended June 30, 2010, warrant holders exercised 626,500 warrants which provided proceeds of $725,600.
NOTE 6 - Stock Repurchase Program

On January 17, 2007, the Company announced a Stock Repurchase Program under the terms of which up to a million shares of its common stock could be purchased during the subsequent twelve months. In March 2008, the repurchase program was expanded up to a total of 2,000,000 shares to be acquired through December 31, 2009. In February 2009, the Board further expanded the repurchase program to a maximum of 3,000,000 shares to be acquired through December 31, 2010. On March 25, 2010, the Board extended the period of the Stock Repurchase Program through December 31, 2011. From the program’s onset through June 30, 2011, the total number of shares repurchased by the Company is 1,914,829. The Stock Repurchase Program authorizes purchases in privately negotiated transactions as well as in the open market.

In October 2008 the Company's board of directors authorized repurchases in private transactions under the Stock Repurchase Program of shares issued under the Company's equity compensation plans to directors, employees and other service providers at the market price on the effective date of the repurchase request. Total repurchases under this amendment are limited to an aggregate of 250,000 shares per calendar year and to a maximum of 25,000 shares annually per individual. Purchases under this amendment for the nine months ended June 30, 2011 and 2010 were 5,750 and 30,806 shares, respectively.

Issuer Purchases of Equity Securities:

<table>
<thead>
<tr>
<th>Period</th>
<th>Total Number of Shares Purchased</th>
<th>Average Price Paid Per Share</th>
<th>Total Number of Shares Purchased As Part of Publicly Announced Program</th>
<th>Maximum Number of Shares that May Yet be Purchased Under the Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1, 2007 – March 31, 2011</td>
<td>1,914,829</td>
<td>$3.32</td>
<td>1,914,829</td>
<td>1,085,171</td>
</tr>
<tr>
<td>April 1, 2011 – April 30, 2011</td>
<td>-</td>
<td>-</td>
<td>1,914,829</td>
<td>1,085,171</td>
</tr>
<tr>
<td>May 1, 2011 – May 31, 2011</td>
<td>-</td>
<td>-</td>
<td>1,914,829</td>
<td>1,085,171</td>
</tr>
<tr>
<td>June 1, 2011 – June 30, 2011</td>
<td>-</td>
<td>-</td>
<td>1,914,829</td>
<td>1,085,171</td>
</tr>
<tr>
<td>Quarterly Subtotal</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1,914,829</td>
<td>$3.32</td>
<td>1,914,829</td>
<td>1,085,171</td>
</tr>
</tbody>
</table>

NOTE 7 - Industry Segments and Financial Information About Foreign and Domestic Operations

The Company currently operates primarily in one industry segment which includes the development, manufacture and marketing of consumer health care products.

The Company operates in foreign and domestic regions. Information about the Company's operations by geographic area is as follows (in thousands):
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>United States</strong></td>
<td>$1,631 (1)</td>
<td>$1,017</td>
<td>$151</td>
</tr>
<tr>
<td><strong>South Africa</strong></td>
<td>$1,126</td>
<td>$2,543 (1)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Singapore</strong></td>
<td>*</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td><strong>Zimbabwe</strong></td>
<td>966</td>
<td>1,105</td>
<td>-</td>
</tr>
<tr>
<td><strong>Brazil</strong></td>
<td>703</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td><strong>France</strong></td>
<td>672</td>
<td>*</td>
<td>-</td>
</tr>
<tr>
<td><strong>Mozambique</strong></td>
<td>*</td>
<td>810</td>
<td>-</td>
</tr>
<tr>
<td><strong>Nigeria</strong></td>
<td>*</td>
<td>1,941 (1)</td>
<td>-</td>
</tr>
<tr>
<td><strong>D. R. of Congo</strong></td>
<td>*</td>
<td>*</td>
<td>94</td>
</tr>
<tr>
<td><strong>India</strong></td>
<td>*</td>
<td>*</td>
<td>202</td>
</tr>
<tr>
<td><strong>United Kingdom</strong></td>
<td>*</td>
<td>*</td>
<td>1,757</td>
</tr>
<tr>
<td><strong>Malaysia</strong></td>
<td>*</td>
<td>*</td>
<td>1,969</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>5,767</td>
<td>6,136</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$11,456</td>
<td>$14,422</td>
<td>$2,204</td>
</tr>
</tbody>
</table>

* Less than 5 percent of total product sales
(1) Comprised of a single customer considered to be a major customer (exceeds 10 percent of net sales).

**NOTE 8 – Contingent Liabilities**

The testing, manufacturing and marketing of consumer products by the Company entail an inherent risk that product liability claims will be asserted against the Company. The Company maintains product liability insurance coverage for claims arising from the use of its products. The coverage amount is currently $5,000,000 for FHC’s consumer health care product.

**NOTE 9 – Income Taxes**

The Company accounts for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of its assets and liabilities, and for net operating loss and tax credit carryforwards.

The Company completes a detailed analysis of its deferred income tax valuation allowances on an annual basis or more frequently if information comes to our attention that would indicate that a revision to its estimates is necessary. In evaluating the Company’s ability to realize its deferred tax assets, management considers all available positive and negative evidence on a country by country basis, including past operating results and forecast of future taxable income. In determining future taxable income, management makes assumptions to forecast U.S. federal and state, U.K. and Malaysia operating income, the reversal of temporary differences, and the implementation of any feasible and prudent tax planning strategies. These assumptions require significant judgment regarding the forecasts of the future taxable income in each tax jurisdiction, and are consistent with the forecasts used to manage the Company’s business. It should be noted that through 2005, the Company realized significant losses on a consolidated basis. The Company has a history of taxable income for three consecutive years in the U.S. and two of the past three years in the U.K., which was used to determine the amount of time the Company can reasonably expect to generate taxable income in the future. In management’s analysis to determine the amount of the deferred tax asset to recognize, management projected future taxable income for the subsequent three years for each tax jurisdiction.
As of June 30, 2011, the Company had federal and state net operating loss carryforwards of approximately $34,512,000 and $27,817,000, respectively, for income tax purposes expiring in years 2011 to 2029. The Company’s U.K. subsidiary, The Female Health Company-UK, plc has U.K. net operating loss carryforwards of approximately $69,089,000 as of June 30, 2011, which can be carried forward indefinitely to be used to offset future U.K. taxable income. The Company’s Malaysian subsidiary, The Female Health Company (M) SDN.BHD, has net operating loss carryforwards of approximately $125,000 as of June 30, 2011, which can be carried forward indefinitely to be used to offset future Malaysian taxable income. With the increasing demand for and profitability of the FC2 female condom, the Company expects utilization of its net operating losses in both the U.K. and the U.S. will continue. However, because some of the U.S. Federal tax losses have a net loss carryforward limitation of fifteen years, it is possible that some of the Company’s early losses carried forward in the U.S. will not be fully utilized. The U.K. net operating losses do not expire. The losses incurred in Malaysia are related to the recent start-up and are expected to be utilized over the next several years.

A reconciliation of income tax expense (benefit) and the amount computed by applying the statutory Federal income tax rate to income before income taxes for the three and nine months ended June 30, 2011 and 2010 is as follows:

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended June 30,</th>
<th>Nine Months Ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2011</td>
<td>2010</td>
</tr>
<tr>
<td>Income tax expense at statutory rates</td>
<td>$147,000</td>
<td>$16,000</td>
</tr>
<tr>
<td>State income tax, net of federal benefits</td>
<td>27,000</td>
<td>2,000</td>
</tr>
<tr>
<td>Effect of AMT expense</td>
<td>-</td>
<td>(34,140)</td>
</tr>
<tr>
<td>Non-deductible expenses</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>Effect of foreign income tax</td>
<td>(33,000)</td>
<td>7,787</td>
</tr>
<tr>
<td>Utilization of NOL carryforwards</td>
<td>(67,420)</td>
<td>(22,000)</td>
</tr>
<tr>
<td>Increase (decrease) in valuation allowance</td>
<td>(59,314)</td>
<td>3,000</td>
</tr>
<tr>
<td>Income tax expense (benefit)</td>
<td>$15,266</td>
<td>$(26,353)</td>
</tr>
</tbody>
</table>

NOTE 10 – FC1/FC2 Transition - Restructuring Costs

On August 5, 2009, the Company announced to its U.K. employees that the Company would evaluate the future of its U.K. facility following the decision of two of its largest customers to switch their purchases from the first generation product, FC1, manufactured in the U.K. facility, to the second generation product, FC2, which is manufactured in Malaysia. As is required by British labor law, the Company went through an evaluation process, working in tandem with employee representatives, in which various manufacturing alternatives were considered. As the process failed to identify a satisfactory alternative, the facility’s manufacturing operations ceased in October 2009, when the final FC1 orders were shipped. The evaluation process concluded in late November 2009, when employees received their termination payments.

The Company evaluated, measured and recognized the restructuring costs under the guidance of ASC Topic 420, Exit or Disposal Cost Obligations, and recognized such costs in the period incurred. The costs associated with this restructuring fall under the scope of associated costs of an exit activity, as suggested by the Interpretive Response in Staff Accounting Bulletin Topic 5(P)(4), including footnote 17. The FC1/FC2 transition was completed in fiscal year 2010, so there are no restructuring costs in fiscal year 2011. The components of the restructuring costs recognized for the three and nine months ended June 30, 2010 were as follows:
### Table: Lease Surrender Payments and Related Costs

<table>
<thead>
<tr>
<th>Description</th>
<th>Three Months Ended June 30, 2010</th>
<th>Nine Months Ended June 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lease surrender payments and related costs</td>
<td>$243,783</td>
<td>$1,734,496</td>
</tr>
<tr>
<td>(Reversal) recognition of excess capacity costs through November 1, 2010</td>
<td>(302,342)</td>
<td>302,683</td>
</tr>
<tr>
<td>Offset: By proportionate recognition of deferred gain on original sale/leaseback of plant</td>
<td>-</td>
<td>(653,706)</td>
</tr>
<tr>
<td>Dilapidations and related costs</td>
<td>16,903</td>
<td>542,971</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$(41,656)</td>
<td>$1,926,444</td>
</tr>
</tbody>
</table>

Although FC1 production ceased in October 2009, the Company continues to conduct significant operating activities in the U.K. Such activities include global sales and marketing of the FC2 female condom, management and direction of Global Manufacturing Operations (including production planning, inventory management, quality assurance and quality control, finished goods release, and compliance with good manufacturing practices), relationships with regulatory agencies world-wide, oversight of the Global Technical Support Team and new product development.

#### Note 11 – Dividends

During fiscal 2010, the Company commenced paying quarterly cash dividends. The Company’s Board of Directors has declared and paid consecutive quarterly cash dividends of $0.05 per share since January 2010. The Company paid cash dividends of $4.2 million during the nine months ended June 30, 2011 and $2.7 million during the nine months ended June 30, 2010.

On July 14, 2011, the Company’s Board of Directors declared a quarterly cash dividend of $0.05 per share. The Company will pay, from its cash on hand, approximately $1.4 million pursuant to the dividend on August 9, 2011 to stockholders of record as of August 2, 2011.

#### Note 12 – Lease Extension

The Company’s corporate headquarters is located in approximately 5,100 square feet of office space located in Chicago, Illinois. On March 10, 2011, the Company signed a lease amendment, effective November 1, 2010, which extended the lease term for this office space for a five year period commencing on November 1, 2011 and ending on October 31, 2016. The lease amendment grants the Company a five month lease abatement beginning November 1, 2010, reduces base rent and provides a tenant improvement allowance. The lease requires escalating monthly payments ranging from $6,797 to $7,859, plus real estate taxes, utilities and maintenance expenses from April 1, 2011 to October 31, 2016. The lease stipulates that after five years, the Company shall have a one-time right to extend the term of the lease for an additional three years by giving the landlord no less than twelve months prior notice in writing.
General

The Female Health Company ("FHC" or the "Company") manufactures, markets and sells the FC2 female condom. FC2 is the only currently available product under a woman's control and approved by the U.S. Food and Drug Administration (FDA) that provides dual protection against unintended pregnancy and sexually transmitted infections ("STIs"), including HIV/AIDS. The Company’s first generation product was the FC1 Female Condom, a Class III medical device approved by FDA in 1993.

FC2, the Company’s second-generation female condom, was developed to:

1. Increase women’s access to prevention that they could initiate through a lower public health sector price
2. Increase HIV/AIDS prevention
3. Lower health care costs
4. Increase gross margins

FC2 was first marketed internationally in March 2007 and has been marketed in the U.S. since August 2009. Since FC2’s introduction in March 2007 through June 30, 2011, approximately 98 million FC2 female condoms have been distributed in 120 countries. It is sold directly to consumers in 13 countries.

FC2 was approved by FDA as a Class III medical device on March 10, 2009. In addition to FDA approval, the FC2 female condom has been approved by other regulatory agencies, including in the European Union, India and Brazil. Based on a rigorous scientific review, the World Health Organization (WHO) agreed that FC2 performs in the same manner as FC1 and cleared FC2 for purchase by U.N. agencies in 2006.

In October 2009, the Company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, the Company retains its ownership of certain world-wide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1.

The FC2 Female Condom offers women dual protection against STI's, including HIV/AIDS, and unintended pregnancy. Because FC2’s primary usage is that of disease prevention, the public health sector is the Company’s main market. Within the public health sector, various organizations supply critical products, at no cost or low cost, to those who need but cannot afford to buy such products for themselves.

FC2 is available in 120 countries. A significant number of countries with the highest potential are in the developing world. The incidence of HIV/AIDS, other STI’s and unwanted pregnancy in these countries represents a remarkable potential for significant sales in a way that helps some of the world’s most underprivileged people. However, conditions in these countries can be volatile and result in unpredictable delays in program development, tender applications and processing orders.
The Company’s customer base consists of large global agencies, country-specific health ministries, non-governmental organizations and commercial partners in various countries. The Company has a relatively small customer base, with a limited number of customers who generally purchase in large quantities. Over the past few years, major customers have been large global agencies, such as the United Nations Population Fund (UNFPA) and the United States Agency for International Development (USAID), through its facilitator, John Snow, Inc., and various Ministries of Health or similar governmental agencies, who either purchase directly or through in-country distributors.

Purchasing patterns vary significantly from one customer to another, and may reflect factors other than simple demand. For example, some Ministries of Health purchase through a formal procurement process in which a tender (request for bid) is issued for either a specific or a maximum unit quantity. In addition to quantity, tenders define the elements required for a qualified bid submission (such as product specifications, regulatory approvals, clearance by WHO, unit pricing and delivery timetable). Bidders have a limited period of time in which to submit bids. Bids are subjected to an evaluation process which is intended to conclude with a tender award to the successful bidder. The entire tender process, from publication to award, may take many months to complete. Administrative issues, politics, bureaucracy, process errors and/or other pressures may delay or derail the process. The purchasing patterns of public sector customers may be impacted by non-demand factors such as changes in leadership, organization, procurement process, bureaucracy or allocation of funding. As our largest customers’ buying patterns are subject to significant factors other than product demand, the Company may experience significant quarter to quarter sales variations due to the timing and shipment of large orders.

In the past few years, the Company’s business model, which includes high gross margins, modest capital expenditures and low expense requirements as compared to production volumes, has permitted the Company to sustain profitable operations without debt and maintain dividend payments during periods of delayed orders. Continuing these accomplishments in future periods will be contingent on a number of factors, including the degree and period of sales volatility and on the strength of global demand for the Company’s product.

Products

Currently, there are only two FDA approved and marketed products that prevent the transmission of HIV/AIDS through sexual intercourse: the male condom and the FC2 female condom. The FC2 female condom is currently the only FDA approved and marketed product controlled by women that prevents STIs, including HIV/AIDS. Used consistently and correctly, it provides women dual protection against STIs (including HIV/AIDS) and unintended pregnancy. The FC2 female condom does not compete with the male condom, but is an alternative to either unprotected sex or male condom usage.

Numerous clinical and behavioral studies have been conducted regarding use of the female condom. Studies show that the female condom is found acceptable by women and their partners in many cultures. Importantly, studies also show that when the female condom is made available with male condoms there is a significant increase in protected sex acts. The increase in protected sex acts varies by country and averages between 10% and 35%.
FHC completed development of FC2, its second generation female condom, in September 2005. FC2 has basically the same physical design, specifications, safety and efficacy profile as FC1. Manufactured from a nitrile polymer, FC2 can be produced more economically than the first generation product, FC1, which was made from a more costly raw material (polyurethane). FC2 consists of a soft, loose fitting sheath and two flexible O rings. FC2 lines the vagina, preventing skin-to-skin contact during intercourse. The inner ring is used to insert the device and lodge it in place. The other ring remains outside the vagina after insertion.

FC2’s primary raw material (a nitrile polymer) offers a number of benefits over natural rubber latex, the raw material most commonly used in male condoms. FC2’s nitrile polymer is stronger than latex, reducing the probability that the female condom sheath will tear during use. Unlike latex, FC2’s nitrile polymer quickly transfers heat. FC2 warms to body temperature immediately upon insertion which may enhance the user’s sensation and pleasure. Unlike the male condom, FC2 may be inserted in advance of arousal, eliminating disruption during sexual intimacy. FC2 is also an alternative to latex sensitive users (7% to 20% of the population) who are unable to use male condoms without irritation. To the Company’s knowledge, there is no reported allergy to the nitrile polymer. FC2 is pre-lubricated, disposable and recommended for use during a single sex act. FC2 is not reusable.

FC2 received FDA approval as a Class III medical device on March 10, 2009, and has been available in the United States since August 2009. In addition to FDA approval, the FC2 female condom has been approved by other regulatory agencies, including in the European Union, India and Brazil. Based on a rigorous scientific review, WHO agreed that FC2 performs in the same manner as FC1 and cleared FC2 for purchase by U.N. agencies in 2006.

Raw Materials

The principal raw material used to produce FC2 is a nitrile polymer. While general nitrile formulations are available from a number of suppliers, the Company has chosen to work closely with the technical market leader in synthetic polymers to develop a grade ideally suited to the bio-compatibility and functional needs of a female condom. The supplier has agreed that the Company is the sole and exclusive owner of the unique polymer formulation that was developed for FC2.

Global Market Potential

The first clinical evidence of AIDS was noted more than thirty years ago. Since then, HIV/AIDS has become the most devastating pandemic in recorded history facing humankind. In November 2009, WHO released statistics indicating that on a world-wide basis, HIV/AIDS is now the leading cause of death in women aged 15 to 44 years old. More than 50% of all new adult cases of HIV/AIDS are now women. According to a May 2010 article in Clinical Infectious Diseases, heterosexual transmission accounts for more than 80% of all new HIV infections in women.
For sexually active couples, male condoms and the FC2 female condom are the only barrier method approved by FDA and cleared by WHO for preventing sexual transmission of HIV/AIDS. In recent years, scientists have sought to develop alternative means of preventing HIV/AIDS. A number of microbicides have failed. The most promising HIV/AIDS vaccine under development has also failed. Several recently released studies and two recently published studies hold promising leads for future approaches in the prevention of HIV/AIDS. The studies include the use of tenofovir and tenofovir in combination with other antiretrovirals. The studies show that under certain conditions and in certain populations use prior to exposure can prevent the transfer of HIV. The range of effectiveness in preventing HIV varied in the studies and none of the regimens were completely effective. Several of the studies included counseling and free male and female condoms. The regimens studied while early in development are promising. UNAIDS and WHO recently recommended that individuals receiving these drugs for prevention should concurrently use male and female condoms, in addition to the test product. To date, it is clear that condoms, (male and female), continue to play a key role in the prevention of STIs, including HIV/AIDS. The Company’s FC2 female condom is the only product that, when used consistently and correctly, gives a woman control over her sexual health by providing dual protection against STIs (including HIV/AIDS) and unintended pregnancy.

To date, it is clear that condoms (male and female) continue to play a key role in the prevention of STIs including HIV/AIDS. The Company’s FC2 female condom is the only product that, when used consistently and correctly, gives a woman control over her sexual health by providing dual protection against sexually transmitted infections (including HIV/AIDS) and unintended pregnancy.

In the United States, the Centers for Disease Control and Prevention (CDC) continues to report that the HIV/AIDS epidemic is taking an increasing toll on women and girls. Women of color, particularly black women, have been especially hard hit. They comprise both the majority of new HIV and AIDS cases among women, and the majority of women living with the disease.

Most HIV/AIDS diagnoses among women in the U.S. are due to high-risk heterosexual contact (80% in 2005). The rate of new HIV infection for black women was approximately 15 times the rate for white women, while the new infection rate among Hispanic women was more than four times that of white women. In 2007, the AIDS diagnoses rate for black women in the United States was 22 times the rate for white women. In the United States, it is estimated that one in 30 black women will be diagnosed with HIV, compared to the one in 508 incidence rate amongst white women.

In March 2008, the CDC announced that a recent study indicated that 26% of female adolescents in the United States have at least one of the most common STIs. Led by the CDC's Sara Forhan, the study is the first to examine the combined national prevalence of common STIs among adolescent women in the United States.

In addition to overall STI prevalence, the study found that by race, African American teenage girls had the highest prevalence, with an overall prevalence of 48 percent compared to 20 percent among both whites and Mexican Americans. Overall, approximately half of all the teens in the study reported ever having sex. Among these girls, the STI prevalence was 40 percent.
In July 2010, President Barack Obama launched a new comprehensive strategy, with an emphasis on prevention, to curb the spread of HIV/AIDS in the United States. His policy builds on previous efforts and seeks to bind state, federal and private efforts. It aims, by 2015, to reduce the number of new infections by 25 percent, decrease the number of people living with HIV by 30% and increase the number of people aware of their positive status from 79% to 90%. Currently, the only products approved by the FDA and available to help achieve the prevention goal of reducing new infections by 25% are male and female condoms. “Reducing new HIV infections, improving care for people living with HIV/AIDS, narrowing health disparities - these are the central goals of our national strategy,” Obama said. The President also called for more private-public partnerships like the one between Washington, D.C., and the MAC AIDS fund to distribute free female condoms around the city.

The Condom Market

The global male condom market (public and private sector) is estimated to be $3 billion annually. The global public health sector market for male condoms is estimated to be greater than 10 billion units annually. Given the rapid spread of HIV/AIDS in India and China, UNAIDS estimates that the annual public health sector demand for condoms, both male and female, will reach 19 billion units within the next ten years.

The FC Female Condom and the Male Condom

Currently, there are only two FDA approved and marketed products that prevent the transmission of HIV/AIDS through sexual intercourse: the male condom and the FC2 female condom. The FC2 female condom is currently the only FDA approved, marketed product controlled by women that prevents STI’s including HIV/AIDS. Used consistently and correctly, it provides women dual protection against STI’s (including HIV/AIDS) and unintended pregnancy. The FC2 female condom does not compete with the male condom, but is an alternative to either unprotected sex or to male condom usage.

FC2’s primary raw material (a nitrile polymer) offers a number of benefits over natural rubber latex, the raw material that is most commonly used in male condoms. FC2’s nitrile polymer is stronger than latex, reducing the probability that the female condom sheath will tear during use. Unlike latex, FC2’s nitrile polymer quickly transfers heat. FC2 warms to body temperature immediately upon insertion which may enhance the user’s sensation and pleasure. Unlike the male condom, FC2 may be inserted in advance of arousal, eliminating disruption during sexual intimacy. FC2 does not require immediate withdrawal and is not tight or constricting. The FC2 female condom can be used with both oil and water-based lubricants, unlike natural rubber latex male condoms which can be used with water-based lubricants only. FC2 is also an alternative for latex sensitive users (7% to 20% of the population) who are unable to use male condoms without irritation. To the Company’s knowledge, there is no reported allergy to nitrile polymer.

Numerous clinical and behavioral studies have been conducted regarding use of the female condom. Studies show that the female condom is found acceptable by women and their partners in many cultures. Importantly, studies also show that when the female condom is made available with male condoms there is a significant increase in protected sex acts. The increase in protected sex acts varies by country and averages between 10% and 35%. 

21
Strategy

The Company’s strategy is to fully develop the global market for the FC2 female condoms. Since the introduction of its first generation product, FC1, the Company has developed contacts and relationships with global public health sector organizations such as WHO, UNFPA, USAID, United Nations Joint Programme on HIV/AIDS (UNAIDS), country-specific health ministries and non-governmental organizations (NGOs), and commercial partners in various countries. To assist with its customers’ prevention programs and provide technical product support, the Company has placed representatives in the major regions of the world: Asia, Africa, Europe, North America and Latin America. The Company’s first generation product, FC1, was produced from a costly raw material (polyurethane), in a labor intensive manufacturing process in a suburb of London, England. To expand women’s access to the female condom, increase volume, reduce cost, and significantly increase gross margin, the Company developed its second generation product, FC2. Because FC2 is a nitrile polymer product and less costly to produce, it was introduced at a price approximately 30% lower than the price at which FC1 had been selling. FC2 is currently being produced at the Company’s facility in Selangor D.E., Malaysia and in Kochi, India, in conjunction with FHC’s exclusive distributor in India, Hindustan Lifecare Limited (“HLL”). The Company made its first substantial sales of FC2 in the second quarter of fiscal 2007. Since the final shipment of FC1 in October 2009, all of the Company’s unit sales have been FC2.

With the product’s primary market currently being the public health sector, the Company incurs minimal sales and marketing expense. Thus, as the demand for the female condom continues to grow in the public health sector, the Company’s operating expenses are likely to grow at a much lower rate than that of volume.

Commercial Markets - Direct to Consumers

The Company has distribution agreements and other arrangements with commercial partners which market directly to consumers in 13 countries, including the United States, Brazil, Spain, France and India. These agreements are generally exclusive for a single country. Under these agreements, the Company sells the FC2 female condom to the distributor partners, who market and distribute the product to consumers in the established territory.

Relationships and Agreements with Public Health Sector Organizations

The Company’s customers are primarily large global agencies, governments and ministries of health which purchase and distribute the FC2 female condom for use in HIV/AIDS prevention programs. The Company offers uniform, volume-based pricing to such agencies, rather than entering into long-term supply agreements. In the United States, FC2 is sold to city and state public health clinics as well as not-for-profit organizations such as Planned Parenthood. FC2 is being distributed as part of New York City’s Female Condom Education and Distribution Project being conducted by the Bureau of HIV/AIDS Prevention and Control. In New York City, FC2 is currently available in 557 locations, including both community based organizations and the N.Y.C. Department of Health and Mental Hygiene units.

Other U.S. cities where city-specific launch programs are being conducted to encourage the use of FC2 include Washington D.C., Chicago, San Francisco, and Houston. Prevention programs including FC2 are being planned for additional U.S. cities including Atlanta, Philadelphia, Baton Rouge and Los Angeles.
Manufacturing Facilities

The Company leases 16,000 sq. ft. of production space in Selangor D.E., Malaysia for the production of FC2. Production capacity is approximately 75-80 million units annually.

The Company's India-based FC2 end-stage production capacity is located in the Cochin Special Export Zone at a facility owned by its exclusive distributor in India, HLL. Production began at that facility in December 2007 with an initial capacity of 7.5 million units per year.

FHC's total FC2 production capacity is approximately 80-85 million units annually. The Company intends to expand its capacity at existing locations and/or manufacture at additional locations as the demand for FC2 develops.

Government Regulation

In the U.S., FC2 is regulated by the FDA. Female condoms as a group were classified by the FDA as a Class III medical device in 1989. Class III medical devices are deemed by the FDA to carry potential risks with use which must be tested prior to FDA approval, referred to as Premarket Approval (PMA), for sale in the U.S. As FC2 is a Class III medical device, prior to selling FC2 in the U.S., the Company was required to submit a PMA application containing technical information on the use of FC2 such as pre-clinical and clinical safety and efficacy studies which were gathered together in a required format and content. FC2 received PMA as a Class III medical device from the FDA in March 2009.

FC2 received the CE Mark which allows it to be marketed throughout the European Union. FC2 has also been approved by regulatory authorities in Brazil, India and other jurisdictions.

The Company believes that FC2's PMA and FDA classification as a Class III medical device create a significant barrier to entry in the U.S. market. The Company estimates that it would take a minimum of four to six years to implement, execute and receive FDA approval of a PMA to market another type of female condom.

Pursuant to section 515(a)(3) of the Safe Medical Amendments Act of 1990 (the "SMA Act"), the FDA may temporarily suspend approval and initiate withdrawal of the PMA if the FDA finds that FC2 is unsafe or ineffective, or on the basis of new information with respect to the device, which, when evaluated together with information available at the time of approval, indicates a lack of reasonable assurance that the device is safe or effective under the conditions of use prescribed, recommended or suggested in the labeling. Failure to comply with the conditions of FDA approval invalidates the approval order. Commercial distribution of a device that is not in compliance with these conditions is a violation of the SMA Act. As an FDA approved medical device, the facilities in which FC2 is produced and tested are subject to periodic FDA inspection to ensure compliance with current Good Manufacturing Processes. The Company's most recent FDA inspection was completed in September 2010.

The FDA's approval order for FC2 includes conditions that relate to product labeling, including information on the package itself and instructions for use called a "package insert" which accompanies each product. The Company believes it is in compliance with the FDA approval order.
The Company believes there are no material issues or material costs associated with the Company's compliance with environmental laws related to the manufacture and distribution of FC1 and FC2.

**Competition**

The Company's FC2 female condom participates in the same market as male condoms and is viewed as additive in terms of prevention and choice. Male condoms cost less and have brand names that are more widely recognized than FC2. In addition, male condoms are generally manufactured and marketed by companies with significantly greater financial resources than the Company.

Other parties have developed and marketed female condoms. None of these female condoms marketed or under development by other parties have secured FDA approval or clearance by WHO for purchase by UN agencies. Some companies have attempted to market female condoms without FDA approval or WHO clearance. It is possible that another female condom may receive FDA approval or WHO clearance or may otherwise compete with the Company's FC2 female condom. These competing products could be manufactured, marketed and sold by companies with significantly greater financial resources than those of the Company.

**Patents and Trademarks**

FC2 patents have been issued by the United States, the European Union, Canada, Australia, South Africa, The People's Republic of China, Greece, Turkey, Spain, Mexico and Japan. Patent applications for FC2 are pending in various other countries around the world through the Patent Cooperation Treaty. There can be no assurance that these patent applications provide the Company with protection against copycat products entering markets during the pendency of the patents.

The Company has the registered trademark “FC2 Female Condom” in the United States. The Company has also secured, or applied for, 12 trademarks in 22 countries to protect the various names and symbols used in marketing the product around the world. These include “femidom” and “femy,” “Reality” and others. In addition, the experience that has been gained through years of manufacturing the FC female condoms (FC1 and FC2) has allowed the Company to develop trade secrets and know-how, including certain proprietary production technologies that further protect its competitive position.

**Overview**

The Company manufactures, markets and sells the FC2 female condom. FC2 is the only currently available product under a woman's control and approved by the FDA that provides dual protection against unintended pregnancy and STIs, including HIV/AIDS. In October 2009, the Company completed the transition from its first generation product, FC1, to its second generation product, FC2, and production of FC1 ceased. Although FC1 production has ceased, the Company retains its ownership of certain world-wide rights to FC1, as well as various patents, regulatory approvals and other intellectual property related to FC1.
During 2003, the Company began development of its second generation female condom, FC2, which was completed in 2005. In August, 2006, after a stringent technical review, WHO cleared FC2 for purchase by U.N. agencies. The first substantial sales of FC2 occurred in the second quarter of fiscal 2007. FC2 received FDA approval as a Class III medical device on March 10, 2009 and became available in the United States in August 2009. In addition to FDA approval, the FC2 female condom has been approved by other regulatory agencies, including the European Union, India, and Brazil. From its introduction in 2007 through June 30, 2011, approximately 98 million FC2 female condoms have been distributed in 120 countries. Since the last shipment of FC1 was sold in October 2009 all units sold have been FC2.

Revenues

Most of the Company’s revenues have been derived from sales of the FC female condoms (FC1 and FC2), and are recognized upon shipment of the product to its customers. Since fiscal 2008, revenue is also being derived from licensing its intellectual property to its exclusive distributor in India, HLL. HLL is authorized to manufacture FC2 at HLL’s facility in Kochi, India for sale in India. HLL is the Company’s exclusive distributor in India and the Company receives a royalty based on the number of units sold by HLL in India. Such revenue appears as royalties on the Consolidated Statements of Income for the three and nine months ended June 30, 2011 and 2010, and is recognized in the period in which the sale is made by HLL.

The Company’s strategy is to develop a global market and distribution network for its product by maintaining relationships with public health sector groups and completing partnership arrangements with companies with the necessary marketing and financial resources and local market expertise. The Company’s customers are primarily large global agencies, governments and ministries of health which purchase and distribute the FC2 female condom for use in HIV/AIDS prevention programs. The Company offers uniform, volume-based pricing to such agencies, rather than entering into long-term supply agreements. In the United States, FC2 is sold to city and state public health clinics as well as not-for-profit organizations such as Planned Parenthood.

The Company’s customer base consists of a limited number of buyers, many of whom purchase in large volumes. Significant quarter to quarter variations may occur due to the timing and shipment of large orders, not from any fundamental change in the Company’s business. During fiscal 2011, the Company’s unit shipments, revenues and net income have been adversely affected by bureaucratic delays and other timing issues involving the receipt and shipment of large orders from Brazil and the Republic of South Africa (RSA). In May 2011, it was announced that Brazil’s Ministry of Health awarded the Company’s distributor, Semina Indústria e Comércio, a tender for up to 20 million units. The tender is for the period ending March 31, 2012. To date, bureaucratic issues have delayed the receipt of orders under this tender. Earlier in 2011, the RSA issued a tender for up to 11 million units which the Company bid on through its RSA distributor. Administrative issues have delayed the award of this tender. The tender quantities described above reflect increasing demand for female condoms. The tender delays reflect the volatility of operating in high potential developing world markets.
The Company manufactures FC2 at its facility located in Selangor D.E., Malaysia. The Company's cost of sales consists primarily of direct material costs, direct labor costs and indirect production and distribution costs. Direct material costs include raw materials used to make FC2, principally a nitrile polymer. Indirect product costs include logistics, quality control and maintenance expenses, as well as costs for helium, nitrogen, electricity and other utilities. All of the key components for the manufacture of the FC2 female condom are essentially available from either multiple sources or multiple locations within a source.

On August 5, 2009, the Company announced to its U.K. employees that the Company was evaluating the future of its U.K. facility following the decision of two of its largest customers to switch their purchases from the first generation product, FC1, manufactured in the U.K. facility, to the second generation product, FC2, which is manufactured in Malaysia. As is required by British labor law, the Company went through an evaluation process, working in tandem with employee representatives, in which various manufacturing alternatives were considered. As the Company was unable to identify a satisfactory alternative, the facility’s manufacturing operations ceased in October 2009. During the nine months ended June 30, 2010, the Company incurred a one-time charge of $1.9 million for restructuring costs related to exiting the lease of its former U.K. manufacturing facility.

While FC1 production ceased in October 2009, the Company continues to conduct significant operating activities in the U.K. Such activities include global sales and marketing of the FC2 female condom, management and direction of Global Manufacturing Operations (including production planning, inventory management, quality assurance and quality control, finished goods release and compliance with good manufacturing practices), relationships with regulatory agencies world-wide, oversight of the Global Technical Support Team and new product development.
The Company had net revenues of $3,517,439 and net income of $416,667, or $0.01 per diluted share, for the three months ended June 30, 2011 compared to net revenues of $1,754,211 and net income of $75,159, or $0.00 per diluted share, for the three months ended June 30, 2010.

Net revenues increased $1,753,228, or 101%, on a 126% increase in unit volume for the three months ended June 30, 2011, compared with the same period last year. Unit sales and revenues for the third quarter of fiscal 2011 were more robust than during the same period last year when revenues were unusually weak. The FC2 average sales price per unit decreased 11% compared with the same period last year due to pricing mix.

Gross profit increased $874,238, or 93%, to $1,813,685 for the three months ended June 30, 2011 from $939,447 for the three months ended June 30, 2010. Gross profit for the three months ended June 30, 2011 was 52% of net revenues versus 54% for the same period last year, reflecting the impact of a one-time production cost that occurred during the period.

Significant quarter to quarter variations result from time to time due to the timing and shipment of large orders and production scheduling rather than from any fundamental changes in the business.

Cost of sales increased $888,990, or 109%, to $1,703,754 on a 126% increase in unit volume in the three months ended June 30, 2011 from $814,764 for the same period last year.

Advertising and promotion expenditures were $114,226 for the three months ended June 30, 2011 versus $38,029 for the same period last year. The increase in fiscal 2011 expenditures relate to the U.S. training program in which health care providers are equipped to educate their clients in the usage of the FC2 female condom.

Selling, general and administrative expenses increased $324,866, or 35%, to $1,246,890 for the three months ended June 30, 2011 from $922,024 for the three months ended June 30, 2010. The increase is primarily due to higher compensation-related expenses partially offset by reduced selling and marketing expenses and reduced consulting fees. The selling, general and administrative expenses in the three months ended June 30, 2010 were significantly reduced by the reversal of an incentive-related accrual.

Research and development costs were $2,068 versus zero spending in the same period last year.

Total operating expenses for the quarter ended June 30, 2011 were $1,363,184, an increase of $444,787, or 48%, from $918,397 in the same quarter in fiscal year 2010.

Operating income for the three months ended June 30, 2011, was $450,501 versus operating income of $21,050 in the same period last year, an increase of $429,451. The increase is due to the higher gross profit generated by higher unit sales in fiscal 2011 somewhat offset by higher operating expenses.
Interest, net and other expense for the three months ended June 30, 2011 was $546, a decrease of $11,112 from the same period in fiscal year 2010, when interest, net and other income was $10,566. The impact of foreign currency transactions for the third quarter of fiscal 2011 was a loss of $18,022 compared to a gain of $17,190 for the same period last year. Beginning October 1, 2009, both the Company’s U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currency and began to report their financial results in U.S. dollars. The subsidiaries’ adoption of the U.S. dollar as their functional currency reduces the Company’s exposure to foreign currency risk. Assets located outside the United States totaled approximately $6.5 million and $6.9 million at June 30, 2011 and 2010, respectively.

The Company's net income increased $341,508 to $416,667 in three months ended June 30, 2011 from a net income of $ 75,159 in the same period of the prior year, as a result of the factors discussed above. Net income was 11.8% and 4.3% of net revenues for the three months ended June 30, 2011 and June 30, 2010, respectively.

Under the guidance of ASC Topic 740, Accounting for Income Taxes, an entity is able to recognize a tax benefit for current or past losses when it can demonstrate that the tax loss carryforward will be utilized before expiration. Management believes that the Company's recent and projected future growth and profitability has made it more likely than not that the Company will utilize its net operating loss carryforwards in the future. The Company will evaluate at the end of each fiscal year and, if appropriate, record a tax benefit.

NINE MONTHS ENDED JUNE 30, 2011 COMPARED TO NINE MONTHS ENDED JUNE 30, 2010

The Company had net revenues of $11,456,052 and net income of $884,333, or $0.03 per diluted share, for the nine months ended June 30, 2011 compared to net revenues of $14,422,032 and net income of $1,221,341, or $0.04 per diluted share, for the nine months ended June 30, 2010. Fiscal 2011 revenues were adversely affected due to the continued delay in large orders from Brazil and RSA. The FC2 average sales price per unit increased 0.5% compared with the same period last year.

Gross profit decreased $2,684,495, or 32%, to $5,637,836 for the nine months ended June 30, 2011 from $8,322,331 for the nine months ended June 30, 2010. Gross profit, as a percentage of net revenues, was 49% for the nine months ended June 30, 2011, versus 58% for the nine months ended June 30, 2010. Gross profit was negatively impacted by lower unit sales and reduced overhead absorption rates.

Net revenues decreased $2,965,980, or 21%, for the nine months ended June 30, 2011 compared with the same period last year. Total unit volume decreased 17% over the same period last year.

Cost of sales decreased $281,485, or 5%, to $5,818,216 on a 17% decrease in unit volume for the nine months ended June 30, 2011 from $6,099,701 for the same period last year. The decrease in cost of sales reflects the lower unit sales in the period as compared to the same period in fiscal 2010.
Advertising and promotion expenditures increased $48,254, to $245,444 for the nine months ended June 30, 2011 from $197,190 for the same period in the prior year. The increase in expenditures is related to both the on-going U.S. training program designed to equip health care providers to educate their clients regarding FC2 female condom usage and a public relations campaign regarding the FC2 public sector launches in various U.S. cities.

Selling, general and administrative expenses decreased $514,998, or 10%, to $4,395,691 for the nine months ended June 30, 2011 from $4,910,689 for the nine months ended June 30, 2010. The decrease results from a decline in compensation-related expenses, lower sales and marketing costs, and reduced legal and consulting fees.

Research and development cost increased $10,548, to $10,929 for the nine months ended June 30, 2011 from $381 for the same period in the prior year.

Operating expenses for the nine months of fiscal 2011 decreased 34% to $4,652,064 compared to $7,034,704 for the nine months of fiscal 2010, which included $1,926,444 in one-time restructuring costs.

The Company's operating income decreased $301,855, to $985,772 in the nine months ended June 30, 2011 from $1,287,627 in the same period of the prior year. The reduction in operating income reflects the reduced profitability due to lower units sales somewhat offset by significantly reduced operating expenses.

Interest, net and other expense for the nine months ended June 30, 2011 was $2,922, a decrease of $30,826 from the same period in fiscal year 2010, when interest, net and other income was $27,904. The impact of foreign currency transactions for the nine months ended June 30, 2011 was a loss of $74,251 compared to a loss of $62,259 for the same period last year. Beginning October 1, 2009, both the Company’s U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currency and began to report their financial results in U.S. dollars. The subsidiaries' adoption of the U.S. dollar as their functional currency reduces the Company's exposure to foreign currency risk.

The Company's net income decreased $337,008, to $884,333 in the nine months ended June 30, 2011 from $1,221,341 in the same period of the prior year, as a result of the factors discussed above.

Factors That May Affect Operating Results and Financial Condition

The Company's future operating results and financial condition are dependent on the Company's ability to increase demand for the FC2 female condom and to cost-effectively manufacture it in sufficient quantities to meet demand. Inherent in this process are a number of factors that the Company must successfully manage in order to achieve favorable future results and improve its financial condition.

Reliance on a Single Product

The Company expects to derive the vast majority, if not all, of its future revenues from the FC2 female condom, its sole current product. While management believes the global potential for the FC2 female condom is significant, the ultimate level of consumer demand around the world is not yet known.
Distribution Network

The Company's strategy is to develop a global distribution network for FC2 by entering into partnership arrangements with financially secure companies with appropriate marketing expertise. This strategy has resulted in distribution in 120 countries, including numerous in-country distributions in the public health sector, particularly in Africa, Latin America and India. The Company has also entered into several partnership agreements for the commercialization of the FC2 female condoms in consumer sector markets around the world. However, the Company is dependent on country governments, global donors, as well as U.S. municipal and state public health departments to continue AIDS/HIV/STI prevention programs that include FC2 as a component of such programs. The Company’s commercial market penetration is dependent on its ability to identify appropriate business partners who will effectively market and distribute FC2 within its contractual territory. Failure by the Company's partners to successfully market and distribute the FC2 female condom or failure of donors and/or country governments to establish and sustain HIV/AIDS prevention programs which include distribution of female condoms, the Company's inability to secure additional agreements with global AIDS prevention organizations, or the Company’s inability to secure agreements in new markets, either in the public or private sectors, could adversely affect the Company’s financial condition and results of operations.

Inventory and Supply

All of the key components for the manufacture of the FC2 female condom are essentially available from either multiple sources or multiple locations within a source.

Global Market and Foreign Currency Risks

The Company manufactures FC2 in a leased facility located in Malaysia. Although a material portion of the Company's future sales are likely to be in foreign markets, FC2 sales are denominated in U.S. dollars only. Manufacturing costs are subject to normal currency risks associated with changes in the exchange rate of the Malaysian ringgit relative to the United States dollar.

Government Regulation

The FC2 female condoms are subject to regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act (the "FDC Act"), and by other state and foreign regulatory agencies. Under the FDC Act, medical devices must receive FDA clearance before they can be sold. FDA regulations also require the Company to adhere to certain current "Good Manufacturing Practices," which include testing, quality control and documentation procedures. The Company's compliance with applicable regulatory requirements is monitored through periodic inspections by the FDA. The failure to comply with applicable regulations may result in fines, delays or suspensions of clearances, seizures or recalls of products, operating restrictions, withdrawal of FDA approval and criminal prosecutions. The Company's operating results and financial condition could be materially adversely affected in the event of a withdrawal of approval from the FDA.
The Company’s operations generated positive cash flow of $4.6 million in the nine months ended June 30, 2011 compared with $3.4 million in the nine months ended June 30, 2010. During the nine months ended June 30, 2011, the Company paid cash dividends of $4.2 million.

Accounts receivable decreased from $4.5 million at September 30, 2010 to $1.3 million at June 30, 2011. The reduction is the result of the timing of large orders. The Company’s credit terms vary from 30 to 90 days, depending on the class of trade and customary terms within a territory, so the accounts receivable balance is also impacted by the mix of purchasers within the quarter. As is typical in the Company’s business, extended credit terms may occasionally be offered as a sales promotion. For the past twelve months, the Company’s average days sales outstanding has been approximately 54 days. Over the past five years, the Company’s bad debt expense has been less than .01% of product sales.

During fiscal 2010, the Company commenced paying quarterly cash dividends. The Company’s Board of Directors has declared and paid six consecutive quarterly cash dividends of $0.05 per share since January, 2010. The Company paid cash dividends of $4.2 and $2.7 million during the nine months ended June 30, 2011 and June 30, 2010, respectively. On July 14, 2011, the Company’s Board of directors declared a quarterly cash dividend of $0.05 per share. The Company will pay, from its cash on hand, approximately $1.4 million pursuant to the dividend on August 9, 2011 to stockholders of record as of August 2, 2011. Any future quarterly dividends and the record date for such dividends will be approved each quarter by the Company’s Board of Directors and announced by the Company. Payment of future dividends is in the discretion of the Board of Directors and the Company may not have sufficient cash flows to continue to pay dividends.

At June 30, 2011, the Company had working capital of $7.6 million and stockholders’ equity of $13.5 million compared to working capital of $8.6 million and stockholders’ equity of $12.1 million as of June 30, 2010.

The Company believes its current cash position is adequate to fund operations of the Company in the next 12 months, although no assurances can be made that such cash will be adequate. However, the Company may sell equity securities to raise additional capital and may borrow funds under its Heartland Bank credit facility.

On August 1, 2011, the Company entered into a Second Amended and Restated Loan Agreement (the “Loan Agreement”) with Heartland Bank (the “Bank”) to expend the term of the Company’s revolving line of credit to August 1, 2012 and revise the structure of the line of credit. The previous structure consisted of a revolving note for up to $1,000,000 with borrowings limited to 50% of eligible accounts receivable and a revolving note for up to $1,000,000 with borrowings limited to the amount of a supporting letter of credit issued by The World Bank or another issuer of equivalent credit quality approved by the Bank. The new structure consists of a single revolving note for up to $2,000,000 with the Bank, with borrowings limited to a borrowing base determined based on 70% or 80% of eligible accounts receivable plus 50% of eligible inventory. Significant restrictive covenants in the Loan Agreement include prohibitions on any merger, consolidation or sale of all or a substantial portion of the Company’s assets and limits on the payment of dividends or the repurchase of shares. The Loan Agreement does not contain any financial covenants that require compliance with ratios or amounts. Dividends and share repurchases are permitted as long as after giving effect to the dividend or share repurchase the Company has a ratio of total liabilities to total stockholders’ equity of no more than 1:1. The revolving note with the Bank will expire August 1, 2012. Borrowings on the revolving note bear interest at a rate of the base rate plus 0.5%. The note is collateralized by substantially all of the assets of the Company. No amounts were outstanding under the previous revolving notes at June 30, 2011, and September 30, 2010.
Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company's exposure to market risk is limited to fluctuations in raw material commodity prices, particularly the nitrile polymer used to manufacture FC2, and foreign currency exchange rate risk associated with the Company's foreign operations. The Company does not utilize financial instruments for trading purposes or to hedge risk and holds no derivative financial instruments which would expose it to significant market risk. Effective October 1, 2009, the Company's U.K. subsidiary and Malaysia subsidiary each adopted the U.S. dollar as its functional currency. The consistent use of the U.S. dollar as the functional currency across the Company reduces its foreign currency risk and stabilizes its operating results. The Company currently has no significant exposure to interest rate risk. The Company has a line of credit with Heartland Bank, consisting of a revolving note for up to $2,000,000 with borrowings limited to a percentage of eligible accounts receivable and eligible inventory. Outstanding borrowings under the line of credit will incur interest at a rate equal to a base rate plus 0.5%. The Company has not had any outstanding borrowings in last five years. There is, therefore, currently no significant exposure to market risk for changes in interest rates. To the extent that the Company incurs future borrowings under its lines of credit, it would be subject to interest rate risk related to such borrowings.

Item 4. Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective. It should be noted that in designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The Company has designed its disclosure controls and procedures to reach a level of reasonable assurance of achieving desired control objectives and, based on the evaluation described above, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective at reaching that level of reasonable assurance.

There was no change in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934, as amended) during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
Item 5. Other Information

Disclosure is included in this Form 10-Q with respect to the following item of Form 8-K for an event that occurred on August 1, 2011:

Item 1.01. Entry into a Material Definitive Agreement – On August 1, 2011, the Company entered into a Second Amended and Restated Loan Agreement (the "Loan Agreement") with Heartland Bank (the "Bank") to extend the term of the Company's revolving line of credit to August 1, 2012 and revise the structure of the line of credit. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Sources of Capital” for a summary of the material terms and conditions of the Loan Agreement. The description of the Loan Agreement in this report does not purport to be complete and is qualified in its entirety by the terms and conditions of the Loan Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Amended and Restated Articles of Incorporation. (1)</td>
</tr>
<tr>
<td>3.2</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company increasing the number of authorized shares of common stock to 27,000,000 shares. (2)</td>
</tr>
<tr>
<td>3.3</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company increasing the number of authorized shares of common stock to 35,500,000 shares. (3)</td>
</tr>
<tr>
<td>3.4</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company increasing the number of authorized shares of common stock to 38,500,000 shares. (4)</td>
</tr>
<tr>
<td>3.5</td>
<td>Amended and Restated By-Laws. (5)</td>
</tr>
<tr>
<td>4.1</td>
<td>Amended and Restated Articles of Incorporation (same as Exhibit 3.1).</td>
</tr>
<tr>
<td>4.2</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company (same as Exhibit 3.2).</td>
</tr>
<tr>
<td>4.3</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company increasing the number of authorized shares of common stock to 35,500,000 shares (same as Exhibit 3.3).</td>
</tr>
<tr>
<td>4.4</td>
<td>Articles of Amendment to the Amended and Restated Articles of Incorporation of the Company increasing the number of authorized shares of common stock to 38,500,000 shares (same as Exhibit 3.4).</td>
</tr>
<tr>
<td>4.5</td>
<td>Articles II, VII and XI of the Amended and Restated By-Laws (included in Exhibit 3.5).</td>
</tr>
<tr>
<td>10.1</td>
<td>Second Amended and Restated Loan Agreement, dated as of August 1, 2011, between the Company and Heartland Bank.</td>
</tr>
<tr>
<td>10.2</td>
<td>Form of Promissory Note for up to $2,000,000 from the Company to Heartland Bank.</td>
</tr>
<tr>
<td>10.3</td>
<td>Second Amendment to Commercial Security Agreement, dated as of August 1, 2011, between the Company and Heartland Bank.</td>
</tr>
<tr>
<td>31.1</td>
<td>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</td>
</tr>
<tr>
<td>31.2</td>
<td>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</td>
</tr>
</tbody>
</table>
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act of 2002). (6)

The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, formatted in XBRL (Extensible Business Reporting Language): (1) the Unaudited Condensed Consolidated Balance Sheets, (2) the Unaudited Condensed Consolidated Statements of Income, (3) the Unaudited Condensed Consolidated Statements of Cash Flows and (4) the Notes to the Unaudited Condensed Consolidated Financial Statements.

(1) Incorporated herein by reference to the Company's Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on October 19, 1999.

(2) Incorporated by reference to the Company's Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on September 21, 2000.

(3) Incorporated by reference to the Company's Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on September 6, 2002.


(5) Incorporated herein by reference to the Company's Registration Statement on Form S-18, as filed with the securities and Exchange Commission on May 25, 1990.

(6) This certification is not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

THE FEMALE HEALTH COMPANY

DATE: August 5, 2011

/s/ O.B. Parrish
O.B. Parrish, Chairman and
Chief Executive Officer

DATE: August 5, 2011

/s/ Donna Felch
Donna Felch, Vice President and Chief
Financial Officer
SECOND AMENDED AND RESTATED
LOAN AGREEMENT

$2,000,000

By and Between

THE FEMALE HEALTH COMPANY

as Borrower

and

HEARTLAND BANK

as Lender

Dated as of August 1, 2011
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>ARTICLE 1 - DEFINITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 1.1 Definitions</td>
</tr>
<tr>
<td>Section 1.2 Other Provisions</td>
</tr>
<tr>
<td>Section 1.3 Exhibits and Schedules</td>
</tr>
</tbody>
</table>

| ARTICLE 2 - CREDIT FACILITY | 10 |
|-----------------------------|
| Section 2.1 Loan | 8 |
| Section 2.2 Repayment of Loan | 8 |
| Section 2.3 Note | 8 |

| ARTICLE 3 - GENERAL LOAN PROVISIONS | 10 |
|-----------------------------------|
| Section 3.1 Interest | 10 |
| Section 3.2 Increased Costs and Reduced Returns | 11 |
| Section 3.3 Manner of Payment | 11 |
| Section 3.4 Payments; Fees | 12 |
| Section 3.5 Collateral | 13 |

| ARTICLE 4 - CONDITIONS PRECEDENT | 13 |
|----------------------------------|
| Section 4.1 Conditions Precedent to the Loan | 13 |
| Section 4.2 Conditions Precedent to Subsequent Loan Advances | 14 |
| Section 4.3 Conditions Precedent to UNFPA as an Eligible Receivable | 15 |

| ARTICLE 5 - REPRESENTATIONS AND WARRANTIES OF BORROWER | 15 |
|--------------------------------------------------------|
| Section 5.1 Representations and Warranties | 15 |
| Section 5.2 Survival of Representations and Warranties, Etc. | 18 |

| ARTICLE 6 - AFFIRMATIVE COVENANTS | 18 |
|-----------------------------------|
| Section 6.1 Preservation of Corporate Existence and Similar Matters | 18 |
| Section 6.2 Compliance with Applicable Law | 18 |
| Section 6.3 Payment of Taxes and Claims | 18 |
| Section 6.4 Accounting Methods and Financial Records | 18 |
| Section 6.5 Restrictions on Use of Proceeds | 18 |
| Section 6.6 Hazardous Waste and Substances; Environmental Requirements | 19 |
| Section 6.7 Accuracy of Information | 19 |
| Section 6.8 Revisions or Updates to Schedules | 19 |
| Section 6.9 Conduct of Business | 19 |
| Section 6.10 Insurance | 19 |
| Section 6.11 Change of Management | 19 |

<p>| ARTICLE 7 - INFORMATION | 19 |
|-------------------------|
| Section 7.1 Financial Statements; Borrowing Base Certificate; Compliance Certificate | 19 |
| Section 7.2 Copies of Other Reports | 20 |
| Section 7.3 Notice of Litigation and Other Matters | 20 |
| Section 7.4 ERISA | 21 |</p>
<table>
<thead>
<tr>
<th>ARTICLE 8 - NEGATIVE COVENANTS</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 8.1</td>
<td>Merger, Consolidation and Sale of Assets</td>
</tr>
<tr>
<td>Section 8.2</td>
<td>Transactions with Affiliates</td>
</tr>
<tr>
<td>Section 8.3</td>
<td>Protection of Lender’s Rights</td>
</tr>
<tr>
<td>Section 8.4</td>
<td>Dividends/Distributions/Payments</td>
</tr>
<tr>
<td>Section 8.5</td>
<td>Borrower’s United Kingdom Subsidiaries</td>
</tr>
<tr>
<td>Section 8.6</td>
<td>Reserved</td>
</tr>
<tr>
<td>Section 8.7</td>
<td>Reserved</td>
</tr>
<tr>
<td>Section 8.8</td>
<td>Liens</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARTICLE 9 - DEFAULT</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 9.1</td>
<td>Events of Default</td>
</tr>
<tr>
<td>Section 9.2</td>
<td>Remedies</td>
</tr>
<tr>
<td>Section 9.3</td>
<td>Application of Proceeds</td>
</tr>
<tr>
<td>Section 9.4</td>
<td>Miscellaneous Provisions Concerning Remedies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ARTICLE 10 - MISCELLANEOUS</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 10.1</td>
<td>Notices</td>
</tr>
<tr>
<td>Section 10.2</td>
<td>Expenses</td>
</tr>
<tr>
<td>Section 10.3</td>
<td>Stamp and Other Taxes</td>
</tr>
<tr>
<td>Section 10.4</td>
<td>Setoff</td>
</tr>
<tr>
<td>Section 10.5</td>
<td>Dispute Resolution</td>
</tr>
<tr>
<td>Section 10.6</td>
<td>Reversal of Payments</td>
</tr>
<tr>
<td>Section 10.7</td>
<td>Injunctive Relief</td>
</tr>
<tr>
<td>Section 10.8</td>
<td>Accounting Matters</td>
</tr>
<tr>
<td>Section 10.9</td>
<td>Assignment; Participation</td>
</tr>
<tr>
<td>Section 10.10</td>
<td>Amendments</td>
</tr>
<tr>
<td>Section 10.11</td>
<td>Performance of Borrower’s Duties</td>
</tr>
<tr>
<td>Section 10.12</td>
<td>Indemnification</td>
</tr>
<tr>
<td>Section 10.13</td>
<td>All Powers Coupled with Interest</td>
</tr>
<tr>
<td>Section 10.14</td>
<td>Survival</td>
</tr>
<tr>
<td>Section 10.15</td>
<td>Severability of Provisions</td>
</tr>
<tr>
<td>Section 10.16</td>
<td>Governing Law</td>
</tr>
<tr>
<td>Section 10.17</td>
<td>Counterparts</td>
</tr>
<tr>
<td>Section 10.18</td>
<td>Final Agreement</td>
</tr>
<tr>
<td>Section 10.19</td>
<td>Purchase of Insurance</td>
</tr>
<tr>
<td>Section 10.20</td>
<td>Oral Agreements</td>
</tr>
</tbody>
</table>

EXHIBIT A | 32 |
EXHIBIT B | 42 |
EXHIBIT C | 44 |
SCHEDULE 5.1(m) | 45 |
SCHEDULE 5.1(p) | 46 |
SCHEDULE 5.1(r) | 47 |
SECOND AMENDED AND RESTATED
LOAN AGREEMENT

THIS SECOND AMENDED AND RESTATED LOAN AGREEMENT (this “Agreement”) is entered into as of this 1st day of August, 2011 by and between THE FEMALE HEALTH COMPANY, a Wisconsin corporation (“Borrower”) and HEARTLAND BANK, a federal savings bank (the “Lender”);

WITNESSETH:

WHEREAS, the Borrower has existing revolving credit facilities with Lender (collectively, the “Existing Loan”), pursuant to an Amended and Restated Loan Agreement dated as of July 20, 2004 between Borrower and Lender, as amended by the First Amendment to Amended and Restated Loan Agreement dated November 1, 2004, as further amended by the Second Amendment to Amended and Restated Loan Agreement dated July 1, 2005, as further amended by the Third Amendment to Amended and Restated Loan Agreement dated July 1, 2006, as further amended by the Fourth Amendment to Amended and Restated Loan Agreement dated July 1, 2007, as further amended by the Fifth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2008, as further amended by the Sixth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2009, as further amended by the Seventh Amendment to Amended and Restated Loan Agreement dated as of January 4, 2010, and as further amended by the Eighth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2010 (as so amended, the “Original Loan Agreement”);

WHEREAS, Borrower and Lender now desire to amend and restate in its entirety the Original Loan Agreement pursuant to the terms and conditions of this Agreement, in order to modify certain terms and conditions of the Existing Loan, including, but not limited to, an extension of the maturity date;

NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants, and agreements herein contained, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto represent and agree as follows:

ARTICLE 1 - DEFINITIONS

Section 1.1 Definitions. For the purposes of this Agreement:

“Affiliate” means, with respect to a Person, (a) any officer, director, employee, member or managing agent of such Person, (b) any spouse, parents, brothers, sisters, children and grandchildren of such Person, (c) any association, partnership, trust, entity or enterprise in which such Person is a director, officer or general partner, (d) any other Person that, (i) directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such given Person, (ii) directly or indirectly beneficially owns or holds 5% or more of any class of voting stock or partnership membership or other interest of such Person or any Subsidiary of such Person, or (iii) 5% or more of the voting stock or partnership membership or other interest of which is directly or indirectly beneficially owned or held by such Person or a Subsidiary of such Person. The term “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other interests, by contract or otherwise.

“Agreement” means this Agreement, including the Exhibits and Schedules hereto, and all amendments, modifications and supplements hereto and thereto and restatements hereof and thereof.

“Agreement Date” means the date as of which this Agreement is dated.

1
“Benefit Plan” means an employee benefit plan as defined in Section 3(35) of ERISA (other than a Multiemployer Plan) in respect of which a Person or any Related Company is, or within the immediately preceding 6 years was, an “employer” as defined in Section 3(5) of ERISA, including such plans as may be established after the Agreement Date.

“Borrower” means The Female Health Company, a Wisconsin corporation and its successors and assigns.

“Borrowing Base” means at any time an amount equal to the sum of:

(a) 80% of the face value of Eligible Receivables due and owing at such time, except for the Semina Eligible Receivables, if any, of which only 70% of the face value due and owing at such time may be included; plus

(b) 50% of the lesser of (i) cost (computed on a basis of standard cost) and (ii) fair market value of Eligible Inventory

“Borrowing Base Certificate” means the certificate delivered by the Borrower in accordance with Section 7.1(c) in the form of Exhibit B attached.

“Borrowing Officer” means each individual of Borrower who is duly authorized by Borrower to submit a request for a Loan Advance.

“Business Day” means any day other than a Saturday, Sunday or other day on which banks in St. Louis, Missouri are authorized to close.

“Code” means the Internal Revenue Code of 1986, as amended from time to time.

“Compliance Certificate” means the certificate in the form of Exhibit C attached, and shall contain statements by the signing officer to the effect that, except as explained in reasonable detail in such Compliance Certificate, (i) the attached Financial Statements are complete and correct in all material respects and have been prepared in accordance with GAAP applied consistently throughout the periods covered thereby and with prior periods (except as disclosed therein), (ii) all of the representations and warranties of Borrower contained in this Agreement and other Loan Documents are true and correct in all material respects as of the date such certification is given as if made on such date (other than representations and warranties, which, by their terms, are applicable only to the Agreement Date or other specified date, which shall be true and correct only as of that date) and, (iii) there exists no Default or Event of Default which is continuing that has not been cured by Borrower or waived in writing by Lender, and (iv) shall set forth the current Leverage Ratio of Borrower. If any Compliance Certificate discloses that a representation or warranty is not true and correct in any material respect, or that a Default or Event of Default has occurred that has not been cured by Borrower or waived in writing by Lender, such Compliance Certificate shall set forth what action Borrower has taken or proposes to take with respect thereto.

“Default” means any of the events specified in Section 9.1 that, with the passage of time or giving of notice or both, would constitute an Event of Default.

“Default Rate” means the annual rate described in Section 3.1(b).

“Dollar” and “$” means freely transferable United States dollars.
“EDGAR” means the Electronic Data Gathering, Analysis, and Retrieval system established by the U.S. Securities and Exchange Commission (“SEC”).

“Effective Date” means the later of (a) the Agreement Date, and (b) the first date on which all of the conditions set forth in Section 4.1 shall have been fulfilled by Borrower or waived by the Lender.

“Effective Interest Rate” means the rate of interest per annum on the Loan in effect from time to time pursuant to the provisions of Section 3.1.

“Eligible Inventory” means items of Inventory of the Borrower held for sale in the ordinary course of the business of the Borrower which are deemed by the Lender in the exercise of its sole and absolute discretion to be eligible for inclusion in the calculation of the Borrowing Base. Unless otherwise approved in writing by the Lender, no Inventory shall be deemed to be Eligible Inventory unless it meets all of the following requirements: (a) such Inventory is owned by the Borrower, is subject to the Security Interest, which is perfected as to such Inventory, and is subject to no other Lien whatsoever other than a Permitted Lien; (b) such Inventory is in good condition and meets, in all material respects, all standards applicable to such goods, their use or sale imposed by any governmental agency, or department or division thereof, having regulatory authority over such matters; (c) such Inventory is currently either usable or saleable, at prices approximating at least the cost thereof, in the normal course of the Borrower’s business; (d) such Inventory is not obsolete or repossessed goods taken in trade; (e) such Inventory is located at one of the locations listed in Schedule 5.1(m) or leased or owned by Borrower and disclosed to Lender; and (f) such Inventory is in the possession and control of the Borrower and not any third party, or, if located in a warehouse or other facility leased by the Borrower, the warehouseman or lessor has delivered to the Lender a waiver and consent in form and substance satisfactory to the Lender. If Borrower includes certain Inventory in the Borrowing Base that meets the requirements of (a) – (f) above that Lender in its sole discretion determines is not eligible for inclusion in the calculation of the Borrowing Base, Lender agrees to promptly provide notice to Borrower of such exclusion.

“Eligible Receivable” means, collectively, all Receivables of Borrower other than the following: (i) Receivables payable by any account debtor that is located outside of the United States of America or payable in any currency other than the currency of the United States of America provided, however, that Semina Industria e Comercio shall not be excluded by virtue of this sub-clause (i) (“Semina”); (ii) Receivables which remain unpaid ninety (90) or more days past the due date; (iii) Receivables with respect to which the account debtor is an Affiliate of Borrower; (iv) Receivables with respect to which the account debtor is the United States of America or any department, agency, instrumentality thereto unless filings in accordance with the U.S. Claims Act have been completed and filed, acknowledged and processed in a manner satisfactory to Lender; (v) Receivables with respect to goods that have been rejected as unsatisfactory by the account debtor; (vi) Receivables which are not invoiced (and dated as of the date of such invoice) and sent to the account debtor within 30 days after delivery of the underlying goods to or performance of the underlying services for the account debtor; (vii) Receivables with respect to which Lender does not have a first and valid, fully perfected security interest; (viii) Receivables with respect to which the account debtor is the subject of bankruptcy or a similar insolvency proceeding or has made an assignment for the benefit of creditors or whose assets have been conveyed to a receiver or trustee; (ix) Receivables with respect to which the account debtor’s obligation to pay the Receivable is conditional upon the account debtor’s approval or is otherwise subject to any repurchase obligation or return right, as with sales made on a bill-and-hold, guarantied sale, sale-and-return, sale on approval (except with respect to Receivables in connection with which account debtors are entitled to return inventory solely on the basis of the quality of such inventory) or consignment basis; (x) Receivables owing by any supplier to Borrower and subject to offset against trade accounts payable owing to such account debtor to the extent of such offset; (xi) Receivables owing by a single account debtor to the extent the Receivables cause the Eligible Receivables owing from such account debtor to be in excess of 20% of all of the Eligible Receivables; (xii) Receivables generated from COD accounts, cash or miscellaneous accounts, accounts on credit hold, and for finance charges or service charges (xiii) Receivables consisting of retainage or retention, (xiv) Receivables consisting of debit memos or chargebacks, and (xv) any Receivable of an account debtor with respect to particular goods still in the possession of Borrower or included in inventory against which the account debtor has filed a financing statement under the UCC or has obtained or purported to have obtained a Lien or security interest. If a previously scheduled Eligible Receivable ceases to be an Eligible Receivable under the above criteria, Borrower shall notify Lender thereof (which notice obligation will be satisfied by the submission of accurate Borrowing Base Certificates as required hereinafter).
Eligible Receivable shall also include those Receivables of Borrower’s wholly owned second-tier subsidiary, The Female Health Company (UK) PLC, payable by the United Nations Population Fund (“UNFPA”), provided such Receivables are not excluded by any of the foregoing criteria for exclusion except for sub-clause (vii).

“Environmental Laws” means all federal, state, local and foreign laws now or hereafter in effect relating to pollution or protection of the environment, including laws relating to emissions, discharges, releases or threatened releases of pollutants, contaminants, chemicals or industrial, toxic or hazardous substances or wastes into the environment (including, without limitation, ambient air, surface water, ground water or land) or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, removal, transport or handling of pollutants, contaminants, chemicals or industrial, toxic or hazardous substances or wastes, and any and all regulations, notices or demand letters issued, entered, promulgated or approved thereunder.

“ERISA” means the Employee Retirement Income Security Act of 1974, as in effect from time to time, and any successor statute.

“Event of Default” means any of the events specified in Section 9.1.

“Financing Statements” means the Uniform Commercial Code financing statements naming the Lender as secured party and Borrower as debtor, in connection with the perfection of the security interests granted by this Agreement or the Security Agreement.

“GAAP” means generally accepted accounting principles in the United States consistently applied and maintained throughout the period indicated and consistent with the prior financial practice of the Person referred to.

“Governmental Approvals” means all authorizations, consents, approvals, licenses and exemptions of, registrations and filings with, and reports to, all governmental bodies, whether federal, state, local, foreign national or provincial, and all agencies thereof.

“Governmental Authority” means any government or political subdivision or any agency, authority, bureau, central bank, commission, department or instrumentality of either, or any court, tribunal, grand jury or arbitrator, in each case whether foreign or domestic.

“Guaranty”, “Guaranteed” or to “Guarantee,” as applied to any obligation of another Person shall mean and include:
(a) a guaranty (other than by endorsement of negotiable instruments for collection in the ordinary course of business), directly or indirectly, in any manner, of any part or all of Such obligation of such other Person, and

(b) an agreement, direct or indirect, contingent or otherwise, and whether or not constituting a guaranty, the practical effect of which is to assure the payment or performance (or payment of damages in the event of nonperformance) of any part or all of such obligation of such other Person whether by (i) the purchase of securities or obligations, (ii) the purchase, sale or lease (as lessee or lessor) of property or the purchase or sale of services primarily for the purpose of enabling the obligor with respect to such obligation to make any payment or performance (or payment of damages in the event of nonperformance) of or on account of any part or all of such obligation or to assure the owner of such obligation against loss, (iii) the supplying of funds to, or in any other manner investing in, the obligor with respect to such obligation, (iv) repayment of amounts drawn down by beneficiaries of letters of credit, or (v) the supplying of funds to or investing in a Person on account of all or any part of such Person’s obligation under a guaranty of any obligation or indemnifying or holding harmless, in any way, such Person against any part or all of such obligation.

“Indebtedness” of any Person means, without duplication (a) all obligations for money borrowed or for the deferred purchase price of property or services (excluding trade payables incurred in the ordinary course of business) or in respect of reimbursement obligations under letters of credit, (b) all obligations represented by bonds, debentures, notes and accepted drafts that represent extensions of credit, (c) all obligations (including, during the noncancellable term of any lease in the nature of a title retention agreement, all future payment obligations under such lease discounted to their present value in accordance with GAAP) secured by any Lien to which any property or asset owned or held by such Person is subject, whether or not the obligation secured thereby shall have been assumed by such Person, (d) all obligations of other Persons which such Person has Guaranteed, including, but not limited to, all obligations of such Person consisting of recourse liability with respect to accounts receivable sold or otherwise disposed of by such Person, (e) the sum of all undrawn amounts and all drawings under any letters of credit for which the Person has reimbursement obligations, and (f) in the case of Borrower (without duplication), the Loan.

“Inventory” means and includes, as to any Person, all of such Person’s then owned or existing and future acquired or arising (a) finished goods intended for sale or lease or for display or demonstration, (b) work in process, (c) raw materials and other materials and supplies of every nature and description used or which might be used in connection with the manufacture, packing, shipping, advertising, selling, leasing or furnishing of goods or otherwise used or consumed in the conduct of business, and (d) documents evidencing and general intangibles relating to any of the foregoing.

“Lender” means Heartland Bank, a federal savings bank, and its successors and assigns.

“Lender’s Office” means the office of the Lender specified in or determined in accordance with the provisions of Section 10.1(c).

“Leverage Ratio” means the ratio of Borrower’s “Total Liabilities” to “Total Stockholders’ Equity”, as each of those terms is set forth or properly determined in the Borrower’s consolidated balance sheet for the most recently completed fiscal quarter contained in Borrower’s Form 10-Q report or 10-K report, as applicable, filed with the SEC, as prepared in accordance with GAAP, adjusted accordingly if any previous Permitted Distribution during the current fiscal quarter has decreased the amount of “Total Stockholders’ Equity”.

5
Liabilities" means all liabilities of a Person determined in accordance with GAAP and includable on a balance sheet of such Person prepared in accordance with GAAP.

"Lien" as applied to the property of any Person means: (a) any mortgage, deed to secure debt, deed of trust, lien, pledge, charge, lease constituting a capitalized lease obligation, conditional sale or other title retention agreement, or other security interest, security title or encumbrance of any kind in respect of any property of such Person or upon the income or profits therefrom, (b) any arrangement, express or implied, under which any property of such Person is transferred, sequestered or otherwise identified for the purpose of subjecting the same to the payment of Indebtedness or performance of any other obligation in priority to the payment of the general, unsecured creditors of such Person, (c) any Indebtedness which is unpaid more than 30 days after the same shall have become due and payable and which if unpaid might by law (including, but not limited to, bankruptcy and insolvency laws) or otherwise be given any priority whatsoever over general unsecured creditors of such Person, and (d) the filing of, or any agreement to give, any financing statement under the UCC or its equivalent in any jurisdiction, except a filing for precautionary purposes made with respect to a true lease or other true bailment.

"Loan" means, collectively, the loans made to Borrower pursuant to Section 2.1 and all extensions, renewals and modifications thereto.

"Loan Documents" means, collectively, this Agreement, the Note, the Security Agreement, the Pledge Agreement and each other instrument, agreement and document executed and delivered by Borrower in connection with this Agreement and each other instrument, agreement or document referred to herein or contemplated hereby.

"Material Adverse Effect" means any act, omission, event or undertaking which would, singly or in the aggregate, have a material adverse effect upon (a) the business, assets, properties, liabilities, condition (financial or otherwise), results of operations or business prospects of Borrower, (b) upon the ability of Borrower to perform any obligations under this Agreement or any other Loan Document to which it is a party, or (c) the legality, validity, binding effect, enforceability or admissibility into evidence of any Loan Document or the ability of Lender to enforce any rights or remedies under or in connection with any Loan Document; in any case, whether resulting from any single act, omission, situation, status, event, or undertaking, together with other such acts, omissions, situations, statuses, events, or undertakings.

"Maturity Date" means August 1, 2012.

"Maximum Available Amount" means the lesser of (a) the Borrowing Base and (b) $2,000,000.

"Multiemployer Plan" means a “multiemployer plan” as defined in Section 4001(a)(3) of ERISA to which Borrower or a Related Company is required to contribute or has contributed within the immediately preceding 6 years.

"Note" means the Promissory Note dated as of even date herewith executed by Borrower and payable to the order of Lender, the form of which is attached hereto and incorporated herein as Exhibit A, and any amendments, modifications, restatements, replacements, renewals or refinancings thereof.

"Obligations" means, in each case whether now in existence or hereafter arising, (a) the principal of and interest and premium, if any, on, and expenses related to, the Loan and (b) all Indebtedness, liabilities, obligations, overdrafts, covenants and duties of Borrower to the Lender of every kind, nature and description, direct or indirect, absolute or contingent, due or not due, contractual or tortious, liquidated or unliquidated, and whether or not evidenced by any note and whether or not for the payment of money, under or in respect of the Loan, this Agreement, the Note or any of the other Loan Documents.
“Obligor” means Borrower, and each other party at any time primarily or secondarily, directly or indirectly, liable on any of the Obligations, and any Subsidiary of Borrower.

“PBGC” means the Pension Benefit Guaranty Corporation or any successor agency.

“Permitted Distribution” means (a) any retirement, redemption, repurchase, or other acquisition for value by Borrower of any capital stock or other equity securities issued by Borrower, or (b) any declaration or payment of a dividend or distribution on or with respect to any shares of Borrower’s capital stock, as long as the payment of the proposed retirement, redemption, repurchase or other acquisition or the proposed dividend or distribution will not cause Borrower’s Leverage Ratio to exceed 1:1.

“Person” means an individual, corporation, partnership, association, trust or unincorporated organization or a government or any agency or political subdivision thereof.

“Pledge Agreement” means the pledge agreement executed by Borrower, whereby a first priority lien is granted to Lender upon sixty-five percent (65%) of the outstanding equity of its wholly owned first tier subsidiary, The Female Health Company Limited.

“Prime Rate” means the per annum rate of interest publicly announced by Lender at its principal office as its “prime rate” as in effect from time to time. Prime Rate is a reference used by Lender in determining interest rates on certain loans and is not intended to be the lowest rate of interest charged on any extension of credit to any debtor. Each change in the Prime Rate shall result in a concurrent change in the interest rate on the Loan for which interest is based upon the Prime Rate.

“Receivables” means and includes, as to any Person, all of such Person’s then owned or existing and future acquired or arising (a) rights to the payment of money or other forms of consideration of any kind (whether as accounts, contract rights, chattel paper, general intangibles, instruments, investment related property or otherwise) including, but not limited to, accounts receivable, letters of credit rights, tax refunds, insurance proceeds, notes, drafts, instruments, documents, acceptances and all other debts, obligations and liabilities in whatever form from any Person and guaranties, security and Liens securing payment thereof, (b) goods, whether now owned or hereafter acquired, and whether sold, delivered, undelivered, in transit or returned, which may be represented by, or the sale or lease of which may have given rise to, any such right to payment or other debt, obligation or liability, and (c) cash and non-cash proceeds of any of the foregoing.

“Related Company” means, as to any Person, any (a) corporation which is a member of the same controlled group of corporations (within the meaning of Section 414(b) of the Code) as such Person, (b) partnership or other trade or business (whether or not incorporated) under common control (within the meaning of Section 414(m) of the Code) with such Person, or (c) member of the same affiliated service group (within the meaning of Section 414(m) of the Code) as such Person or any corporation described in clause (a) above or any partnership, trade or business described in clause (b) above.

“Restricted Distribution” by any Person means (a) its retirement, redemption, purchase, or other acquisition for value of any capital stock or other equity securities or partnership interests issued by such Person, (b) the declaration or payment of any dividend or distribution on or with respect to any such securities or partnership interests, (c) any loan or advance by such Person to, or other investment by such Person in, the holder of any of such securities or partnership interests, and (d) any other payment by such Person in respect of such securities or partnership interests.
“Restricted Payment” means (a) any redemption, repurchase or prepayment or other retirement, prior to the stated maturity thereof or prior to the due date of any regularly scheduled installment or amortization payment with respect thereto, of any Indebtedness of a Person (other than the Obligations and trade debt), and (b) the payment by any Person of the principal amount of or interest on any Indebtedness (other than trade debt) owing to an Affiliate of such Person.

“Security Agreement” means, collectively, the security agreement to be executed by Borrower to the benefit of Lender, granting a security interest in all of the assets of Borrower to secure the obligations of Borrower under the Loan and any amendments thereto, together with the agreement of the Subsidiary of Borrower creating a lien upon the Receivables of such Subsidiary.

“Security Interest” means the Liens of the Lender on and in any collateral effected by the Security Agreement, or pursuant to the terms hereof or thereof.

“Subsidiary” means a Person of which an aggregate of 50% or more of the stock of any class or classes or 50% or more of membership or other ownership interests is owned of record or beneficially by such other Person or by one or more Subsidiaries of such other Person or by such other Person and one or more Subsidiaries of such Person, (i) if the holders of such stock or other ownership interests (A) are ordinarily, in the absence of contingencies, entitled to vote for the election of a majority of the directors (or other individuals performing similar functions) of such Person, even though the right so to vote has been suspended by the happening of such a contingency, or (B) are entitled, as such holders, to vote for the election of a majority of the directors (or individuals performing similar functions) of such Person, whether or not the right so to vote exists by reason of the happening of a contingency, or (ii) in the case of such other ownership interests, if such ownership interests constitute a majority voting interest.

“Termination Event” means (a) a “Reportable Event” as defined in Section 4043(b) of ERISA, but excluding any such event as to which the provision for 30 days’ notice to the PBGC is waived under applicable regulations, (b) the filing of a notice of intent to terminate a Benefit Plan or the treatment of a Benefit Plan amendment as a termination under Section 4041 of ERISA, or (c) the institution of proceedings to terminate a Benefit Plan by the PBGC under Section 4042 of ERISA or the appointment of a trustee to administer any Benefit Plan.

“UCC” means the Uniform Commercial Code as in effect from time to time in the State of Missouri.

“United Kingdom Subsidiaries” means The Female Health Company Limited, a first tier Subsidiary of Borrower, and The Female Health Company (UK) PLC, a second tier Subsidiary of Borrower.

“Unfunded Vested Accrued Benefits” means, with respect to any Benefit Plan at any time, the amount (if any) by which (a) the present value of all vested nonforfeitable benefits under such Benefit Plan exceeds (b) the fair market value of all Benefit Plan assets allocable to such benefits, as determined using such reasonable actuarial assumptions and methods as are specified in the Schedule B (Actuarial Information) to the most recent Annual Report (Form 5500) filed with respect to such Benefit Plan.

Section 1.2 Other Provisions.

(a) All terms in this Agreement, the Exhibits and Schedules hereto shall have the same defined meanings when used in any other Loan Documents, unless the context shall require otherwise.
(b) Except as otherwise expressly provided herein, all accounting terms not specifically defined or specified herein shall have the meanings generally attributed to such terms under GAAP including, without limitation, applicable statements and interpretations issued by the Financial Accounting Standards Board and bulletins, opinions, interpretations and statements issued by the American Institute of Certified Public Accountants or its committees.

(c) All personal pronouns used in this Agreement, whether used in the masculine, feminine or neuter gender, shall include all other genders; the singular shall include the plural, and the plural shall include the singular.

(d) The words “hereof”, “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provisions of this Agreement.

(e) Titles of Articles and Sections in this Agreement are for convenience only, do not constitute part of this Agreement and neither limit nor amplify the provisions of this Agreement, and all references in this Agreement to Articles, Sections, Subsections, paragraphs, clauses, subclauses, Schedules or Exhibits shall refer to the corresponding Article, Section, Subsection, paragraph, clause or subclause of, or Schedule or Exhibit attached to, this Agreement, unless specific reference is made to the articles, sections or other subdivisions or divisions of, or to schedules or exhibits to, another document or instrument.

(f) Each definition of a document in this Agreement shall include such document as amended, modified, supplemented or restated from time to time in accordance with the terms of this Agreement.

(g) Except where specifically restricted, reference to a party to a Loan Document includes that party and its successors and assigns permitted hereunder or under such Loan Document.

(h) Unless otherwise specifically stated, whenever a time is referred to in this Agreement or in any other Loan Document, such time shall be the local time in St. Louis, Missouri.

(i) Whenever the phrases “to the knowledge of Borrower,” or “known to,” or words of similar import relating to the knowledge of Borrower are used herein, such phrase shall mean and refer to the actual knowledge of the President, the chief financial officer or any officer or manager of the Borrower, or the knowledge that such Persons would have obtained if they had engaged in good faith in the diligent performance of their duties, including the making of such reasonable specific inquiries (excepting those situations and circumstances wherein a reasonably prudent person would not consider it appropriate to make any such inquiry) as may be necessary of the appropriate persons in a good faith attempt to ascertain the accuracy of the matter to which such phrase relates.

(j) The terms accounts, chattel paper, documents, equipment, instruments, general intangibles and inventory, as and when used (without being capitalized) in this Agreement or the Security Agreement, shall have the meanings given those terms in the UCC.

Section 1.3 Exhibits and Schedules. All Exhibits and Schedules attached hereto are by reference made a part hereof.
ARTICLE 2 - CREDIT FACILITY

Section 2.1 Loan. Upon the terms and subject to the conditions of, and in reliance upon the representations and warranties made under, this Agreement, the Lender has made or shall make loans to Borrower from time to time from the date hereof to the Maturity Date (each, a “Loan Advance”), as requested by Borrower in accordance with the terms of Section 2.1.2, in an aggregate principal amount outstanding not to exceed at any time $2,000,000.

2.1.1 Limitation on Loan Advances. Notwithstanding anything to the contrary contained herein, no Loan Advance shall be made if such advance would result in the aggregate amount of all Loan Advances to exceed the Maximum Available Amount. No Loan Advance will be made on or after the Maturity Date.

2.1.2 Loan Advance Borrowing Procedure. Subject to the limitations set forth herein, Borrower may request a Loan Advance by submitting a Loan Advance Request to Lender via mail or facsimile in the form of Exhibit A attached to the Note. Every such request for a Loan Advance shall be irrevocable. Only a request from a Borrowing Officer to Lender that specifies (i) the amount of the Loan Advance to be made and (ii) the date the proceeds of such Loan Advance is requested to be made available to Borrower (the “Loan Advance Date”) shall be treated as a “Loan Advance Request”. Each Loan Advance Request shall be written. Provided that all conditions precedent thereto hereunder have been met and all limitations thereto are in compliance. Lender will make the amount of each such requested advance available to Borrower in immediately available funds in Dollars at the Lender’s Office.

Section 2.2 Repayment of Loan. The Loan is due and payable and shall be repaid in full by the Borrower on the Maturity Date in the amount of the then unpaid balance of that Loan and all accrued and unpaid interest thereon.

Section 2.3 Note. The Loan and the obligation of Borrower to repay such Loan shall be evidenced by the Note, payable to the order of the Lender. The Note shall be dated the Effective Date and be duly and validly executed and delivered by Borrower.

Section 2.4 Prepayment of Loan.

(a) Voluntary Prepayments. Borrower shall have the right at any time and from time to time to wholly or partially repay the Loan at any time without premium or penalty. Any amount prepaid may, subject to compliance with the conditions and limitations herein, be re-borrowed.

(b) Mandatory Prepayments. If at any time the principal balance outstanding of the Loan exceeds the Maximum Available Amount, Borrower shall on demand make a payment to Lender in the amount of the excess. Each such prepayment shall be applied to reduce such Loan.

ARTICLE 3 - GENERAL LOAN PROVISIONS

Section 3.1 Interest.

(a) Interest Rate of Loan. The Loan shall bear interest at a per annum rate as described in the Note.
(b) Default Rate. From and after the occurrence of an Event of Default, the unpaid principal amount of each Obligation shall bear interest until paid in full (or, if earlier, until such Event of Default is cured or waived in writing by the Lender) at a rate per annum equal to four percent (4%) plus the rate otherwise in effect under Section 3.1, payable on demand. The interest rate provided for in this Section 3.1(b) shall to the extent permitted by applicable law apply to and accrue on the amount of any judgment entered with respect to any Obligation and shall continue to accrue at such rate during any proceeding described in Section 9.1(g) or (h).

(c) The interest rates provided for in Sections 3.1(a) and (b) shall be computed on the basis of a year of 360 days and the actual number of days elapsed.

(d) It is not intended by the Lender, and nothing contained in this Agreement, the Note or any other Loan Document shall be deemed, to establish or require the payment of a rate of interest in excess of the Maximum Rate permitted by applicable law (the “Maximum Rate”). If, in any month, the Effective Interest Rate, absent such limitation, would have exceeded the Maximum Rate, then the Effective Interest Rate for that month shall be the Maximum Rate, and if, in future months, the Effective Interest Rate would otherwise be less than the Maximum Rate, then the Effective Interest Rate shall remain at the Maximum Rate until such time as the amount of interest paid hereunder equals the amount of interest which would have been paid if the same had not been limited by the Maximum Rate. In the event the Lender receives, collects or applies as interest any sum in excess of the Maximum Rate, such excess amount shall be applied to the reduction of the principal balance of the applicable Obligation, and, if no such principal is then outstanding, such excess or part thereof remaining shall be paid to Borrower.

Section 3.2 Increased Costs and Reduced Returns. Borrower agrees that if any law now or hereafter in effect and whether or not presently applicable to the Lender or any request, guideline or directive of any Governmental Authority (whether or not having the force of law and whether or not failure to comply therewith would be unlawful) or the interpretation or administration thereof by any Governmental Authority, shall either (a)(i) impose, affect, modify or deem applicable any reserve, special deposit, capital maintenance or similar requirement against the Loan, (ii) impose on the Lender any other condition regarding the Loan, this Agreement, the Note or the facilities provided hereunder, or (iii) result in any requirement regarding capital adequacy (including any risk-based capital guidelines) affecting the Lender being imposed or modified or deemed applicable to the Lender, or (b) subject the Lender to any taxes, not including taxes on the income of Lender, on the recording, registration, notarization or other formalization of the Loan or the Note, and the result of any event referred to in clause (a) or (b) above shall be to increase the cost to the Lender of making, funding or maintaining the Loan or to reduce the amount of any sum receivable by the Lender or the Lender’s rate of return on capital with respect to the Loan to a level below that which the Lender could have achieved but for such imposition, modification or deemed applicability (taking into consideration the Lender’s policies with respect to capital adequacy) by an amount deemed by Lender (in the exercise of its discretion) to be material, then, upon demand by the Lender, Borrower shall immediately pay to the Lender additional amounts which shall be sufficient to compensate the Lender for such increased cost, tax or reduced rate of return, and which amount shall be reimbursed to Borrower if Lender receives a refund or credit therefor. A certificate of the Lender to Borrower claiming compensation under this Section 3.2 shall be final, conclusive and binding on all parties for all purposes in the absence of manifest error. Such certificate shall set forth the nature of the occurrence giving rise to such compensation, the additional amount or amounts to be paid to it hereunder, and the method by which such amounts were determined. In determining such amount, the Lender may use any reasonable averaging and attribution methods.

Section 3.3 Manner of Payment. Each payment (including prepayments) by Borrower on account of the principal of or interest on the Loan or of any fee or other amounts payable to the Lender under this Agreement or the Note shall be made not later than 2:00 p.m. on the date specified for payment under this Agreement (or if such day is not a Business Day, the next succeeding Business Day) to the Lender at the Lenders Office, in Dollars, in immediately available funds and shall be made without any setoff, counterclaim or deduction whatsoever. Borrower hereby irrevocably authorizes the Lender and each Affiliate of the Lender to charge any account of Borrower maintained with the Lender or such Affiliate with such amounts as may be necessary from time to time to pay any Obligations when due.
Section 3.4 Payments; Fees.

(a) **Scheduled Payments on Loan.** Borrower shall make payments of interest accrued on the Loan monthly, in arrears, beginning on the first day of the first full calendar month following the Effective Date and continuing on the first day of each calendar month thereafter and on the Maturity Date. Borrower shall pay interest accrued on the Loan after the Maturity Date, on demand.

(b) **Final Payment.** On the Maturity Date, Borrower shall pay to the Lender, in same day funds, an amount equal to the aggregate amount of the Loan outstanding and due on such date, together with accrued interest thereon, all fees payable to the Lender pursuant to the provisions of this Agreement, and any and all other Obligations then due and outstanding.

(c) **Interest Calculation.** For purposes of interest calculation only, (i) a payment by check, draft or other instrument received on a Business Day shall be deemed to have been applied to the relevant Obligation on the second following Business Day, (ii) a payment in cash or by wire transfer received at or before 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the Business Day when it is received, and (iii) a payment in cash or by wire transfer received on a day that is not a Business Day or after 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the next Business Day.

(d) **Returned Instruments.** If a payment is made by check, draft or other instrument and the check, draft or other instrument is returned to Lender unpaid, the application of the payment to the Obligation will be reversed and will be treated as never having been made.

(e) **Compelled Return of Payments or Proceeds.** If Lender is for any reason compelled to surrender any payment or any proceeds of any collateral under the Security Agreement because such payment or the application of such proceeds is for any reason invalidated, declared fraudulent, set aside, or determined to be void or voidable as a preference, an impermissible setoff, or a diversion of trust funds, then this Agreement and the Obligations to which such payment or proceeds was applied or intended to be applied shall be revived as if such application was never made; and Borrower shall be liable to pay to Lender, and shall indemnify Lender for and hold Lender harmless from any loss with respect to, the amount of such payment or proceeds surrendered. This Section shall be effective notwithstanding any contrary action that Lender may take in reliance upon its receipt of any such payment or proceeds. Any such contrary action so taken by Lender shall be without prejudice to Lender’s rights under this Agreement and shall be deemed to have been conditioned upon the application of such payment or proceeds having become final and irrevocable. The provisions of this Section shall survive the payment and satisfaction of all of the Obligations.

(f) **Due Dates Not on Business Days.** If any payment required hereunder becomes due on a date that is not a Business Day, then such due date shall be deemed automatically extended to the next Business Day.

(g) **Renewal Fee.** Borrower has paid to Lender a fee in an amount equal to Two Thousand Five Hundred and NO/100 Dollars ($2,500.00) in connection with the renewal of the Loan and in order to compensate Lender for the costs associated with structuring, processing, approving and closing the Loan renewal, but excluding expenses for which Borrower has agreed elsewhere in this Agreement to reimburse Lender. The fee shall be fully earned by Lender when received and, except as otherwise set forth herein, shall not be subject to refund or rebate. All fees are for compensation for services and are not, and shall not be deemed to be, interest or a charge for the use of money.
(h) **Nonusage fee.** The Borrower shall pay to Lender a monthly nonusage fee in an amount equal to one half of one percent (0.50%) per annum of the difference between (i) the Maximum Available Amount and (ii) the average principal amount of the Loan Advances during such monthly period. Such nonusage fee shall be calculated on a monthly basis, in arrears, and shall payable to Lender within three (3) Business Days of delivery of a statement from Lender relating thereto.

**Section 3.5 Collateral.** The Loan shall be secured by the Pledge Agreement, and the Collateral as defined in the Security Agreement.

**ARTICLE 4 - CONDITIONS PRECEDENT**

**Section 4.1 Conditions Precedent to the Loan.** Notwithstanding any other provision of this Agreement, the Lender’s obligation to make the Loan is subject to the fulfillment of each of the following conditions prior to or contemporaneously with the making of such Loan:

(a) **Closing Documents.** The Lender shall have received each of the following documents, or otherwise shall confirm in the continuing effectiveness of any such documents, all of which shall be satisfactory in form and substance to the Lender and its counsel:

1. this Agreement, duly executed and delivered by Borrower;

2. A Certificate of No Change, together with any amendments to the Articles of Incorporation and By-Laws of Borrower since July 15, 2004;

3. a certificate evidencing the good standing of Borrower in the jurisdiction of its incorporation and in each other jurisdiction in which it is qualified as a foreign corporation to transact business;

4. the Financing Statements (and required continuations thereof) and evidence satisfactory to the Lender that the Financing Statements have been filed in each jurisdiction where such filing may be necessary or appropriate to perfect the Security Interest;

5. copies of all the financial statements referred to in Section 5.1 and meeting the requirements thereof;

6. copies of each of the other Loan Documents (excluding the Pledge Agreement), duly executed by the parties thereto with evidence satisfactory to the Lender and its counsel of the due authorization, binding effect and enforceability of each such Loan Document (excluding the Pledge Agreement) on each such party and such other documents and instruments as the Lender may reasonably request;

7. opinion of Borrower’s counsel opining to such matters as Lender and/or its legal counsel may require; and
(B) with respect to any Loan Advance request, a Borrowing Base Certificate.

(b) No Injunctions, Etc. Except as disclosed in Borrower’s Form 10-Q report for the quarter ended March 31, 2011, no action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before any court, governmental agency or legislative body to enjoin, restrain or prohibit or to obtain substantial damages in respect of or which is related to or arises out of this Agreement or the consummation of the transactions contemplated hereby or which, in the Lender’s sole discretion, would make it inadvisable to consummate the transactions contemplated by this Agreement.

(c) Material Adverse Change. As of the Effective Date, there shall not have occurred any change which, in the Lender’s sole discretion, has had or may have a Material Adverse Effect as compared to the condition of Borrower presented by the most recent financial statements of Borrower.

(d) Solvency. The Lender shall have received evidence satisfactory to it that, after giving effect to any such Loan (i) Borrower has assets having value, both at fair value and at present fair saleable value, greater than the amount of its liabilities, and (ii) Borrower’s assets are sufficient in value to provide Borrower with sufficient working capital to enable it profitably to operate its businesses and to meet its obligations as they become due, and (iii) Borrower has adequate capital to conduct the business in which it is and proposes to be engaged.

(e) No Default or Event of Default. There shall be no Default or Event of Default and all of the representations and warranties made or deemed to be true and correct in all material respects at the time of the Loan to be made at such time and the application of the proceeds thereof except that representations and warranties which, by their terms, are applicable only to the Agreement Date or other specified date shall be true and correct only as of that date.

Section 4.2 Conditions Precedent to Subsequent Loan Advances. Notwithstanding any other provision of this Agreement, the Lender’s obligation to make any subsequent advance under the Loan is subject to the fulfillment of each of the following conditions prior to or contemporaneously with the making of each future Loan:

(a) All of the conditions in Section 4.1 have been and remain satisfied;

(b) The representations and warranties contained in the Loan Documents shall be true and correct in all material respects as of the time of any such advance and with the same force and effect as if made at such time except that representations and warranties which, by their terms, are applicable only to the Agreement Date or other specified date shall be true and correct only as of that date, with such exceptions as have been disclosed to Lender in writing by Borrower as addenda to the Schedules and are reasonably satisfactory to Lender, such representations and warranties shall be deemed made with respect to the most recent Financial Statements and other financial data delivered by Borrower to Lender;

(c) There shall be no Existing Default and no Default or Event of Default will occur as a result of the making of the Loan Advance, as the case may be, or Borrower’s use of the proceeds thereof;

(d) Since the date of the most recent prior Loan Advance, as applicable, there shall not have been any change which has had or is reasonably likely to have a Material Adverse Effect on Borrower; and
Section 4.3 Conditions Precedent to UNFPA as an Eligible Receivable. Prior to the inclusion of the UNFPA as an Eligible Receivable in the Borrowing Base, each of the following conditions must be satisfied:

(a) Borrower shall cause an opinion of United Kingdom counsel opining on the due incorporation and valid existence of each of the Borrower’s United Kingdom Subsidiaries, and on the valid issuance of the share capital of each of the Borrower’s United Kingdom Subsidiaries, all in form and substance reasonably satisfactory to Lender and its counsel and addressing such other matters reasonably required by Lender;

(b) Lender shall have received, at Borrower’s cost and expense, current and appropriate records searches with respect to Borrower’s United Kingdom Subsidiaries, showing only permitted and anticipated Liens reasonably acceptable to Lender, and, if required, Lender shall also have received bankruptcy, litigation, tax and other lien searches on Borrower’s United Kingdom Subsidiaries, reasonably satisfactory to Lender in all respects; and

(c) Borrower shall deliver an executed Pledge Agreement in form and substance satisfactory to Lender.

ARTICLE 5 - REPRESENTATIONS AND WARRANTIES OF BORROWER

Section 5.1 Representations and Warranties. Borrower represents and warrants to the Lender as follows:

(a) Organization; Power; Qualification. Borrower is a corporation, duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, has the power and authority to own properties and to carry on business as now being and hereafter proposed to be conducted and is duly qualified and authorized to do business in each jurisdiction in which failure to be so qualified and authorized would have a Material Adverse Effect.

(b) Subsidiaries and Ownership of Borrower. The Subsidiaries of Borrower are set forth in Exhibit 21 of Borrower’s most recent Form 10-K filed with the SEC.

(c) Authorization of Agreement, Note, Loan Documents and Borrowing. Borrower has the right and power and has taken all necessary action to authorize it to execute, deliver and perform this Agreement and each of the other Loan Documents to which it is a party in accordance with their respective terms and to borrow hereunder. This Agreement and each of the other Loan Documents to which it is a party have been duly executed and delivered by the duly authorized officers of Borrower and each is, or when executed and delivered in accordance with this Agreement will be, a legal, valid and binding obligation of Borrower enforceable in accordance with its terms.

(d) Compliance of Agreement, Note, Loan Documents and Borrowing with Laws, Etc. The execution, delivery and performance of this Agreement and each of the other Loan Documents to which Borrower is a party in accordance with their respective terms and the borrowings hereunder do not and will not, by the passage of time, the giving of notice or otherwise, (i) require any Governmental Approval or violate any applicable law relating to Borrower or any of its Affiliates, (ii) conflict with, result in a breach of or constitute a default under (A) the articles of incorporation or by-laws of Borrower, (B) any indenture, agreement or other instrument to which Borrower is a party or by which any of its property may be bound or (C) any Governmental Approval relating to Borrower, or, (iii) result in or require the creation or imposition of any Lien upon or with respect to any property now owned or hereafter acquired by Borrower, except the Lien in favor of Lender created by the Security Agreement.
Compliance with Law; Governmental Approvals. Borrower (i) has all Governmental Approvals, including permits relating to federal, state and local Environmental Laws, ordinances and regulations required by any applicable law for it to conduct its business, each of which is in full force and effect, is final and not subject to review on appeal and is not the subject of any pending attack by direct or collateral proceeding, and (ii) is in compliance with each Governmental Approval applicable to it and in compliance with all other applicable laws relating to it, including, without being limited to, all Environmental Laws and all occupational health and safety laws applicable to Borrower or its properties, except in the case of both (i) and (ii) above for instances of noncompliance which would not, singly or in the aggregate, cause a Default or Event of Default or have a Material Adverse Effect and in respect of which adequate reserves have been established on the books of Borrower.

Litigation. Except as disclosed in Borrower’s Form 10-Q report for the quarter ended March 31, 2011, there are no actions, suits or proceedings pending against or in any other way relating adversely to or affecting Borrower or any of its, his, her or their property in any court or before any arbitrator of any kind or before or by any governmental body.

Tax Returns and Payments. All United States federal, state and local and foreign national, provincial and local and all other tax returns of Borrower required by applicable law to be filed have been duly filed, and all United States federal, state and local and foreign national, provincial and local and all other taxes, assessments and other governmental charges or levies upon such entities and their properties, income, profits and assets which are due and payable have been paid, except any such nonpayment which is at the time permitted under Section 8.3. The charges, accruals and reserves on the books of Borrower in respect of United States federal, state and local taxes and foreign national, provincial and local taxes for all fiscal years and portions thereof since the organization of such entities are in the judgment of Borrower adequate.

Burdensome Provisions. Borrower is not a party to any indenture, agreement, lease or other instrument, or subject to any charter or corporate restriction, Governmental Approval or applicable law, compliance with the terms of which might have a Material Adverse Effect.

Financial Statements. Borrower has furnished to the Lender a copy of (i) its certified audited financial statement of September 30, 2010, and the related statements of income, cash flow and retained earnings for the twelve-month period then ended and a summary of adjustments to such statements to comply with GAAP, and (ii) the balance sheet as of March 31, 2011 and the related statement of income for the 12 (and 6) month period, respectively, then ended. Such financial statements are complete and correct in all material respects and present fairly and in all material respects the financial position of Borrower as at the dates thereof and the results of operations of Borrower for the periods then ended, subject to normal year-end adjustments. Except as disclosed or reflected in such financial statements or the notes thereto, Borrower did not have any material liabilities, contingent or otherwise, and there were no material unrealized or anticipated losses of Borrower.

Adverse Change. Since the date of the financial statements described in clause (i) of Section 5.1(f), (i) no change in the business, assets, liabilities, condition (financial or otherwise), results of operations or business prospects of Borrower has occurred that has had, or may have, a Material Adverse Effect, and (ii) no event has occurred or failed to occur which has had, or may have, a Material Adverse Effect.
(k) Absence of Defaults. Borrower is not in default under its articles of incorporation or by-laws and no event has occurred which has not been remedied, cured or waived (i) that constitutes a Default or an Event of Default or (ii) that constitutes or that, with the passage of time or giving of notice, or both, would constitute a default or event of default by Borrower under any material agreement (other than this Agreement) or judgment, decree or order to which Borrower is a party or by which Borrower or any of its properties may be bound or which would require Borrower to make any payment thereunder prior to the scheduled maturity date therefor.

(l) Accuracy and Completeness of Information. All written information, reports and other papers and data produced by or on behalf of Borrower and furnished to the Lender were, at the time the same were so furnished, complete and correct in all material respects to the extent necessary to give the recipient a true and accurate knowledge of the subject matter, no fact is known to Borrower which has had, or may in the future have, a Material Adverse Effect which has not been set forth in the financial statements or disclosure delivered prior to the Effective Date, in each case referred to in Section 5.1(i), or in any written information, reports or other papers or data or otherwise disclosed in writing to the Lender prior to the Effective Date. The documents furnished or written statements, taken as a whole, made to the Lender by Borrower in connection with the negotiation, preparation or execution of this Agreement or any of the Loan Documents do not contain any untrue statement of a fact material to the creditworthiness of Borrower and do not omit to state a material fact necessary in order to make the statements contained therein not misleading.

(m) Place of Business. The chief executive office and business locations of Borrower are set forth in Schedule 5.1(m).

(n) Federal Regulations. Borrower is not engaged, principally or as one of its important activities, in the business of extending credit for the purpose of “purchasing” or “carrying” any “margin stock” (as each of the quoted terms is defined or used in Regulations G and U of the Board of Governors of the Federal Reserve System).

(o) Investment Company Act. Borrower is not an “investment company” or a company “controlled” by an “investment company” (as each of the quoted terms is defined or used in the Investment Company Act of 1940, as amended).

(p) ERISA. Neither Borrower nor any Related Company maintains or contributes to any Benefit Plan other than those listed on Schedule 5.1(p). Each Benefit Plan is in substantial compliance with ERISA, and neither Borrower nor any Related Company has received any notice asserting that a Benefit Plan is not in compliance with ERISA. No material liability to the PBGC or to a Multiemployer Plan has been, or is expected by Borrower to be, incurred by Borrower or any Related Company.

(q) Employee Relations. Borrower is not party to any collective bargaining agreement. Borrower knows of no pending, threatened or contemplated strikes, work stoppage or other labor disputes involving its employees or those of its Subsidiaries.

(r) Intellectual Property. Borrower and its Subsidiaries own and possess or have the right to use all intellectual property (such as copyrights, patents, trademarks and trade names) required to conduct their business as now and presently planned to be conducted without, to its knowledge, conflict in any material respect with the rights of others. Schedule 5.1(r) lists all patents, registered trademarks, registered copyrights and applications for any of the foregoing owned by Borrower and its Subsidiaries.
(s) United Kingdom Subsidiaries. Each of Borrower’s United Kingdom Subsidiaries is directly or indirectly owned 100% by Borrower and is
duly incorporated and validly existing under the laws of the jurisdiction of its incorporation, has the power and authority to own properties and to carry on
business as now being conducted and is duly qualified and authorized to do business in each jurisdiction in which failure to be so qualified and authorized
would have a Material Adverse Effect. The stock of each United Kingdom Subsidiary has been validly issued. Upon execution of the Pledge Agreement,
Lender shall have a first priority lien on sixty-five percent (65%) of the outstanding share capital in the first-tier United Kingdom Subsidiary and there are no
other liens or encumbrances on such share capital. There are no liens or encumbrances on the share capital of Borrower’s second-tier United Kingdom
Subsidiary.

Section 5.2 Survival of Representations and Warranties, Etc. All representations and warranties set forth in this Article 5 and in other
Loan Documents (including, but not limited to, any such representation, warranty or statement made in or in connection with any amendment thereto) shall
constitute representations and warranties made under this Agreement. All representations and warranties made under this Agreement shall be made or
deemed to be made at and as of the Agreement Date, at and as of the Effective Date and at and as of the date of each Loan, including, but not limited to, each
Loan Advance, except that representations and warranties which, by their terms are applicable only to one such date shall be deemed to be made only at and
as of such date. All representations and warranties made or deemed to be made under this Agreement shall survive and not be waived by the execution and
delivery of this Agreement, any investigation made by or on behalf of the Lender or any borrowing hereunder.

ARTICLE 6 - AFFIRMATIVE COVENANTS

Until all of the Obligations have been indefeasibly paid in full, Borrower and each of its Subsidiaries will:

Section 6.1 Preservation of Corporate Existence and Similar Matters. With respect to each of Borrower and Borrower’s United
Kingdom Subsidiaries, preserve and maintain its corporate existence, rights, franchises, licenses and privileges in the jurisdiction of its incorporation and
qualify and remain qualified as a foreign corporation and authorized to do business in each jurisdiction in which the character of its properties or the nature
of its business requires such qualification or authorization, except to the extent the failure to do so would not have a Material Adverse Effect.

Section 6.2 Compliance with Applicable Law. Comply with all applicable laws relating to Borrower and its United Kingdom
Subsidiaries.

Section 6.3 Payment of Taxes and Claims. Pay or discharge when due (a) all taxes, assessments and governmental charges or levies
imposed upon it or upon its income or profits or upon any properties belonging to it, and (b) all lawful claims of materialmen, mechanics, carriers,
warehousemen and landlords for labor, materials, supplies and rentals which, if unpaid, would become a Lien on any properties of Borrower.

Section 6.4 Accounting Methods and Financial Records. Maintain a system of accounting, and keep such books, records and accounts
(which shall be true and complete), as may be required or as may be necessary to permit the preparation of financial statements in accordance with GAAP
consistently applied.

Section 6.5 Restrictions on Use of Proceeds. Borrower will use the proceeds of the Loan only for Borrower’s and its Subsidiaries’
Section 6.6  Hazardous Waste and Substances; Environmental Requirements. In addition to, and not in derogation of, the requirements of Section 6.2 and of the Security Agreement, governmental standards and regulations applicable to Borrower or to any of its assets in respect of occupational health and safety laws, rules and regulations and Environmental Laws, promptly notify the Lender of its receipt of any notice of a violation of any such law, rule, standard or regulation and indemnify and hold the Lender harmless from all loss, cost, damage, liability, claim and expense incurred by or imposed upon the Lender on account of Borrower’s failure to perform its obligations under this Section 6.6.

Section 6.7  Accuracy of Information. All written information, reports, statements and other papers and data furnished to the Lender, whether pursuant to Article 7 or any other provision of this Agreement or any of the other Loan Documents, shall be, at the time the same is so furnished, complete and correct in all material respects to the extent necessary to give the Lender true and accurate knowledge of the subject matter.

Section 6.8  Revisions or Updates to Schedules. Should any of the information or disclosures provided on any of the Schedules originally attached hereto become incorrect in any material respect, Borrower shall provide as soon as possible (but by no later than the end of the then current fiscal quarter of Borrower) to the Lender such revisions or updates to such Schedule(s) as may be necessary or appropriate to update or correct such Schedule(s); provided that no such revisions or updates to any Schedule(s) shall be deemed to have cured any breach of warranty or representation resulting from the inaccuracy or incompleteness of any such Schedule(s) unless and until the Lender, in its sole discretion, shall have accepted in writing such revisions or updates to such Schedule(s).

Section 6.9  Conduct of Business. Engage only in businesses in substantially the same fields as the businesses conducted on the Effective Date.

Section 6.10  Insurance. Borrower shall at all times maintain, in addition to the insurance required by the Security Agreement, insurance with responsible insurance companies against such risks, in such amounts as in amounts and under policies issued by insurers acceptable to the Lender, including such theft, hazard, public liability, products liability, third party property damage and business interruption insurance as is consistent with reasonable business practices. All premiums on such insurance shall be paid by Borrower and copies of the policies delivered to the Lender.

Section 6.11  Change of Management. Borrower shall give prior written notice to Lender of any change in the following executive officers of Borrower: Chief Executive Officer.

ARTICLE 7 - INFORMATION

Until all of the Obligations have been indefeasibly paid in full, Borrower will furnish to the Lender at the Lender’s Office:

Section 7.1  Financial Statements; Borrowing Base Certificate; Compliance Certificate.

(a)  Certified Year-End Statements. As soon as available, but in any event within 120 days after the end of each fiscal year of Borrower, copies of the consolidated and consolidating balance sheet of Borrower, as at the end of such fiscal year and the related statements of income, shareholders’ equity and cash flow for such fiscal year, in each case setting forth in comparative form the figures for the previous year-end and reported on, without qualification, certified by independent certified public accountants selected by Borrower, and acceptable to the Lender.
Quarterly Financial Statements. As soon as available, but in any event within 45 days after the end of each fiscal quarter of Borrower, copies of the unaudited consolidated and consolidating balance sheet of Borrower as at the end of such fiscal quarter and the related unaudited income statement for such fiscal quarter and for the portion of the fiscal year of Borrower through such quarter, and, with respect to such quarterly financial statements delivered at the end of each fiscal year of Borrower, such financial statement shall be certified by the chief financial officer of Borrower to the best of his or her knowledge as presenting fairly the financial condition and results of operations of Borrower as at the date thereof and for the periods ended on such date, subject to normal year end adjustments.

All such financial statements shall be complete and correct in all material respects, and all such financial statements shall be prepared in accordance with GAAP (except, with respect to interim financial statements, for the omission of footnotes) applied consistently throughout the periods reflected therein.

(c) Borrowing Base Certificate. Within thirty (30) days after the end of each quarter, a Borrowing Base Certificate as of the close of business on the last Business Day of the preceding quarter.

(d) Compliance Certificate. Borrower shall deliver to Lender, concurrently with Borrower’s delivery of the financial statements set forth in section 7.1(a) above, a Compliance Certificate prepared as of the close of business on the last Business Day of such fiscal year.

(e) Authorization. Borrower authorizes the Lender to discuss the financial condition of Borrower with Borrower’s independent certified public accountants and agrees that such discussion or communication shall be without liability to either the Lender or Borrower’s independent certified public accountants.

Section 7.2 Copies of Other Reports.

(a) Promptly upon receipt thereof, copies of all reports, if any, submitted to Borrower by its independent public accountants, including, without limitation, all management reports.

(b) To the extent not available on Borrower’s web site or EDGAR, promptly upon preparation and filing of the same, copies of any and all filings by Borrower with the SEC, including, but not limited to, Forms 10-K, 10-Q and any other material reports filed by Borrower with the SEC.

(c) Within thirty (30) days following the end of each fiscal quarter of Borrower, an Accounts Receivable aging report showing the name, address and outstanding account balances of each account debtor, and the aging of the account balances of each such debtor by the following aging categories; 0-30 days, 31-60 days, 61-90 days, and over 90 days.

(d) From time to time and promptly upon each request, such forecasts, data, certificates, reports, statements, opinions of counsel, documents or further information regarding the business, assets, liabilities, financial condition, results of operations or business prospects of Borrower and its Subsidiary as the Lender may reasonably request. The rights of the Lender under this Section 7.2(d) are in addition to and not in derogation of its rights under any other provision of this Agreement or any Loan Document.

Section 7.3 Notice of Litigation and Other Matters.

Notice of: (a) the commencement of all proceedings and investigations by or before any governmental or nongovernmental body and all actions and proceedings in any court or before any arbitrator against or in any other way relating adversely to, or adversely affecting, Borrower, any Subsidiary of Borrower or any of their respective property, assets or businesses, (b) any amendment of the articles of incorporation and/or by-laws of Borrower, (c) any change in the business, assets, liabilities, financial condition, results of operations or business prospects of Borrower, any Subsidiary of Borrower and any change in the executive officers of Borrower which would reasonably be expected to have a Material Adverse Effect, and (d) any (i) Default or Event of Default, or (ii) event that constitutes or that, with the passage of time or giving of notice or both, would constitute a default or event of default by Borrower under any material agreement (other than this Agreement) to which Borrower or it Subsidiary is a party or by which Borrower or its Subsidiary or any of its or their property may be bound if the exercise of remedies thereunder by the other party to such agreement would have, either individually or in the aggregate, a Material Adverse Effect.
Section 7.4 **ERISA.** As soon as possible and in any event within 30 days after Borrower knows, or has reason to know, that: (a) any Termination Event with respect to a Benefit Plan has occurred or will occur, (b) the aggregate present value of the Unfunded Vested Accrued Benefits under all Plans has increased to an amount in excess of $0, or (c) Borrower are in “default” (as defined in Section 4219(c)(5) of ERISA) with respect to payments to a Multiemployer Plan required by reason of its complete or partial withdrawal (as described in Section 4203 or 4205 of ERISA) from such Multiemployer Plan, (d) a certificate of the President or the chief financial officer of Borrower setting forth the details of such of the events described in clauses (a) through (c) as applicable and the action which is proposed to be taken with respect thereto and, simultaneously with the filing thereof, copies of any notice or filing which may be required by the PBGC or other agency of the United States government with respect to such of the events described in clauses (a) through (c) as applicable.

ARTICLE 8 - NEGATIVE COVENANTS

Until all of the Obligations have been indefeasibly paid in full, Borrower will not directly or indirectly, and will not permit any Subsidiary directly or indirectly:

Section 8.1 **Merger, Consolidation and Sale of Assets.** Merge or consolidate with any other Person or sell, lease or transfer or otherwise dispose of all or a substantial portion of its assets to any Person.

Section 8.2 **Transactions with Affiliates.** Effect any transaction with any Affiliate on a basis less favorable to Borrower than would be the case if such transaction had been effected with a Person not an Affiliate.

Section 8.3 **Protection of Lender’s Rights.** By any amendment of the Borrower’s Articles of Incorporation or By-laws, or the equivalent document of any United Kingdom Subsidiary of Borrower, or through any consolidation, merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, seek to avoid the observance or performance of the terms to be observed or performed hereunder by Borrower, but will at all times take such actions as are necessary or appropriate in order to protect the rights of Lender under the Loan Documents, including, but not limited to, this Agreement, and at all times in good faith assist in the carrying out of all the provisions of the Loan Documents and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Lender against impairment.

Section 8.4 **Dividends/Distributions/Payments.** Declare, pay, or set apart for payment any Restricted Payment or Restricted Distribution other than a Permitted Distribution.

Section 8.5 **Borrower’s United Kingdom Subsidiaries.** Borrower shall not permit any of its United Kingdom Subsidiaries to place any lien or other encumbrance securing funded indebtedness upon any of the assets of either United Kingdom Subsidiary. Borrower shall not permit the issuance of any share capital or equivalent interest in either of its United Kingdom Subsidiaries.
Section 8.6 Reserved.

Section 8.7 Reserved.

Section 8.8 Liens. Other than in favor of Lender, grant any Lien other than purchase money security interests in capital assets, not to exceed in the aggregate $250,000 for any consecutive twelve month period.

ARTICLE 9 - DEFAULT

Section 9.1 Events of Default. Each of the following shall constitute an Event of Default, whatever the reason for such event and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment or order of any court or any order, rule or regulation of any governmental or nongovernmental body:

(a) Default in Payment of Loan. Borrower shall default in any payment of principal of, or interest on, the Loan or the Note on the due date thereof (whether at maturity, by reason of acceleration or otherwise).

(b) Other Payment Default. Borrower shall default in the payment, as and when due, of principal of or interest on, any other Obligation, and such default shall continue for five (5) days after demand.

(c) Misrepresentation. Any representation or warranty made or deemed to be made by any of the Borrower under this Agreement or any other Loan Document or any amendment hereto or thereto shall at any time prove to have been incorrect or misleading in any material respect when made.

(d) Default in Performance. (i) Borrower shall default in the performance or observance of a term, covenant, condition or agreement contained in Articles 6, 7 or 8; (ii) Borrower shall default in the performance or observance of any other term, covenant, condition or agreement contained in this Agreement and the default is not cured to the satisfaction of Lender within ten (10) days after the sooner to occur of Borrower’s receipt of notice of such default from Lender or the date on which such default first became known to any officer of Borrower; or (iii) Borrower shall default in the performance or observance of any non-payment term, covenant, condition or agreement related to the Loan and the passage without cure of the applicable cure period, if any.

(e) Indebtedness Cross-Default. (i) Borrower or any Subsidiary shall fail to pay when due and payable the principal of or interest on any Indebtedness (other than the Loan or Note), which indebtedness is in an amount equal to or greater than $250,000.00 or (ii) the maturity of any Indebtedness in excess of $250,000.00 shall have been accelerated as a result of such default or event of default in accordance with the provisions of any indenture, contract or instrument providing for the creation of or concerning such Indebtedness, where such Indebtedness is in an amount equal to or greater than $250,000.00 or (iii) any event shall have occurred and be continuing which, with or without the passage of time or the giving of notice, or both, would permit any holder or holders of such Indebtedness, any trustee or agent acting on behalf of such holder or holders or any other Person, to accelerate such maturity where such Indebtedness is in an amount equal to or greater than $250,000,00.
(f) **Voluntary Bankruptcy Proceeding.** Any Obligor shall (i) commence a voluntary case under the federal bankruptcy laws (as now or hereafter in effect), (ii) commence a proceeding seeking to take advantage of any other laws, domestic or foreign, relating to bankruptcy, insolvency, reorganization, winding up or composition for adjustment of debts, (iii) consent to or fail to contest in a timely and appropriate manner any petition filed against it in an involuntary case under such bankruptcy laws or other laws, (iv) apply for or consent to, or fail to contest in a timely and appropriate manner, the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of a substantial part of its property, domestic or foreign, (v) admit in writing its inability to pay its debts as they become due, (vi) make a general assignment for the benefit of creditors, or (vii) take any corporate action for the purpose of authorizing any of the foregoing.

(g) **Involuntary Bankruptcy Proceeding.** A case or other proceeding shall be commenced against any Obligor in any court of competent jurisdiction seeking (i) relief under the federal bankruptcy laws (as now or hereafter in effect) or under any other laws, domestic or foreign, relating to bankruptcy, insolvency, reorganization, winding up or adjustment of debts, or (ii) the appointment of a trustee, receiver, custodian, liquidator or the like of any Obligor or of all or any substantial part of the assets, domestic or foreign, of any Obligor, and such case or proceeding shall continue undismissed or unstayed for a period of 90 consecutive calendar days, or an order granting the relief requested in such case or proceeding against any Obligor (including, but not limited to, an order for relief under such federal bankruptcy laws) shall be entered.

(h) **Loan Documents.** Any Event of Default under any other Loan Document shall exist or any Obligor shall default in the performance or observance of any material term, covenant, condition or agreement contained in, or the payment of any other sum covenanted to be paid by any Obligor under, any such Loan Document; or any provision of this Agreement, or of any other Loan Document after delivery thereof hereunder, shall for any reason cease to be valid and binding, or any Obligor or other party thereto (other than the Lender) shall so state in writing; or this Agreement or any other Loan Document, after delivery thereof hereunder, shall for any reason cease to create a valid, perfected and first priority Lien on, or security interest in, any of the collateral purported to be covered thereby.

(i) **Judgment.** A judgment or judgments in an amount, individually or in the aggregate, in excess of $100,000.00 shall be entered against any Obligor by any court and such judgment or order shall continue undischarged or unstayed for 60 days.

(j) **Attachment.** A warrant or writ of attachment or execution or similar process shall be issued against any property of any Obligor and such warrant or process shall continue undischarged or unstayed for 90 days.

(k) **Material Adverse Change.** There occurs any act, omission, event, undertaking or circumstance or series of acts, omissions, events, undertakings or circumstances which have, or in the sole judgment of the Lender would have, either individually or in the aggregate, a Material Adverse Effect.

(l) **ERISA.** (i) Any Termination Event with respect to a Benefit Plan shall occur that, after taking into account the excess, if any, of (A) the fair market value of the assets of any other Benefit Plan with respect to which a Termination Event occurs on the same day (but only to the extent that such excess is the property of Borrower) over (B) the present value on such day of all vested nonforfeitable benefits under such other Benefit Plan, results in an Unfunded Vested Accrued Benefit in excess of $50,000, (ii) any Benefit Plan shall incur an “accumulated funding deficiency” (as defined in Section 412 of the Code or Section 302 of ERISA) for which a waiver has not been obtained in accordance with the applicable provisions of the Code and ERISA, or (iii) Borrower are in “default” (as defined in Section 4219(c)(5) of ERISA) with respect to payments to a Multiemployer Plan resulting from Borrower’s complete or partial withdrawal (as described in Section 4203 or 4205 of ERISA) from such Multiemployer Plan.
Section 9.2 Remedies.

(a) Automatic Acceleration and Termination of Facilities. Upon the occurrence of an Event of Default specified in Section 9.1(f) or Section 9.1(g), (i) the principal of and the interest on the Loan and the Note at the time outstanding, and all other amounts owed to the Lender under this Agreement or any of the Loan Documents and all other Obligations, shall thereupon become due and payable without presentment, demand, protest or other notice of any kind, all of which are expressly waived, anything in this Agreement or any of the Loan Documents to the contrary notwithstanding, and (ii) the commitment of the Lender to make advances under this Agreement shall immediately terminate.

(b) Other Remedies. If any Event of Default (other than as specified in Section 9.1(f) or Section 9.1(g)) shall have occurred and be continuing, the Lender, in its sole and absolute discretion, may do any of the following: (i) declare the principal of and interest on the Loan and the Note at the time outstanding, and all other amounts owed to the Lender under this Agreement or any of the Loan Documents and all other Obligations, to be forthwith due and payable, whereupon the same shall immediately become due and payable without presentment, demand, protest or other notice of any kind, all of which are expressly waived, anything in the Agreement or the Loan Documents to the contrary notwithstanding, together with interest on such amounts at the Default Rate and (ii) terminate the Loan and any commitment of the Lender to make advances hereunder.

(c) Further Remedies. If any Event of Default shall have occurred and be continuing, the Lender, in its sole and absolute discretion, may exercise any and all of its rights under the Security Agreement.

Section 9.3 Application of Proceeds. All proceeds from each sale of, or other realization upon, all or any part of any collateral under the Security Agreement following an Event of Default shall be applied or paid over as follows: (a) First: to the payment of all costs and expenses incurred in connection with such sale or other realization, including reasonable attorneys’ fees, (b) Second: to the payment of the Obligations (with Borrower remaining liable for any deficiency) in any order which the Lender may elect, and (c) Third: the balance (if any) of such proceeds shall be paid to Borrower or, subject to any duty imposed by law or otherwise, to whomsoever is entitled thereto.

Section 9.4 Miscellaneous Provisions Concerning Remedies.

(a) Rights Cumulative. The rights and remedies of the Lender under this Agreement, the Note and each of the Loan Documents shall be cumulative and not exclusive of any rights or remedies which it would otherwise have. In exercising such rights and remedies, the Lender may be selective and no failure or delay by the Lender in exercising any right shall operate as a waiver of such right nor shall any single or partial exercise of any power or right preclude its other or further exercise or the exercise of any other power or right.

(b) Limitation of Liability. Nothing contained in this Article 9 or elsewhere in this Agreement or in any of the Loan Documents shall be construed as requiring or obligating the Lender or any agent or designee of the Lender to make any demand or to make any inquiry as to the nature or sufficiency of any payment received by it or to present or file any claim or notice, and neither the Lender nor any of its agents or designees shall have any liability to Borrower for actions taken pursuant to this Article 9, any other provision of this Agreement or any of the Loan Documents, so long as the Lender or such agent or designee shall act reasonably and in good faith.
(c) **Appointment of Receiver.** In any action under this **Article 9,** the Lender shall be entitled to the appointment of a receiver, without notice of any kind whatsoever, to exercise such power as the court shall confer upon such receiver.

**ARTICLE 10 - MISCELLANEOUS**

Section 10.1 **Notices.**

(a) **Method of Communication.** All notices and the communications hereunder and thereunder shall be in writing. Notices in writing shall be delivered personally or sent by overnight courier service, by certified or registered mail, postage pre-paid, or by facsimile transmission and shall be deemed received, in the case of personal delivery, when delivered, in the case of overnight courier service, on the next Business Day after delivery to such service, in the case of mailing, on the third day after mailing (or, if such day is a day on which deliveries of mail are not made, on the next succeeding day on which deliveries of mail are made) and, in the case of facsimile transmission, upon transmittal.

(b) **Addresses for Notices.** Notices to any party shall be sent to it at the following addresses, or any other address of which all the other parties are notified in writing.

If to Borrower: The Female Health Company
515 N. State Street, Suite 2225
Chicago, IL 60654
Attention: Donna Felch
Facsimile No.: (312) 280-9360

With a copy to: Reinhart Boerner Van Deuren s.c.
1000 North Water Street, Suite 1700
Milwaukee, WI 53202
Attention: Benjamin G. Lombard
Facsimile No.: (414) 298-8097

If to the Lender: Heartland Bank
212 S. Central Avenue
St. Louis, MO 63105
Attention: Colin McNulty
Facsimile No.: (314) 512-8501

With a copy to: Carmody MacDonald P.C.
120 S. Central Ave., Suite 1800
St. Louis, MO 63105
Attention: Mark B. Hillis
Facsimile No.: (314) 854-8660

(c) **Lender’s Office.** The Lender hereby designates its office designated above or any subsequent office which shall have been specified for such purpose by written notice to Borrower, as the office to which payments due are to be made and at which Loan will be disbursed.
Section 10.2 Expenses. Borrower agrees to pay or reimburse on demand all costs and expenses incurred by the Lender, including, without limitation, the reasonable fees and disbursements of counsel, in connection with the preparation, due diligence, administration, enforcement and termination of this Agreement and each of the other Loan Documents. The foregoing shall not be construed to limit any other provisions of the Loan Documents regarding costs and expenses to be paid by Borrower.

Section 10.3 Stamp and Other Taxes. Borrower will pay any and all stamp, registration, recordation and similar taxes, fees or charges and shall indemnify the Lender against any and all liabilities with respect to or resulting from any delay in the payment or omission to pay any such taxes, fees or charges, which may be payable or determined to be payable in connection with the execution, delivery, performance or enforcement of this Agreement and any of the Loan Documents or the perfection of any rights or security interest thereunder.

Section 10.4 Setoff. In addition to any rights now or hereafter granted under applicable law, and not by way of limitation of any such rights, upon and after the occurrence of any Default or Event of Default, the Lender is hereby authorized by Borrower at any time or from time to time, without notice to Borrower or to any other Person, any such notice being hereby expressly waived, to set off and to appropriate and to apply any and all deposits (general or special, time or demand, including, but not limited to, indebtedness evidenced by certificates of deposit, whether matured or unmatured) and any other indebtedness at any time held or owing by the Lender to or for the credit or the account of Borrower against and on account of the Obligations irrespective of whether or not (a) the Lender shall have made any demand under this Agreement or any of the Loan Documents, or (b) the Lender shall have declared any or all of the Obligations to be due and payable as permitted by Section 9.2 and although such Obligations shall be contingent or unmatured.

Section 10.5 Dispute Resolution.

(a) Consent to Jurisdiction; Waiver of Venue Objection; Service of Process. WITHOUT LIMITING THE RIGHT OF THE LENDER TO BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR AGAINST PROPERTY OF THE BORROWER ARISING OUT OF OR RELATING TO THIS AGREEMENT (AN “ACTION”) IN THE COURTS OF OTHER JURISDICTIONS, THE BORROWER HEREBY IRREVOCABLY SUBMITS TO AND ACCEPTS THE NON-EXCLUSIVE JURISDICTION OF ANY MISSOURI STATE COURT IN ST. LOUIS COUNTY, OR THE UNITED STATES FEDERAL DISTRICT COURT FOR THE EASTERN DISTRICT OF MISSOURI, AND THE BORROWER HEREBY IRREVOCABLY AGREES THAT ANY ACTION MAY BE HEARD AND DETERMINED IN SUCH MISSOURI STATE COURT OR IN SUCH FEDERAL COURT. THE BORROWER HEREBY IRREVOCABLY WAIVES AND DISCLAIMS, TO THE FULLEST EXTENT THAT THE BORROWER MAY EFFECTIVELY DO SO, ANY DEFENSE OR OBJECTION (INCLUDING, WITHOUT LIMITATION, ANY DEFENSE OR OBJECTION TO VENUE BASED ON THE GROUNDS OF FORUM NON CONVENIENS) WHICH THE BORROWER MAY NOW OR HEREAFTER HAVE TO THE MAINTENANCE OF ANY ACTION IN ANY JURISDICTION. THE BORROWER HEREBY IRREVOCABLY AGREES THAT THE SUMMONS AND COMPLAINT OR ANY OTHER PROCESS IN ANY ACTION IN ANY JURISDICTION MAY BE SERVED BY MAILING (USING CERTIFIED OR REGISTERED MAIL, POSTAGE PREPAID) TO THE BORROWER’S ADDRESS. SUCH SERVICE WILL BE COMPLETE ON THE DATE SUCH PROCESS IS SO DELIVERED, AND THE BORROWER WILL HAVE THIRTY DAYS FROM SUCH COMPLETION OF SERVICE IN WHICH TO RESPOND IN THE MANNER PROVIDED BY LAW. THE BORROWER MAY ALSO BE SERVED IN ANY OTHER MANNER PERMITTED BY LAW, IN WHICH EVENT THE BORROWER’S TIME TO RESPOND SHALL BE THE TIME PROVIDED BY LAW.
Section 10.6 Reversal of Payments. To the extent Borrower makes a payment or payments to the Lender or the Lender receives any payment or proceeds of any collateral for the Security Agreement for Borrower’s benefit, which payment(s) or proceeds or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, state or federal law, common law or equitable cause, then, the Lender shall have the continuing and exclusive right to apply, reverse and reapply any and all payments to any portion of the Obligations, and, to the extent of such payment or proceeds received, the Obligations or part thereof intended to be satisfied shall be revived and continued in full force and effect, as if such payment or proceeds had not been received by the Lender.

Section 10.7 Injunctive Relief. Borrower recognizes that, in the event Borrower fails to perform, observe or discharge any of its obligations or liabilities under this Agreement, any remedy of law may prove to be inadequate relief to the Lender; therefore, Borrower agrees that the Lender, at the Lender’s option, shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual damages.

Section 10.8 Accounting Matters. All financial and accounting calculations, measurements and computations made for any purpose relating to this Agreement, including, without limitation, all computations utilized by Borrower to determine whether it is in compliance with any covenant contained herein, shall, unless there is an express written direction or consent by the Lender to the contrary, be performed in accordance with GAAP.

Section 10.9 Assignment; Participation. All the provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, except that Borrower may not assign or transfer any of its rights under this Agreement. The Lender may assign or participate to one or more Persons, all or a portion of its rights and obligations hereunder and under the Note and, in connection with any such assignment, may assign its rights and obligations under the Security Agreement, provided, however, that Lender shall obtain the prior written consent of Borrower so long as no Event of Default exists if Lender desires to assign the Loan. The Lender may, in connection with any assignment or participation, disclose to the assignee or participant any information relating to Borrower furnished to the Lender by or on behalf of Borrower.

Section 10.10 Amendments. Any term, covenant, agreement or condition of this Agreement or any of the other Loan Documents may be amended or waived and any departure therefrom may be consented to if, but only if, such amendment, waiver or consent is in writing signed by the Lender and, in the case of an amendment, by Borrower. Unless otherwise specified in such waiver or consent, a waiver or consent given hereunder shall be effective only in the specific instance and for the specific purpose for which given.

Section 10.11 Performance of Borrower’s Duties. Borrower’s obligations under this Agreement and each of the Loan Documents shall be performed by Borrower at its sole cost and expense. If Borrower shall fail to do any act or thing which it has covenanted to do under this Agreement or any of the Loan Documents, the Lender may (but shall not be obligated to) do the same or cause it to be done either in the name of the Lender or in the name and on behalf of Borrower, and Borrower hereby irrevocably authorizes the Lender so to act.
Section 10.12  **Indemnification.** Borrower agrees to reimburse the Lender for all reasonable costs and expenses, including counsel fees and disbursements, incurred and to indemnify and hold the Lender harmless from and against all losses suffered by the Lender, other than losses resulting from the Lender’s gross negligence or willful misconduct, in connection with (a) the exercise by the Lender of any right or remedy granted to it under this Agreement or any of the Loan Documents, (b) any claim, and the prosecution or defense thereof arising out of or in any way connected with this Agreement or any of the Loan Documents.

Section 10.13  **All Powers Coupled with Interest.** All powers of attorney and other authorizations granted to the Lender and any Persons designated by the Lender pursuant to any provisions of this Agreement or any of the Loan Documents shall be deemed coupled with an interest and shall be irrevocable so long as any of the Obligations remain unpaid or unsatisfied or the Loan has not been terminated.

Section 10.14  **Survival.** Notwithstanding any termination of this Agreement, (a) until all Obligations have been paid in full and this Agreement terminated, the Lender shall retain its security interest and shall retain all rights under this Agreement and the Security as fully as though this Agreement had not been terminated, and (b) the indemnities to which the Lender is entitled under the provisions of this Article 10 and any other provision of this Agreement and the Loan Documents shall continue in full force and effect and shall protect the Lender against events arising after such termination as well as before.

Section 10.15  **Severability of Provisions.** Any provision of this Agreement or any other Loan Document which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remainder of such provision or the remaining provisions hereof or thereof or affecting the validity or enforceability of such provision in any other jurisdiction.

Section 10.16  **Governing Law.** This Agreement and the Note and the other Loan Documents shall be construed in accordance with and governed by the law of the State of Missouri, exclusive of its choice of law rules.

Section 10.17  **Counterparts.** This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same agreement.

Section 10.18  **Final Agreement.** This Agreement and the other Loan Documents are intended by the parties hereto as the final, complete and exclusive expression of the agreement among them with respect to the subject matter hereof and thereof. This Agreement and the other Loan Documents supersede any and all prior oral or written agreements between the parties hereto relating to the subject matter hereof and thereof.

Section 10.19  **Purchase of Insurance.** UNLESS YOU, BORROWER, PROVIDE EVIDENCE OF THE INSURANCE COVERAGE REQUIRED BY YOUR AGREEMENT WITH US, THE LENDER, WE MAY PURCHASE INSURANCE AT YOUR EXPENSE TO PROTECT OUR INTERESTS UNDER THIS AGREEMENT. THIS INSURANCE MAY, BUT NEED NOT, PROTECT YOUR INTERESTS. THE COVERAGE THAT WE PURCHASE MAY NOT PAY ANY CLAIM THAT YOU MAKE OR ANY CLAIM THAT IS MADE AGAINST YOU. YOU MAY LATER CANCEL ANY INSURANCE PURCHASED BY US, BUT ONLY AFTER PROVIDING EVIDENCE THAT YOU HAVE OBTAINED INSURANCE AS REQUIRED BY THIS AGREEMENT. IF WE PURCHASE INSURANCE, YOU WILL BE RESPONSIBLE FOR THE COSTS OF THAT INSURANCE, INCLUDING THE INSURANCE PREMIUM, INTEREST AND ANY OTHER CHARGES WE MAY IMPOSE IN CONNECTION WITH THE PLACEMENT OF THE INSURANCE, UNTIL THE EFFECTIVE DATE OF THE CANCELLATION OF EXPIRATION OF THE INSURANCE. THE COSTS OF THE INSURANCE MAY BE ADDED TO YOUR TOTAL OUTSTANDING BALANCE OR OBLIGATION THE COSTS OF THE INSURANCE MAY BE MORE THAN THE COST OF INSURANCE YOU MAY BE ABLE TO OBTAIN ON YOUR OWN.
Section 10.20  **Oral Agreements.** ORAL AGREEMENTS OR COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT INCLUDING PROMISES TO EXTEND OR RENEW SUCH DEBT ARE NOT ENFORCEABLE. TO PROTECT YOU (BORROWER) AND US (CREDITOR) FROM MISUNDERSTANDING OR DISAPPOINTMENT, ANY AGREEMENTS WE REACH COVERING SUCH MATTERS ARE CONTAINED IN THIS WRITING, WHICH IS THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN US, EXCEPT AS WE MAY LATER AGREE IN WRITING TO MODIFY IT. THE LOAN DOCUMENTS, AS AMENDED, MODIFIED AND SUPPLEMENTED HEREBY, ARE INCORPORATED HEREIN BY THIS REFERENCE AND SHALL BE DEEMED TO CONSTITUTE A PART OF THIS WRITING.

[The remainder of this page is intentionally blank.]
IN WITNESS WHEREOF, the parties hereto have caused this Agreement as of the day and year first written above.

THIS AGREEMENT CONTAINS A BINDING JURY WAIVER PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.

BORROWER:

THE FEMALE HEALTH COMPANY,
a Wisconsin corporation

By: /s/ O.B. Parrish

Name: O.B. Parrish
Title: Chairman and CEO

STATE OF ILLINOIS )
) SS
COUNTY OF COOK )

On this 1st day of August, 2011, before me appeared O.B. Parrish, in his/her capacity as Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, to me personally known, who, being by me duly sworn, did say that he/she is the Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, and that said instrument was signed in behalf of said corporation by authority of its Board of Directors, and said O.B. Parrish, as Chairman and CEO, acknowledged said instrument to be the free act and deed of said corporation.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in the County and State aforesaid, the day and year first above written.

/s/ Jacqueline F. Martin
Notary Public

My Commission Expires: 02/26/2014

Signature Page
IN WITNESS WHEREOF, the parties hereto have caused this Agreement as of the day and year first written above.

THIS AGREEMENT CONTAINS A BINDING JURY WAIVER PROVISION WHICH MAY BE ENFORCED BY THE PARTIES.

“LENDER”

HEARTLAND BANK,
a federal savings bank

By: /s/ Colin McNulty

Name: Colin McNulty
Title: Assistant Vice President

STATE OF MISSOURI   )
COUNTY OF ST. LOUIS )

On this 1st day of August, 2011, before me appeared Colin McNulty, to me personally known, who being by me duly sworn did say that he/she is an Assistant Vice President of HEARTLAND BANK, a federal savings bank, and that said instrument was signed on behalf of said bank and said Colin McNulty, as Assistant Vice President, acknowledged said instrument to be the free act and deed of said bank.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal on the day and year last above written.

/s/ Michelle Brewer
Notary Public

My Commission Expires: 09/19/2011

Signature Page
FOR VALUE RECEIVED, the undersigned, THE FEMALE HEALTH COMPANY, a Wisconsin corporation (the “Borrower”), hereby promises to pay to the order of HEARTLAND BANK, a federal savings bank (the “Lender”), at its office at 212 S. Central Avenue, Clayton, Missouri 63105 (the “Lender’s Address”), or at such other office as the Lender may subsequently designate in writing, (i) on August 1, 2012 (the “Maturity Date”), the principal amount of Two Million Dollars (US $2,000,000.00), or, if less, the aggregate unpaid principal amount of all advances made hereunder by the Lender to the Borrower prior to said date, (ii) interest on such principal amount at the interest rate per annum for each advance, as determined in accordance with the terms specified below (but in no event in excess of the maximum rate permitted by applicable law), and (iii) any and all other sums which may be owing to the Lender by the Borrower pursuant to this Note. All advances made hereunder by the Lender to the Borrower and all payments made on account of principal hereof and interest hereunder shall be recorded by the Lender and, prior to any transfer hereof, endorsed on the grid attached hereto; provided, however, that the Lender’s failure to record any such advance or payment shall not limit or otherwise affect the obligations of the Borrower under this Note.

1. Definitions. Each initially capitalized term used herein shall have the meaning set forth in Schedule A. Any capitalized terms used herein, but not otherwise defined herein or on Schedule A attached hereto, shall have the meaning ascribed to such term(s) as set forth in the Loan Agreement.

2. Advances. Subject to the terms and conditions hereof and the Loan Agreement, and in reliance upon the representations and warranties of the Borrower contained in the Loan Agreement, the Lender agrees to make advances to the Borrower from time to time during the period commencing on the date of this Note and ending on the Maturity Date in an aggregate principal amount at any time outstanding not to exceed the Commitment. The Borrower agrees that it will use the proceeds of any such advance for the purposes set forth in the Loan Agreement. Borrower further agrees that it will not use the proceeds of any such advance for any illegal or unlawful purpose. Each request for an advance hereunder shall be made by a Borrowing Officer on written notice received by the Lender in the form set forth on Exhibit A attached hereto not later than 12:00 noon (St. Louis time) of the Business Day of such advance, shall specify the amount thereof, and shall be irrevocable and binding upon the Borrower. Except as the Borrower and the Lender may otherwise mutually agree, the proceeds of each advance hereunder shall be wired to an account specified by the Borrower.

3. Interest Rate. For the period from the date hereof until maturity (whether by acceleration or otherwise) the Borrower promises to pay interest, in arrears, on the from time to time unpaid principal amount of each advance hereunder on the first Business Day of each month following the Effective Date, at the Stated Rate; provided, however, that with respect to any advance or other obligation of the Borrower hereunder which is not paid at maturity, or which remains unpaid following the commencement, by or against the Borrower, of a case under Title 11 of the United States Code, the Borrower promises to pay interest on such advance or other obligation from the date of maturity or the date such case is commenced, until such advance or other obligation is paid in full, payable upon demand, at a rate per annum (in lieu of the Stated Rate in effect at such time) equal at all times to the Overdue Rate, but in no event in excess of the maximum rate permitted by law. All computations of interest with respect to each advance hereunder shall be made by the Lender on the basis of a year of 360 days for the actual number of days (including the first day, but excluding the last day) in the period for which such interest is payable. After maturity, by acceleration or otherwise, and/or upon an Event of Default, this Note shall bear interest at the Default Rate. A late charge equal to five percent (5%) of the payment amount shall be assessed for each payment not received by Lender by the date ten (10) days after the due date thereof.

Exhibit A
4. Payments.

(a) **Time of Payments.** All payments of principal, interest, fees, and other amounts due under this Note shall be made to the Lender at the Lender’s Address in lawful money of the United States not later than 2:00 p.m. (St. Louis time) on the day when due, without defense, claim, counterclaim, setoff or right of recoupment.

(b) **Final Payment.** On the Maturity Date of this Note as provided in the Loan Agreement, Borrower shall pay to the Lender, in same day funds, an amount equal to the aggregate principal amount outstanding under this Note and due on such date, together with accrued interest thereon, all fees payable to the Lender pursuant to the provisions of this Note and the Loan Agreement and any and all other Obligations then outstanding and due and payable.

(c) **Interest Calculation.** For purposes of interest calculation only, (i) a payment by check, draft, or other instrument received on a Business Day shall be deemed to have been applied to the relevant Obligation on the second following Business Day, (ii) a payment in cash or by wire transfer received at or before 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the Business Day when it is received, and (iii) a payment in cash or by wire transfer received on a day that is not a Business Day or after 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the next Business Day.

(d) **Due Dates Not on Business Days.** If any payment required hereunder becomes due on a date that is not a Business Day, then such payment shall be due on the next Business Day, the amount of such payment, in such case, to include all interest accrued to the date of actual payment.

(e) **Prepayments Generally.** The Borrower shall have the right to prepay the unpaid principal balance of the indebtedness evidenced by this Note in whole or in part, without penalty. All prepayments, whether voluntary or mandatory pursuant to acceleration, shall be applied first to any expenses due Lender under this Note or under any other documents securing or evidencing obligations of Borrower to Lender with respect to the Loan, then to accrued interest on the unpaid principal balance of this Note, and the balance, if any, shall be applied to the principal sum hereof in inverse order of maturity and shall not relieve Borrower of making installment payments hereon when due. Amounts prepaid may be re-advanced to Borrower in accordance with the terms and conditions of the Loan Agreement.

5. Oral Agreements. ORAL AGREEMENTS OR COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT INCLUDING PROMISES TO EXTEND OR RENEW SUCH DEBT ARE NOT ENFORCEABLE, REGARDLESS OF THE LEGAL THEORY UPON WHICH IT IS BASED THAT IS IN ANY WAY RELATED TO THE CREDIT AGREEMENT. TO PROTECT YOU (BORROWER(S)) AND US (CREDITOR) FROM MISUNDERSTANDING OR DISAPPOINTMENT, ANY AGREEMENTS WE REACH COVERING SUCH MATTERS ARE CONTAINED IN THIS WRITING, WHICH IS THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN US, EXCEPT AS WE MAY LATER AGREE IN WRITING TO MODIFY IT.

Exhibit A
6. **Default; Remedies after a Default.** Any one or more of the following constitutes an Event of Default hereunder: (a) the occurrence of any Event of Default under (or as defined in) the Loan Agreement; or (b) the occurrence of an Event of Default under (or as defined in) any of the other Loan Documents. Upon the occurrence of an Event of Default, remedies available to Lender shall include, but will not necessarily be limited to, the right to declare the entire principal balance hereof and accrued and unpaid interest thereon immediately due and payable and those other remedies specified in the Loan Agreement and in the other Loan Documents.

7. **Expenses; Indemnification.** The Borrower agrees to pay on demand all reasonable costs and expenses incurred by the Lender in connection with the preparation, execution, delivery, administration, modification, amendment, and enforcement (whether through legal proceedings, negotiations or otherwise) of this Note or any of the other Loan Documents (such costs and expenses to include, without limitation, the reasonable fees and disbursements of legal counsel). The Borrower agrees to indemnify and hold harmless the Lender and each of its directors, officers, employees, agents, affiliates, and advisors from and against any and all claims, damages, losses, liabilities, and expenses (including, without limitation, the reasonable fees and disbursements of legal counsel) which may be incurred by or asserted against the Lender or any such director, officer, employee, agent, affiliate, or advisor in connection with or arising out of any investigation, subpoena, litigation, or proceeding related to or arising out of this Note or any of the other Loan Documents or any transaction contemplated hereby or thereby (but in any case excluding any such claims, damages, losses, liabilities, costs, or expenses incurred by reason of the gross negligence, willful misconduct, or bad faith of the indemnitee). The obligations of the Borrower under this paragraph shall survive the payment in full of the indebtedness evidenced by this Note or by any Other Note.

8. **Assignment.** The Lender may assign to one or more banks or other entities all or a portion of its rights under this Note. In the event of an assignment of all of its rights, the Lender may transfer this Note to the assignee. The Lender may, in connection with any assignment or proposed assignment, disclose to the assignee or proposed assignee any information relating to the Borrower furnished to the Lender by or on behalf of the Borrower.

9. **Amendments, etc.** No amendment or waiver of any provision of this Note, nor consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and separately acknowledged in writing by the Lender, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

10. **Governing Law.** This Note shall be governed by, and construed and enforced in all respects in accordance with, the laws of the State of Missouri applicable to contracts made and to be performed entirely within such State, without giving effect to its conflicts of laws, principles or rules.

11. **Right of Set-off.** At any time that an Event of Default exists, the Lender is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to place an administrative hold upon or to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Lender to or for the credit or the account of the Borrower against any and all of the Obligations, irrespective of whether or not the Lender shall have made any demand under this Note or any Other Note and although the Obligations may be unmatured. The Lender agrees promptly to notify the Borrower after any such administrative hold, set-off and/or application made by the Lender; provided, however, that the failure to give such notice shall not affect the validity of such administrative hold, set-off and/or application. The rights of the Lender under this paragraph shall be in addition to all other rights and remedies (including, without limitation, other rights of set-off) which the Lender may have under applicable law.

Exhibit A
12. Notices. All notices hereunder and under the Loan Documents shall be in writing and sent by certified or registered mail, return receipt requested, or by overnight delivery service, with all charges prepaid. Notices to the Lender shall be sent to the Lender’s Address. Notices to the Borrower shall be sent to the Borrower’s Address until the Borrower specifies another address in a notice delivered to the Lender in accordance with this paragraph. Notice will be deemed received upon actual receipt at the Lender’s Address or the Borrower’s Address, as the case may be.

13. Consent to Jurisdiction; Waiver of Venue Objection; Service of Process. WITHOUT LIMITING THE RIGHT OF THE LENDER TO BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR AGAINST PROPERTY OF THE BORROWER ARISING OUT OF OR RELATING TO THIS NOTE (AN “ACTION”) IN THE COURTS OF OTHER JURISDICTIONS, THE BORROWER HEREBY IRREVOCABLY SUBMITS TO AND ACCEPTS THE NON-EXCLUSIVE JURISDICTION OF ANY MISSOURI STATE COURT OR ANY FEDERAL COURT SITTING IN ST. LOUIS CITY OR COUNTY, AND THE BORROWER HEREBY IRREVOCABLY AGREES THAT ANY ACTION MAY BE HEARD AND DETERMINED IN SUCH MISSOURI STATE COURT OR IN SUCH FEDERAL COURT. THE BORROWER HEREBY IRREVOCABLY WAIVES AND DISCLAIMS, TO THE FULLEST EXTENT THAT THE BORROWER MAY EFFECTIVELY DO SO, ANY DEFENSE OR OBJECTION (INCLUDING, WITHOUT LIMITATION, ANY DEFENSE OR OBJECTION TO VENUE BASED ON THE GROUNDS OF FORUM NON CONVENIENS) WHICH THE BORROWER MAY NOW OR HEREAFTER HAVE TO THE MAINTENANCE OF ANY ACTION IN ANY JURISDICTION. THE BORROWER HEREBY IRREVOCABLY AGREES THAT THE SUMMONS AND COMPLAINT OR ANY OTHER PROCESS IN ANY ACTION IN ANY JURISDICTION MAY BE SERVED BY MAILING (USING CERTIFIED OR REGISTERED MAIL, POSTAGE PREPAID) TO THE BORROWER’S ADDRESS. SUCH SERVICE WILL BE COMPLETE ON THE DATE SUCH PROCESS IS SO DELIVERED, AND THE BORROWER WILL HAVE THIRTY DAYS FROM SUCH COMPLETION OF SERVICE IN WHICH TO RESPOND IN THE MANNER PROVIDED BY LAW. THE BORROWER MAY ALSO BE SERVED IN ANY OTHER MANNER PERMITTED BY LAW, IN WHICH EVENT THE BORROWER’S TIME TO RESPOND SHALL BE THE TIME PROVIDED BY LAW.

14. Waiver of Jury Trial. TO THE FULLEST EXTENT PERMITTED BY LAW, THE BORROWER HEREBY WAIVES AND DISCLAIMS ANY RIGHT TO TRIAL BY JURY (WHICH THE LENDER ALSO WAIVES AND DISCLAIMS) IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM OF ANY KIND ARISING OUT OF OR RELATING TO THIS NOTE.

15. Collateral. This Note is secured as provided in the Loan Agreement.

16. Miscellaneous. No failure on the part of the Lender to exercise, and no delay in exercising, any right under this Note shall operate as a waiver thereof, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

17. Superseding Note. This Note supersedes and replaces all other promissory notes labeled “Loan Number Two” executed between the parties hereto in connection with the Loan Agreement, including the Promissory Note dated July 20, 2004, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July, 2005, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2006, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2007 in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2008 in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2009, in the principal face amount of $500,000 executed by Borrower to the order of Lender, and the Promissory Note dated July 1, 2010, in the principal face amount of $1,000,000 executed by Borrower to the order of Lender (collectively, the “Prior Notes”).

Exhibit A
Upon the Lender’s acceptance of this Note and the satisfaction and occurrence of each of the conditions precedent to the effectiveness of this Note, the Prior Notes shall be deemed canceled and of no further force or effect; provided, however, that (i) nothing in the foregoing shall be deemed to waive any outstanding principal, accrued interest, fees, or late charges under the Prior Notes, and (ii) the execution, delivery, and/or acceptance of this Note shall not be deemed to have terminated, extinguished, released, constituted a novation of, or discharged the indebtedness evidenced under the Prior Notes, which indebtedness shall continue under and be governed by this Note. No reference to this Note need be made in any instrument or document at any time referring to the Prior Notes, a reference to the Prior Notes in any such instrument or document to be deemed to be reference to this Note as the same may be amended, restated, modified, extended, and/or supplemented from time to time. Nothing herein is intended to extinguish, cancel or impair the lien priority or effect of any security agreement, pledge agreement or mortgage with respect to the Borrower’s obligations hereunder and under any other document relating hereto.

[Remainder of page intentionally left blank.]
IN WITNESS WHEREOF, the Borrower has executed this Note as of the date first above written.

THIS AGREEMENT CONTAINS A BINDING JURY WAIVER PROVISION.

THE FEMALE HEALTH COMPANY

By: ________________________________
Name: ______________________________
Title: ______________________________

STATE OF ________________________  )
   COUNTY OF ______________________ ) SS

On this ___ day of __________, 2011, before me appeared ______________, in his/her capacity as ______________ of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, to me personally known, who, being by me duly sworn, did say that he/she is the ______________ of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, and that said instrument was signed in behalf of said corporation by authority of its ______________, and said ______________, as ______________, acknowledged said instrument to be the free act and deed of said corporation.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in the County and State aforesaid, the day and year first above written.

Notary Public

My Commission
Expires: ______________________________

Borrower’s Address:
515 N. State Street
Suite 2225
Chicago, Illinois  60654

Exhibit A
## ADVANCES AND PAYMENTS OF PRINCIPAL AND INTEREST

<table>
<thead>
<tr>
<th>DATE</th>
<th>AMOUNT OF ADVANCE</th>
<th>AMOUNT OF PRINCIPAL PAID OR PREPAID</th>
<th>AMOUNT OF INTEREST PAID</th>
<th>UNPAID PRINCIPAL BALANCE OF ADVANCES</th>
<th>NOTATION MADE BY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exhibit A
SCHEDULE A

Definitions

“Affiliate” means, with respect to a Person, (a) any officer, director, employee, member or managing agent of such Person, (b) any spouse, parents, brothers, sisters, children and grandchildren of such Person, (c) any association, partnership, trust, entity or enterprise in which such Person is a director, officer or general partner, (d) any other Person that, (i) directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such given Person, (ii) directly or indirectly beneficially owns or holds 5% or more of any class of voting stock or partnership, membership or other interest of such Person or any Subsidiary of such Person, or (iii) 5% or more of the voting stock or partnership, membership or other interest of which is directly or indirectly beneficially owned or held by such Person or a Subsidiary of such Person. The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other interests, by contract or otherwise.

“Base Rate” means, for any day, the prime rate established and announced by Lender from time to time in the ordinary course of its business (which rate may not be the best or lowest rate offered to Lender’s corporate customers), provided, that if such Base Rate is discontinued or replaced by a comparable rate, then it shall mean the comparable rate.

“Borrower” means THE FEMALE HEALTH COMPANY, a Wisconsin corporation.

“Borrower’s Address” means 515 N. State Street, Suite 2225, Chicago, Illinois 60654.

“Borrowing Officer” means each individual of Borrower who is duly authorized by Borrower to submit a request for a Loan Advance.

“Business Day” means any day other than a Saturday, Sunday, or other day on which banks in St. Louis, Missouri are authorized to close.

“Commitment” means the agreement of the Lender to fund advances to the Borrower in an aggregate principal amount not to exceed, at any time outstanding, US $2,000,000.00.

“Default Rate” means a rate of interest equal to four percent per annum (4%) in excess of the Stated Rate.

“Dollar” and “$” means freely transferable United States dollars.

“Effective Date” means the later of (a) the Agreement Date, as defined in the Loan Agreement, and (b) the first date on which all of the conditions set forth in Section 4.1 of the Loan Agreement shall have been fulfilled or waived by the Lender.

“Events of Default” has the meaning specified in paragraph 6 of this Note, or any Event of Default as defined in the Loan Agreement.

“Lender” means Heartland Bank, a federal savings bank, and its successors and assigns.

“Lender’s Address” means 212 S. Central Avenue, Clayton, Missouri 63105.

Exhibit A
“Loans” means any loan made to Borrower pursuant to Section 2.1 of the Loan Agreement and all extensions, renewals and modifications thereto, as well as all such Loans collectively.

“Loan Agreement” means that certain Second Amended and Restated Loan Agreement dated as of the date hereof, as the same may be amended, modified, or restated.

“Loan Documents” means, collectively, this Note, the Loan Agreement, the Security Agreement, and each other instrument, agreement and document executed and delivered by Borrower in connection with this Note and each other instrument, agreement, or document referred to herein or contemplated hereby.

“Material Adverse Effect” means any act, omission, event or undertaking which would, singly or in the aggregate, have a material adverse effect upon (a) the business, assets, properties, liabilities, condition (financial or otherwise), results of operations or business prospects of Borrower, (b) upon the ability of Borrower to perform any obligations under this Note or any other Loan Document to which it is a party, or (c) the legality, validity, binding effect, enforceability or admissibility into evidence of any Loan Document or the ability of Lender to enforce any rights or remedies under or in connection with any Loan Document; in any case, whether resulting from any single act, omission, situation, status, event, or undertaking, together with other such acts, omissions, situations, statuses, events, or undertakings.

“Maturity Date” means August 1, 2012.

“Note” means this Note and any and all amendments, modifications, restatements, renewals or refinancings thereof.

“Obligations” means, in each case whether now in existence or hereafter arising, (a) the principal of and interest and premium, if any, on, and expenses related to, the Loans and (b) all indebtedness, liabilities, obligations, overdrafts, covenants and duties of Borrower to the Lender of every kind, nature and description, direct or indirect, absolute or contingent, due or not due, contractual or tortious, liquidated or unliquidated, and whether or not evidenced by any note and whether or not for the payment of money under or in respect of the Loans, this Note, any Note or any of the other Loan Documents.

“Obligors” means Borrower, and each other party at any time primarily or secondarily, directly or indirectly, liable on any of the Obligations.

“Other Note” means any promissory note which may be given in renewal or extension of all or any part of the indebtedness evidenced by this Note or which may amend or restate the terms pursuant to which such indebtedness is to remain outstanding.

“Overdue Rate” means, in respect of any amount not paid when due under this Note or any Other Note, a rate per annum during the period commencing on the due date of such amount until such amount is paid in full equal to 4% per annum in excess of the Stated Rate.

“Person” means an individual, corporation, partnership, association, trust or unincorporated organization or a government or any agency or political subdivision thereof.

“Stated Rate” means a rate of interest of Base Rate plus .50% per annum (each change in the Base Rate will result in a simultaneous change in the Stated Rate).

Exhibit A
EXHIBIT A

FORM OF REQUEST FOR AN ADVANCE

Heartland Bank
212 South Central Avenue
St. Louis, Missouri  63105
Attn.: ___________

Re: Promissory Note, dated as of August 1, 2011 between THE FEMALE HEALTH COMPANY (“Borrower”) and HEARTLAND BANK (“Lender”), as it may be amended, modified, restated, or replaced from time to time (the “Note”)

Ladies and Gentlemen:

The undersigned is a Borrowing Officer and, as such is authorized to make and deliver this request for an advance pursuant to the Note. All capitalized words used herein that are defined in the Note have the meanings defined in the Note.

Borrower hereby requests that Lender make a Loan of $__________ to Borrower under the terms of the Note dated August 1, 2011. The proceeds of the advance should be deposited in account number ___________________________ with [Lender].

The undersigned hereby certifies on behalf of Borrower that:

(i) There is no Event of Default.

(ii) The representations and warranties of Borrower in the Loan Agreement are true as if made on the date hereof (other than representations and warranties, which, by their terms, are applicable only to the Agreement Date (as defined in the Second Amended and Restated Loan Agreement entered into in connection with the Note) or other specified date, which shall be true and correct only as of that date).

(iii) The amount of the requested advance will not, when added to the current amount of the aggregate Loans exceed the Commitment.

(iv) All conditions precedent to an advance as set forth in the Loan Agreement have been satisfied.

(v) The proceeds of this advance will be used for the following purpose: ____________________________________________.

Executed this _____ day of _______, 20__. 

THE FEMALE HEALTH COMPANY

By:

Name: ____________________________________________

Title: ____________________________________________

Exhibit A
EXHIBIT B

Borrowing Base Certificate

TO: Heartland Bank

As of the quarter ending ______________, 20__

("Effective Date")

Pursuant to the Second Amended and Restated Loan Agreement dated as of August 1, 2011 between The Female Health Company and Heartland Bank (the "Loan Agreement"), as the same may be amended, the undersigned officer of The Female Health Company hereby certifies to Heartland Bank that the following information is true, correct and complete in all material respects as of _____________________, 20__.

1. Face Value of Eligible Receivables as of preceding Business Day
   $ 
2. 80% of Line 1¹
   $ 
3. Cost of Eligible Inventory, figured on a first-in first-out basis
   $ 
4. Fair Market Value of Eligible Inventory
   $ 
5. Lesser of Line Item “3” or “4” x 50%
   $ 
6. Total Borrowing Base (Add Line Item “2” and “5”)
   $ 
7. Total Revolving Credit Facility
   $ 2,000,000.00
8. Borrower’s Maximum Revolving Credit Availability (Lesser of Line Item “6” or Line Item “7”)
   $ 
9. Aggregate principal amount of outstanding Loan
   $ 
10. Unused Revolving Credit Availability (Line Item “8” minus Line Item “9”)
    $ 

If Line Item “10” is negative, this Certificate is accompanied by the mandatory repayment, as required by Section 2.4(b) of the Loan Agreement.

Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Loan Agreement.

The undersigned represents and warrants that the foregoing is true, complete and correct, and that the information reflected in this Certificate complies with the representations and warranties set forth in the Loan Agreement. The undersigned also represents and warrants that there is no Default or Event of Default under the said Loan Agreement.

¹Except for Semina Eligible Receivables, if any, of which only 70% of the face value due and owing at such time may be included

Exhibit B
Dated this ___ day of ____________, 20__

THE FEMALE HEALTH COMPANY

By:  
Name:  
Title:  

Exhibit B
EXHIBIT C
Compliance Certificate

To: Heartland Bank

Except as explained in reasonable detail below under Exceptions,

(i) the attached Financial Statements are complete and correct in all material respects (subject, in the case of Financial Statements other than annual statements, to normal year-end audit adjustments and absence of footnotes) and have been prepared in accordance with GAAP applied consistently throughout the periods covered thereby and with prior periods (except as disclosed therein),

(ii) all of the representations and warranties of Borrower contained in that certain Second Amended and Restated Loan Agreement dated as of August 1, 2011 (the “Loan Agreement”) and other Loan Documents (as defined in the Loan Agreement) are true and correct in all material respects as of the date of this Certificate, other than representations and warranties, which, by their terms, are applicable only to the date of the Loan Agreement and the Loan Documents,

(iii) there exists no Default or Event of Default (as defined in the Loan Agreement) which is continuing that has not been waived in writing by Lender and no Event of Default has occurred that has not been waived in writing by Lender, and

(iv) the Leverage Ratio of the Borrower as of the end of the month preceding the date hereof is: __:__.

Note: If disclosing that a representation or warranty is not true and correct in any material respect, or that a Default or Event of Default has occurred that has not been waived in writing by Lender, set forth what action Borrower has taken or proposes to take with respect thereto.

Exceptions, explanations and actions taken or proposes to be taken:

Dated this ____ day of ____________, 20__

THE FEMALE HEALTH COMPANY

By: ________________________________
Name: ______________________________
Title: ______________________________

Exhibit C
SCHEDULE 5.1(m)
Borrower’s Locations
Schedule 5.1(r)

Intellectual Property of Borrower and its Subsidiaries
PROMISSORY NOTE

US $2,000,000.00

St. Louis, Missouri

Dated as of August 1, 2011

FOR VALUE RECEIVED, the undersigned, THE FEMALE HEALTH COMPANY, a Wisconsin corporation (the “Borrower”), hereby promises to pay to the order of HEARTLAND BANK, a federal savings bank (the “Lender”), at its office at 212 S. Central Avenue, Clayton, Missouri 63105 (the “Lender’s Address”), or at such other office as the Lender may subsequently designate in writing, (i) on August 1, 2012 (the “Maturity Date”), the principal amount of Two Million Dollars (US $2,000,000.00), or, if less, the aggregate unpaid principal amount of all advances made hereunder by the Lender to the Borrower prior to said date, (ii) interest on such principal amount at the interest rate per annum for each advance, as determined in accordance with the terms specified below (but in no event in excess of the maximum rate permitted by applicable law), and (iii) any and all other sums which may be owing to the Lender by the Borrower pursuant to this Note. All advances made hereunder by the Lender to the Borrower and all payments made on account of principal hereof and interest hereunder shall be recorded by the Lender and, prior to any transfer hereof, endorsed on the grid attached hereto; provided, however, that the Lender’s failure to record any such advance or payment shall not limit or otherwise affect the obligations of the Borrower under this Note.

1. **Definitions.** Each initially capitalized term used herein shall have the meaning set forth in Schedule A. Any capitalized terms used herein, but not otherwise defined herein or on Schedule A attached hereto, shall have the meaning ascribed to such term(s) as set forth in the Loan Agreement.

2. **Advances.** Subject to the terms and conditions hereof and the Loan Agreement, and in reliance upon the representations and warranties of the Borrower contained in the Loan Agreement, the Lender agrees to make advances to the Borrower from time to time during the period commencing on the date of this Note and ending on the Maturity Date in an aggregate principal amount at any time outstanding not to exceed the Commitment. The Borrower agrees that it will use the proceeds of any such advance for the purposes set forth in the Loan Agreement. Borrower further agrees that it will not use the proceeds of any such advance for any illegal or unlawful purpose. Each request for an advance hereunder shall be made by a Borrowing Officer on written notice received by the Lender in the form set forth on Exhibit A attached hereto not later than 12:00 noon (St. Louis time) of the Business Day of such advance, shall specify the amount thereof, and shall be irrevocable and binding upon the Borrower. Except as the Borrower and the Lender may otherwise mutually agree, the proceeds of each advance hereunder shall be wired to an account specified by the Borrower.

3. **Interest Rate.** For the period from the date hereof until maturity (whether by acceleration or otherwise) the Borrower promises to pay interest, in arrears, on the from time to time unpaid principal amount of each advance hereunder on the first Business Day of each month beginning the second calendar month following the Effective Date, at the Stated Rate; provided, however, that with respect to any advance or other obligation of the Borrower hereunder which is not paid at maturity, or which remains unpaid following the commencement, by or against the Borrower, of a case under Title 11 of the United States Code, the Borrower promises to pay interest on such advance or other obligation from the date of maturity or the date such case is commenced, until such advance or other obligation is paid in full, payable upon demand, at a rate per annum (in lieu of the Stated Rate in effect at such time) equal at all times to the Overdue Rate, but in no event in excess of the maximum rate permitted by law. All computations of interest with respect to each advance hereunder shall be made by the Lender on the basis of a year of 360 days for the actual number of days (including the first day, but excluding the last day) in the period for which such interest is payable. After maturity, by acceleration or otherwise, and/or upon an Event of Default, this Note shall bear interest at the Default Rate. A late charge equal to five percent (5%) of the payment amount shall be assessed for each payment not received by Lender by the date ten (10) days after the due date therefor.
4. **Payments.**

(a) **Time of Payments.** All payments of principal, interest, fees, and other amounts due under this Note shall be made to the Lender at the Lender’s Address in lawful money of the United States not later than 2:00 p.m. (St. Louis time) on the day when due, without defense, claim, counterclaim, setoff or right of recoupment.

(b) **Final Payment.** On the Maturity Date of this Note as provided in the Loan Agreement, Borrower shall pay to the Lender, in same day funds, an amount equal to the aggregate principal amount outstanding under this Note and due on such date, together with accrued interest thereon, all fees payable to the Lender pursuant to the provisions of this Note and the Loan Agreement and any and all other Obligations then outstanding and due and payable.

(c) **Interest Calculation.** For purposes of interest calculation only, (i) a payment by check, draft, or other instrument received on a Business Day shall be deemed to have been applied to the relevant Obligation on the second following Business Day, (ii) a payment in cash or by wire transfer received at or before 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the Business Day when it is received, and (iii) a payment in cash or by wire transfer received on a day that is not a Business Day or after 2:00 p.m., St. Louis, Missouri time, on a Business Day shall be deemed to have been applied to the relevant Obligation on the next Business Day.

(d) **Due Dates Not on Business Days.** If any payment required hereunder becomes due on a date that is not a Business Day, then such payment shall be due on the next Business Day, the amount of such payment, in such case, to include all interest accrued to the date of actual payment.

(e) **Prepayments Generally.** The Borrower shall have the right to prepay the unpaid principal balance of the indebtedness evidenced by this Note in whole or in part, without penalty. All prepayments, whether voluntary or mandatory pursuant to acceleration, shall be applied first to any expenses due Lender under this Note or under any other documents securing or evidencing obligations of Borrower to Lender with respect to the Loan, then to accrued interest on the unpaid principal balance of this Note, and the balance, if any, shall be applied to the principal sum hereof in inverse order of maturity and shall not relieve Borrower of making installment payments hereon when due. Amounts prepaid may be re-advanced to Borrower in accordance with the terms and conditions of the Loan Agreement.
5. **Oral Agreements.** ORAL AGREEMENTS OR COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT INCLUDING PROMISES TO EXTEND OR RENEW SUCH DEBT ARE NOT ENFORCEABLE, REGARDLESS OF THE LEGAL THEORY UPON WHICH IT IS BASED THAT IS IN ANY WAY RELATED TO THE CREDIT AGREEMENT. TO PROTECT YOU (BORROWER(S)) AND US (CREDITOR) FROM MISUNDERSTANDING OR DISAPPOINTMENT, ANY AGREEMENTS WE REACH COVERING SUCH MATTERS ARE CONTAINED IN THIS WRITING, WHICH IS THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN US, EXCEPT AS WE MAY LATER AGREE IN WRITING TO MODIFY IT.

6. **Default: Remedies after a Default.** Any one or more of the following constitutes an Event of Default hereunder: (a) the occurrence of any Event of Default under (or as defined in) the Loan Agreement; or (b) the occurrence of an Event of Default under (or as defined in) any of the other Loan Documents. Upon the occurrence of an Event of Default, the remedies available to Lender shall include, but will not necessarily be limited to, the right to declare the entire principal balance hereof and accrued and unpaid interest thereon immediately due and payable and those other remedies specified in the Loan Agreement and in the other Loan Documents.

7. **Expenses; Indemnification.** The Borrower agrees to pay on demand all reasonable costs and expenses incurred by the Lender in connection with the preparation, execution, delivery, administration, modification, amendment, and enforcement (whether through legal proceedings, negotiations or otherwise) of this Note or any of the other Loan Documents (such costs and expenses to include, without limitation, the reasonable fees and disbursements of legal counsel). The Borrower agrees to indemnify and hold harmless the Lender and each of its directors, officers, employees, agents, affiliates, and advisors from and against any and all claims, damages, losses, liabilities, and expenses (including, without limitation, the reasonable fees and disbursements of legal counsel) which may be incurred by or asserted against the Lender or any such director, officer, employee, agent, affiliate, or advisor in connection with or arising out of any investigation, subpoena, litigation, or proceeding related to or arising out of this Note or any of the other Loan Documents or any transaction contemplated hereby or thereby (but in any case excluding any such claims, damages, losses, liabilities, costs, or expenses incurred by reason of the gross negligence, willful misconduct, or bad faith of the indemnitee). The obligations of the Borrower under this paragraph shall survive the payment in full of the indebtedness evidenced by this Note or by any Other Note.

8. **Assignment.** The Lender may assign to one or more banks or other entities all or a portion of its rights under this Note. In the event of an assignment of all of its rights, the Lender may transfer this Note to the assignee. The Lender may, in connection with any assignment or proposed assignment, disclose to the assignee or proposed assignee any information relating to the Borrower furnished to the Lender by or on behalf of the Borrower.

9. **Amendments, etc.** No amendment or waiver of any provision of this Note, nor consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and separately acknowledged in writing by the Lender, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.
10. **Governing Law.** This Note shall be governed by, and construed and enforced in all respects in accordance with, the laws of the State of Missouri applicable to contracts made and to be performed entirely within such State, without giving effect to its conflicts of laws, principles or rules.

11. **Right of Set-off.** At any time that an Event of Default exists, the Lender is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to place an administrative hold upon or to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Lender to or for the credit or the account of the Borrower against any and all of the Obligations, irrespective of whether or not the Lender shall have made any demand under this Note or any Other Note and although the Obligations may be unmatured. The Lender agrees promptly to notify the Borrower after any such administrative hold, set-off and/or application made by the Lender; provided, however, that the failure to give such notice shall not affect the validity of such administrative hold, set-off and/or application. The rights of the Lender under this paragraph shall be in addition to all other rights and remedies (including, without limitation, other rights of set-off) which the Lender may have under applicable law.

12. **Notices.** All notices hereunder and under the Loan Documents shall be in writing and sent by certified or registered mail, return receipt requested, or by overnight delivery service, with all charges prepaid. Notices to the Lender shall be sent to the Lender's Address. Notices to the Borrower shall be sent to the Borrower's Address until the Borrower specifies another address in a notice delivered to the Lender in accordance with this paragraph. Notice will be deemed received upon actual receipt at the Lender's Address or the Borrower's Address, as the case may be.

13. **Consent to Jurisdiction; Waiver of Venue Objection; Service of Process.** WITHOUT LIMITING THE RIGHT OF THE LENDER TO BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR AGAINST PROPERTY OF THE BORROWER ARISING OUT OF OR RELATING TO THIS NOTE (AN “ACTION”) IN THE COURTS OF OTHER JURISDICTIONS, THE BORROWER HEREBY IRREVOCABLY SUBMITS TO AND ACCEPTS THE NON-EXCLUSIVE JURISDICTION OF ANY MISSOURI STATE COURT OR ANY FEDERAL COURT SITTING IN ST. LOUIS CITY OR COUNTY, AND THE BORROWER HEREBY IRREVOCABLY AGREES THAT ANY ACTION MAY BE HEARD AND DETERMINED IN SUCH MISSOURI STATE COURT OR IN SUCH FEDERAL COURT. THE BORROWER HEREBY IRREVOCABLY WAIVES AND DISCLAIMS, TO THE FULLEST EXTENT THAT THE BORROWER MAY EFFECTIVELY DO SO, ANY DEFENSE OR OBJECTION (INCLUDING, WITHOUT LIMITATION, ANY DEFENSE OR OBJECTION TO VENUE BASED ON THE GROUNDS OF FORUM NON CONVENIENS) WHICH THE BORROWER MAY NOW OR HEREAFTER HAVE TO THE MAINTENANCE OF ANY ACTION IN ANY JURISDICTION. THE BORROWER HEREBY IRREVOCABLY AGREES THAT THE SUMMONS AND COMPLAINT OR ANY OTHER PROCESS IN ANY ACTION IN ANY JURISDICTION MAY BE SERVED BY MAILING (USING CERTIFIED OR REGISTERED MAIL, POSTAGE PREPAID) TO THE BORROWER’S ADDRESS. SUCH SERVICE WILL BE COMPLETE ON THE DATE SUCH PROCESS IS SO DELIVERED, AND THE BORROWER WILL HAVE THIRTY DAYS FROM SUCH COMPLETION OF SERVICE IN WHICH TO RESPOND IN THE MANNER PROVIDED BY LAW. THE BORROWER MAY ALSO BE SERVED IN ANY OTHER MANNER PERMITTED BY LAW, IN WHICH EVENT THE BORROWER’S TIME TO RESPOND SHALL BE THE TIME PROVIDED BY LAW.
14. **Waiver of Jury Trial.** TO THE FULLEST EXTENT PERMITTED BY LAW, THE BORROWER HEREBY WAIVES AND DISCLAIMS ANY RIGHT TO TRIAL BY JURY (WHICH THE LENDER ALSO WAIVES AND DISCLAIMS) IN ANY ACTION, SUIT, PROCEEDING OR COUNTERCLAIM OF ANY KIND ARISING OUT OF OR RELATING TO THIS NOTE.

15. **Collateral.** This Note is secured as provided in the Loan Agreement.

16. **Miscellaneous.** No failure on the part of the Lender to exercise, and no delay in exercising, any right under this Note shall operate as a waiver thereof, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

17. **Superseding Note.** This Note supersedes and replaces all other promissory notes labeled “Loan Number Two” executed between the parties hereto in connection with the Loan Agreement, including the Promissory Note dated July 20, 2004, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2005, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2006, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2007, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2008, in the principal face amount of $500,000 executed by Borrower to the order of Lender, the Promissory Note dated July 1, 2009, in the principal face amount of $500,000 executed by Borrower to the order of Lender, and the Promissory Note dated July 1, 2010, in the principal face amount of $1,000,000 executed by Borrower to the order of Lender (collectively, the “Prior Notes”). Upon the Lender’s acceptance of this Note and the satisfaction and occurrence of each of the conditions precedent to the effectiveness of this Note, the Prior Notes shall be deemed canceled and of no further force or effect; provided, however, that (i) nothing in the foregoing shall be deemed to waive any outstanding principal, accrued interest, fees, or late charges under the Prior Notes, and (ii) the execution, delivery, and/or acceptance of this Note shall not be deemed to have terminated, extinguished, released, constituted a novation of, or discharged the indebtedness evidenced under the Prior Notes, which indebtedness shall continue under and be governed by this Note. No reference to this Note need be made in any instrument or document at any time referring to the Prior Notes, a reference to the Prior Notes in any such instrument or document to be deemed to be reference to this Note as the same may be amended, restated, modified, extended, and/or supplemented from time to time. Nothing herein is intended to extinguish, cancel or impair the lien priority or effect of any security agreement, pledge agreement or mortgage with respect to the Borrower’s obligations hereunder and under any other document relating hereto.

[Remainder of page intentionally left blank.]
IN WITNESS WHEREOF, the Borrower has executed this Note as of the date first above written.

THIS AGREEMENT CONTAINS A BINDING JURY WAIVER PROVISION.

THE FEMALE HEALTH COMPANY

By: /s/ O.B. Parrish
Name: O.B. Parrish
Title: Chairman and CEO

STATE OF ILLINOIS )
) SS
COUNTY OF COOK )

On this 1st day of August, 2011, before me appeared O.B. Parrish, in his/her capacity as Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, to me personally known, who, being by me duly sworn, did say that he/she is the Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, and that said instrument was signed in behalf of said corporation by authority of its Board of Directors, and said O.B. Parrish, as Chairman and CEO, acknowledged said instrument to be the free act and deed of said corporation.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in the County and State aforesaid, the day and year first above written.

/s/ Jacqueline F. Martin
Notary Public

My Commission Expires: 02/26/2014

Borrower’s Address:
515 N. State Street
Suite 2225
Chicago, Illinois 60654
<table>
<thead>
<tr>
<th>DATE</th>
<th>AMOUNT OF ADVANCE</th>
<th>AMOUNT OF PRINCIPAL PAID OR PREPAID</th>
<th>AMOUNT OF INTEREST PAID</th>
<th>UNPAID PRINCIPAL BALANCE OF ADVANCES</th>
<th>NOTATION MADE BY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
"Affiliate" means, with respect to a Person, (a) any officer, director, employee, member or managing agent of such Person, (b) any spouse, parents, brothers, sisters, children and grandchildren of such Person, (c) any association, partnership, trust, entity or enterprise in which such Person is a director, officer or general partner, (d) any other Person that, (i) directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such given Person, (ii) directly or indirectly beneficially owns or holds 5% or more of any class of voting stock or partnership, membership or other interest of such Person or any Subsidiary of such Person, or (iii) 5% or more of the voting stock or partnership, membership or other interest of which is directly or indirectly beneficially owned or held by such Person or a Subsidiary of such Person. The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities or partnership or other interests, by contract or otherwise.

"Base Rate" means, for any day, the prime rate established and announced by Lender from time to time in the ordinary course of its business (which rate may not be the best or lowest rate offered to Lender’s corporate customers), provided, that if such Base Rate is discontinued or replaced by a comparable rate, then it shall mean the comparable rate.

"Borrower" means THE FEMALE HEALTH COMPANY, a Wisconsin corporation.

"Borrower’s Address" means 515 N. State Street, Suite 2225, Chicago, Illinois 60654.

"Borrowing Officer" means each individual of Borrower who is duly authorized by Borrower to submit a request for a Loan Advance.

"Business Day" means any day other than a Saturday, Sunday, or other day on which banks in St. Louis, Missouri are authorized to close.

"Commitment" means the agreement of the Lender to fund advances to the Borrower in an aggregate principal amount not to exceed, at any time outstanding, US $2,000,000.00.

"Default Rate" means a rate of interest equal to four percent per annum (4%) in excess of the Stated Rate.

"Dollar" and "$" means freely transferable United States dollars.

"Effective Date" means the later of (a) the Agreement Date, as defined in the Loan Agreement, and (b) the first date on which all of the conditions set forth in Section 4.1 of the Loan Agreement shall have been fulfilled or waived by the Lender.

"Events of Default" has the meaning specified in paragraph 6 of this Note, or any Event of Default as defined in the Loan Agreement.

"Lender" means Heartland Bank, a federal savings bank, and its successors and assigns.
“Lender’s Address” means 212 S. Central Avenue, Clayton, Missouri 63105.

“Loans” means any loan made to Borrower pursuant to Section 2.1 of the Loan Agreement and all extensions, renewals and modifications thereto, as well as all such Loans collectively.

“Loan Agreement” means that certain Amended and Restated Loan Agreement entered into by and between Lender and Borrower, dated as of July 20, 2004, as amended by the First Amendment to Amended and Restated Loan Agreement dated November 1, 2004, and as further amended by the Second Amendment to Amended and Restated Loan Agreement dated July 1, 2005, and as further amended by the Third Amendment to Amended and Restated Loan Agreement dated July 1, 2006, and as further amended by the Fourth Amendment to Amended and Restated Loan Agreement dated July 1, 2007, as further amended by a Fifth Amendment to Amended and Restated Loan Agreement dated July 1, 2008, as further amended by a Sixth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2009, as further amended by a Seventh Amendment to Amended and Restated Loan Agreement dated as of January 4, 2010, as further amended by an Eighth Amendment to Amended and Restated Loan Agreement dated as of July 10, 2010, and as further amended by a Second Amended and Restated Loan Agreement dated as of the date herewith, as the same may be amended, modified, or restated.

“Loan Documents” means, collectively, this Note, the Loan Agreement, the Security Agreement, and each other instrument, agreement and document executed and delivered by Borrower in connection with this Note and each other instrument, agreement, or document referred to herein or contemplated hereby.

“Material Adverse Effect” means any act, omission, event or undertaking which would, singly or in the aggregate, have a material adverse effect upon (a) the business, assets, properties, liabilities, condition (financial or otherwise), results of operations or business prospects of Borrower, (b) upon the ability of Borrower to perform any obligations under this Note or any other Loan Document to which it is a party, or (c) the legality, validity, binding effect, enforceability or admissibility into evidence of any Loan Document or the ability of Lender to enforce any rights or remedies under or in connection with any Loan Document; in any case, whether resulting from any single act, omission, situation, status, event, or undertaking, together with other such acts, omissions, situations, statuses, events, or undertakings.

“Maturity Date” means August 1, 2012.

“Note” means this Note and any and all amendments, modifications, restatements, renewals or refinancings thereof.

“Obligations” means, in each case whether now in existence or hereafter arising, (a) the principal of and interest and premium, if any, on, and expenses related to, the Loans and (b) all indebtedness, liabilities, obligations, overdrafts, covenants and duties of Borrower to the Lender of every kind, nature and description, direct or indirect, absolute or contingent, due or not due, contractual or tortious, liquidated or unliquidated, and whether or not evidenced by any note and whether or not for the payment of money under or in respect of the Loans, this Note, any Note or any of the other Loan Documents.
“Obligors” means Borrower, and each other party at any time primarily or secondarily, directly or indirectly, liable on any of the Obligations.

“Other Note” means any promissory note which may be given in renewal or extension of all or any part of the indebtedness evidenced by this Note or which may amend or restate the terms pursuant to which such indebtedness is to remain outstanding.

“Overdue Rate” means, in respect of any amount not paid when due under this Note or any Other Note, a rate per annum during the period commencing on the due date of such amount until such amount is paid in full equal to 4% per annum in excess of the Stated Rate.

“Person” means an individual, corporation, partnership, association, trust or unincorporated organization or a government or any agency or political subdivision thereof.

“Stated Rate” means a rate of interest of Base Rate plus .50% per annum (each change in the Base Rate will result in a simultaneous change in the Stated Rate).
Heartland Bank
212 South Central Avenue
St. Louis, Missouri 63105
Attn.:  

Re: Promissory Note, dated as of August 1, 2011 between THE FEMALE HEALTH COMPANY ("Borrower") and HEARTLAND BANK ("Lender"), as it may be amended, modified, restated, or replaced from time to time (the "Note")

Ladies and Gentlemen:

The undersigned is a Borrowing Officer and, as such is authorized to make and deliver this request for an advance pursuant to the Note. All capitalized words used herein that are defined in the Note have the meanings defined in the Note.

Borrower hereby requests that Lender make a Loan of $__________ to Borrower under the terms of the Note dated August 1, 2011. The proceeds of the advance should be deposited in account number ___________________________ with [Lender].

The undersigned hereby certifies on behalf of Borrower that:

(i) There is no Event of Default.

(ii) The representations and warranties of Borrower in the Loan Agreement are true as if made on the date hereof.

(iii) The amount of the requested advance will not, when added to the current amount of the aggregate Loans exceed the Commitment.

(iv) All conditions precedent to an advance as set forth in the Loan Agreement have been satisfied.

(v) The proceeds of this advance will be used for the following purpose:

____________________________________________________.

Executed this _____ day of _______, 20__.  

THE FEMALE HEALTH COMPANY

By: __________________________
Name: _____________________
Title: ______________________
SECOND AMENDMENT TO
COMMERCIAL SECURITY AGREEMENT

THIS SECOND AMENDMENT TO COMMERCIAL SECURITY AGREEMENT (hereinafter referred to as this “Amendment”), is made and entered into as of this 1st day of August, 2011, by THE FEMALE HEALTH COMPANY, a Wisconsin corporation, whose mailing address is 515 N. State Street, Suite 2225, Chicago, Illinois 60654 (“Grantor”), to and for the benefit of HEARTLAND BANK, a federal savings bank, whose mailing address is 212 South Central Ave., Suite 200, Clayton, Missouri 63105 (“Lender”). This Amendment amends that certain Commercial Security Agreement dated as of November 1, 2004 by and between the parties hereto, as amended by that certain First Amendment to Commercial Security Agreement dated as of July 1, 2010 (collectively, and together with this Amendment, the “Security Agreement”).

WITNESSETH:

WHEREAS, the Lender and Grantor entered into an Amended and Restated Loan Agreement dated as of July 20, 2004, as amended by the First Amendment to Amended and Restated Loan Agreement dated November 1, 2004, as further amended by the Second Amendment to Amended and Restated Loan Agreement dated July ___, 2005, as further amended by the Third Amendment to Amended and Restated Loan Agreement dated July 1, 2006, as further amended by the Fourth Amendment to Amended and Restated Loan Agreement dated July 1, 2007, as further amended by the Fifth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2008, as further amended by the Sixth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2009, as further amended by the Seventh Amendment to Amended and Restated Loan Agreement dated as of January 4, 2010, and as further amended by the Eighth Amendment to Amended and Restated Loan Agreement dated as of July 1, 2010 (as so amended, the “Loan Agreement”), pursuant to which Lender has made available to Grantor from time to time certain term and revolving credit facilities;

WHEREAS, Grantor and Lender have agreed to amend and restate the Loan Agreement by executing a Second Amended and Restated Loan Agreement to change the terms and conditions of two (2) revolving credit facilities, including closing a certain revolving credit facility in the amount of One Million Dollars ($1,000,000) (Loan Number 303301693) and increasing the other revolving credit facility from One Million Dollars ($1,000,000) to Two Million Dollars ($2,000,000) (the “Two Million Dollar Loan”), and are desirous of amending and restating the promissory note evidencing the Two Million Dollar Loan to reflect the same, and in order to induce the Lender to do so, and as a condition precedent thereto, the parties hereto have agreed to modify certain provisions contained in the Security Agreement, all on the terms and conditions hereafter set forth; and

NOW, THEREFORE, in consideration of the mutual covenants herein contained and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:

Section 1. Definitions, References. Capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Security Agreement. Each reference to “hereof,” “hereunder,” “herein,” and “hereby” and each other similar reference and each reference to “this Agreement” and each other similar reference contained in the Security Agreement shall from the date hereof refer to the Security Agreement as amended hereby.
Section 2. Amendment to the Security Agreement. The Security Agreement is hereby amended as follows:

2.1 The definition of “Loan Agreement” is hereby deleted in its entirety and is hereby replaced with the following:

Loan Agreement. The words “Loan Agreement” mean that certain Second Amended and Restated Loan Agreement dated as of August 1, 2011, as the same may be amended, renewed, or extended.

2.2 The definition of “Notes” is hereby deleted in its entirety and is hereby replaced with the following:

Notes. The word “Notes” means the Promissory Note dated as of August 1, 2011, made by Grantor payable to the order of Lender evidencing the obligation of Grantor to pay the aggregate unpaid principal amount of the loan made by Lender to Grantor in the principal face amount of $2,000,000, and all extensions, renewals and modifications thereto.

2.3 The following definition of “Related Documents” is hereby added to the Security Agreement:

Related Documents. The words “Related Documents” mean, collectively, the Loan Agreement, the Notes, and each other instrument, agreement and document executed and delivered by Grantor in connection with the Loan Agreement and each other instrument, agreement or document referred to in the Loan Agreement or contemplated thereby.

Section 3. Representations and Warranties. The Grantor hereby represents and warrants to the Lender that all of the representations and warranties of Grantor set forth in the Security Agreement remain true, correct and accurate in all respects.

Section 4. Voluntary Agreement. Each party represents and warrants to the other that it has consulted or has had the opportunity to consult with counsel regarding this Amendment that it is fully aware of the terms contained herein and that it has voluntarily and without coercion or duress of my kind entered into this Amendment.

Section 5. Benefit of Security Agreement. This Amendment shall be binding upon and shall inure to and for the benefit of the parties hereto, their heirs, administrators, personal representatives, successors and assigns.

Section 6. Authority. By his or her execution hereof, each of the persons signing on behalf of the parties hereto hereby represents and warrants that each is fully authorized to act and execute this Amendment on behalf of their respective party.
Section 7.  Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which shall constitute together but one and the same agreement.

Section 8.  Severability. The invalidity of any portion hereof shall not affect the validity, force or effect of the remaining portions hereof. If it is ever held that any restriction hereunder is too broad to permit enforcement of such restriction to its fullest extent, such restriction shall be enforced to the maximum extent permitted by law.

Section 9.  Headings; Recitals. The various headings of this Amendment are inserted for convenience only and shall not affect the meaning or interpretation of this Amendment or any provisions hereof. The recitals set forth herein are hereby incorporated into this Amendment and form a part hereof, the truth and accuracy of which is evidenced by each party's execution hereof.

Section 10.  Governing Law. This Amendment shall be binding upon and inure to and for the benefit of the parties hereto and their respective successors and assigns and shall be governed by and construed in accordance with the laws of the State of Missouri. Without limitation of the foregoing, Grantor may not assign or transfer the Security Agreement without the prior written consent of the Lender.

Section 11.  Missouri Revised Statute §432.047. ORAL AGREEMENTS OR COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FOREBEAR FROM ENFORCING REPAYMENT OF A DEBT INCLUDING PROMISES TO EXTEND OR RENEW SUCH DEBT ARE NOT ENFORCEABLE, REGARDLESS OF THE LEGAL THEORY UPON WHICH IT IS BASED THAT IS IN ANY WAY RELATED TO THE CREDIT AGREEMENT. TO PROTECT YOU (GRANTOR(S)) AND US (LENDER) FROM MISUNDERSTANDING OR DISAPPOINTMENT, ANY AGREEMENTS WE REACH COVERING SUCH MATTERS ARE CONTAINED IN THIS WRITING, WHICH IS THE COMPLETE AND EXCLUSIVE STATEMENT OF THE AGREEMENT BETWEEN US, EXCEPT AS WE MAY LATER AGREE IN WRITING TO MODIFY IT.

Section 12.  Full Force and Effect. Except as specifically amended hereby, all of the terms and conditions of the Security Agreement and all loan documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and the same are hereby ratified and confirmed. No reference to this Amendment need be made in any instrument or document at any time referring to the Security Agreement, a reference to the Security Agreement in any of such to be deemed to be reference to the Security Agreement, as amended hereby.

[Remainder of Page Intentionally Left Blank]
IN WITNESS HEREOF, this Second Amendment to Commercial Security Agreement has been duly executed as of the day and year first written above.

“GRANTOR”

THE FEMALE HEALTH COMPANY,

a Wisconsin corporation

By: /s/ O.B. Parrish
Name: O.B. Parrish
Title: Chairman and CEO

STATE OF ILLINOIS )
) SS
COUNTY OF COOK )

On this 1st day of August, 2011, before me appeared O.B. Parrish, in his/her capacity as Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, to me personally known, who, being by me duly sworn, did say that he/she is the Chairman and CEO of THE FEMALE HEALTH COMPANY, a Wisconsin corporation, and that said instrument was signed in behalf of said corporation by authority of its Board of Directors, and said O.B. Parrish, as Chairman and CEO, acknowledged said instrument to be the free act and deed of said corporation.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my official seal in the County and State aforesaid, the day and year first above written.

/s/ Jacqueline F. Martin
Notary Public

My Commission Expires: 02/26/2014
IN WITNESS HEREOF, this Second Amendment to Commercial Security Agreement has been duly executed as of the day and year first written above.

“LENDER”

Heartland Bank,
a federal savings bank

By:  /s/ Colin McNulty

Name:  Colin McNulty
Title:  Assistant Vice President

STATE OF MISSOURI  
) SS  
COUNTY OF ST. LOUIS  

On this 1st day of August, 2011, before me appeared Colin McNulty, to me personally known, who being by me duly sworn did say that he/she is an Assistant Vice President of Heartland Bank, a federal savings bank, and that said instrument was signed on behalf of said bank and said Colin McNulty, as Assistant Vice President, acknowledged said instrument to be the free act and deed of said bank.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal on the day and year last above written.

/s/ Michelle Brewer
Notary Public

My Commission Expires: 09/19/2011
I, O. B. Parrish, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Female Health Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

   (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

   (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

   (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2011

/s/ O. B. Parrish
O. B. Parrish
Chief Executive Officer
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Donna Felch, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Female Health Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
   (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2011

/s/ Donna Felch
Donna Felch
Chief Financial Officer
Certification of Periodic Financial Report
Pursuant to 18 U.S.C. Section 1350

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of The Female Health Company (the "Company") certifies that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2011 fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 5, 2011
/s/ O. B. Parrish
O. B. Parrish
Chief Executive Officer

Dated: August 5, 2011
/s/ Donna Felch
Donna Felch
Chief Financial Officer

This certification is made solely for purpose of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.